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Zusammenfassung 1  
 1
Zusammenfassung 
Die heterologe Expression komplexer Naturstoff-Biosynthesewege spielt eine immer größer 
werdende Rolle bei der Entdeckung und Modifikation von Wirkstoffen aus der Natur und 
gewinnt somit zunehmend an Bedeutung in der biotechnologischen Forschung. Diese 
Methode ermöglicht die Produktion komplexer Metabolite in leicht handhabbaren 
Wirtsorganismen und bildet so die Grundlage für die Entwicklung neuer Naturstoffderivate 
durch genetische Manipulation der Biosynthesewege. Die vorliegende Arbeit beschreibt eine 
innovative Strategie für die heterologe Expression des komplexen Phenalinolacton-
Biosynthesewegs aus dem Streptomyceten Tü6071. Mit Hilfe der Red/ET Rekombination 
wurde dieses Gencluster, das auf 2 Cosmiden vorlag, kloniert und in verschiedenen 
Streptomyceten-Stämmen heterolog exprimiert. Das somit etablierte Expressionssystem bietet 
nun die Möglichkeit, durch gezielte genetische Manipulation der Biosynthesewege in 
Escherichia coli und anschließende heterologe Expression neue, möglicherweise wirksamere 
Naturstoffe und Naturstoffderivate zu entwickeln. 
Der zweite Teil dieser Arbeit beschäftigt sich mit Untersuchungen zur Biosynthese einer 
ungewöhnlichen Klasse von Sekundärstoffen: den GE81112 Tetrapeptiden. Um die 
zugrundeliegende Biosynthese dieser Naturstoffe nun detailliert zu untersuchen, wurde eine 
Strategie für die Klonierung und Identifizierung des entsprechenden Genclusters entwickelt, 
das schließlich auf zwei überlappenden Cosmiden identifiziert wurde. Gleichzeitig konnten 
Methoden zur genetischen Manipulation des Stammes entwickelt werden, die es ermöglichten 
das Gencluster durch Geninaktivierungsexperimente zu identifizieren. Mit Hilfe der 
erhaltenen Ergebnisse konnte schließlich ein erstes Model für die GE81112 Biosynthese 
erarbeitet werden. Die in dieser Arbeit erhaltenen Einblicke in die Biosynthese können in 
Zukunft einen wichtigen Beitrag zur Entwicklung neuer GE81112 Derivate leisten.  
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Abstract 
The heterologous expression of natural product biosynthetic pathways is of increasing interest 
in biotechnology and drug discovery. This approach enables the production of complex 
metabolites in more amenable host organisms and provides the basis for the generation of 
novel analogs through genetic engineering. In this thesis, we describe a straightforward 
strategy for the heterologous expression of the highly complex phenalinolactone biosynthetic 
pathway, which was recently cloned from Streptomyces sp. Tü6071. Using Red/ET 
recombineering, the phenalinolactone pathway was reconstituted from two cosmids and 
heterologously expressed in several Streptomyces strains. The established expression system 
now provides a convenient platform for functional investigations of the biosynthetic genes and 
the generation of novel analogs, by genetic engineering of the pathway in Escherichia coli. 
The second part of this thesis describes work on a distinct class of secondary metabolites, the 
GE81112 tetrapeptide family. We developed a strategy for the cloning and identification of 
the GE81112 biosynthetic gene cluster, in order to investigate the biosynthetic pathway in 
detail. Generation of a cosmid library enabled us to identify the corresponding biosynthetic 
gene cluster on two overlapping cosmids. In parallel, we established methods to manipulate 
the strain genetically, allowing us to verify the identity of the GE81112 gene cluster by gene 
inactivation experiments. In addition, we characterized several proteins from the pathway 
using enzymatic assays in vitro. Taken together, these data have enabled us to propose a 
preliminary model for GE81112 biosynthesis. The results also open the door to developing 
new derivatives of these promising compounds by genetic engineering.  
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1 Introduction 
1.1 Natural products as a robust source of new drugs and drug leads 
Microorganisms produce a vast number of secondary metabolites with useful biological 
activities for both human and veterinary medicine, including compounds which function as 
antibiotics, immunosuppressive and antitumor agents, as well as herbizides, insecticides and 
antiparasitic agents. Figure 1.1 exemplifies a further characteristic feature of these so-called 
‘natural products’: their significant structural diversity. The recruitment of many different 
building blocks, as well as the activity of diverse modifying enzymes, leads to the 
construction of highly complex chemical structures. 
 
 
 
Figure 1.1: Prominent natural products used in clinical applications. 
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Natural product research, as we know it today, began with the serendipitous discovery of 
penicillin in 1929 by Alexander Fleming – an event which inaugurated a new era in the 
treatment of bacterial diseases [1]. Since then, many natural products and synthetically 
modified natural product derivatives have been successfully developed for clinical use to treat 
human diseases, across a broad range of therapeutic areas [2]. Even today, natural products 
continue to play a dominant role in the discovery of leads for the development of new drugs. 
In fact, approximately 50% of the pharmaceuticals currently in clinical use are of natural 
product origin .  
A special focus in the field of natural product research is the development of new 
antibiotics [3]. Motivating these efforts is the fact that infectious diseases remain the second-
leading cause of death worldwide and the third-leading cause of mortality in economically-
advanced countries [4]. In order to deal with growing bacterial resistance to existing drugs, 
there is a pressing need for the discovery and development of new antibiotics [5]. Despite the 
fact that large pharmaceutical companies have significantly de-emphasized natural product 
discovery over the past several years, many new and interesting molecules with unique 
scaffolds and/or novel modes of action have been found during this time by research efforts in 
academia and small pharma companies [6]. Smaller biotechnology companies, in particular, 
have increased their focus on natural product research, mainly in the infectious diseases but 
also in anticancer areas (Figure 1.2) [6]. These findings emphasize that natural product 
research continues to provide significant value in the discovery of novel chemical structures 
and bioactive leads for clinical development. 
 
 
 
Figure 1.2:  New substances derived from natural products.  
  
Among the natural producers of secondary metabolites, beside plants, microorganisms are a 
particularly promising source of novel bioactive entities. In nature, the diversity of 
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microorganisms is enormous and only a very minor portion of bacterial and fungal species 
have been cultured to date and examined for secondary metabolite production [7]. The 
majority of bioactive compounds were isolated from, non-filametous bacteria, fungi and 
actinomycetes [7;8].  
With respect of secondary metabolism, actinomycetes are the most-intensively studied 
group; among them, the genus Streptomyces has been proven to be the most proficient 
producer of secondary metabolites, at least under standard laboratory conditions [9]. A wide 
array of bioactive molecules has been isolated from streptomycetes, leading to their historical 
importance in natural product discovery [3].  
 
1.2 Streptomycetes as important natural product producers  
Streptomycetes are soil-dwelling bacteria and ubiquitous in nature. Their ability to colonise 
the soil is greatly facilitated by growth as a vegetative hyphal mass which can differentiate 
into spores that assist in spread and persistence (Figure 1.3). The spores are a semi-dormant 
stage in the life-cycle, and can survive in soil for long periods (several years). 
 
  
Figure 1.3: Streptomycetes colonies. 
(a) Typical colony morphologies of Streptomyce sp. isolated from the soil. (b) A panoramic 
view of the colony morphology of Streptomyces coelicolor. Both peripheral and aerial mycelia 
develop from the central mass of the colony. Metabolites, including the blue antibiotic 
actinorhodin, are excreted into the medium and into aqueous droplets on the hydrophobic 
surface of the colony. (Figures reproduced from reference [9]). 
 
Streptomycetes produce many extracellular enzymes, such as cellulases, xylanases, amylases, 
maltases, and others. These catalysts make them important players in soil biodegradation 
processes, as they are able to decompose complex mixtures of polymers in dead plants, 
animal and fungal material [10]. Further characteristics of these strains are their high G+C 
content (72% on average), linear chromosomes and and large genome sizes. The sequenced 
genome of Streptomyces coelicolor comprises 8.6 Mbp [11], whereas the S. avermitilis 
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genome contains 9 Mbp [12]. However, their most notable characteristic is their capability to 
produce biologically active secondary metabolites, a feature which has made them the focus 
of natural product research.  
Streptomycetes were first recognized as natural product producers some 60 years ago, 
with the discovery of streptomycin [13]. Since then, the majority of known antibiotics have 
been isolated from streptomycetes. Of the 12000 or so antibiotics known by 1995, 55% were 
derived from streptomycetes and 11% from other actinomycetes [14]. Among these 
antibiotics are drugs which have been in clinical use as antibiotics for many years, including 
the macrolide antibiotic erythromycin A synthesized by the actinomycete Saccharopolyspora 
erythraea [15] and the aromatic polyketide tetracycline [16] (Figure 1.4). 
 
 
 
Figure 1.4: Natural compounds from actinomycetes and streptomycetes which serve as important 
medicines.  
 
Another prominent example of a therapeutically relevant streptomycete natural product is the 
cyclic lipopeptide antibiotic daptomycin (Cubicin®) from S. roseosporus. Daptomycin was 
approved in the United States in 2003 and in Germany in 2006 for the treatment of skin 
infections caused by Gram-positive pathogens. In addition to antibiotics, streptomycetes have 
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also yielded important anticancer compounds, such as the cytostatic doxorubicin [17], which 
is widely used in chemotherapy (Figure 1.4). 
As the vast majority of therapeutically important secondary metabolites are produced 
from Streptomyces sp., making them a proven source for therapeutically-useful compounds, 
they should be the continued focus of research to identify new bioactive substances. In the last 
years intense efforts have also been made to discover new groups of microbial producers with 
the assumption that an increase to discover new organisms correlates with the potential to 
discover chemical diversity (new structures). These investigations dealt with marine bacteria, 
pathogenic bacteria (pseudomonads) or organisms that are difficulte to cultivate 
(cyanobacteria) [18-20]. Among the bacteria discovered in these screenings especially the 
group of myxobacteria have attracted attention as proficient producers of novel bioactive 
compounds [21]. 
In the majority of the cases, these secondary metabolites are the end products of 
complex, multistep biosynthetic processes. Understanding the mechanisms involved in the 
biosynthesis of the compounds is an essential prerequisite for optimizing production and 
yield. Furthermore, directed manipulation of the genes governing secondary metabolism 
offers a promising alternative to total or semi-synthesis, to generate altered natural products. 
The success of this approach depends on the cloning and subsequent genetic and biochemical 
characterization of the corresponding biosynthetic pathways.  
Fortunately, in the majority of cases, the compounds are produced by sets of genes 
which are clustered in the bacterial chromosome; this feature presumably allows the 
microorganisms to co-regulate the expression of the many genes. The first proof that the 
genes for antibiotic biosynthesis are clustered was provided by Malpartida and Hopwood in 
1984 [22]. The researchers isolated and cloned a continuous DNA fragment from S. coelicolor 
which apparently carried the complete genetic information required for the biosynthesis of the 
antibiotic actinorhodin. Indeed, the cloned DNA fragment could complement several 
actinorhodin non-producing mutants. Furthermore, introduction of the DNA fragment into the 
heterologous host S. pavulus directed actinorhodin biosynthesis – providing proof that the 
cluster of genes located on this DNA fragment was responsible for the production of the 
antibiotic actinorhodin. The advantage for natural product researchers is that if a single gene 
within the gene cluster is located, the others can mostly be identified fairly straightforwardly 
by chromosomal walking.  
Many molecular tools have been developed for targeted genetic manipulation in 
streptomycetes over the last several decades [10] and hundreds of biosynthetic gene clusters 
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have been identified to date. Together, these developments have enabled detailed analysis of 
the molecular principles that govern multiple pathways [23]. Recently, this field has been 
revolutionized by advances in sequencing technologies, which now allow the rapid 
sequencing of entire bacterial genomes in a matter of days. The first Streptomyces strain to be 
sequenced was S. coelicolor [11]. Before the genome of S. coelicolor was sequenced, it was 
known that the strain produces three antibiotics, actinorhodin, prodiginin and the 
nonribosomal peptide calcium-dependent antibiotic (CDA) [10;11]. However, the genome 
sequence revealed a further 23 gene clusters (comprising approximately 5% of the total 
genome), which are likely to be dedicated to secondary metabolism.  
Thirty gene clusters were identified in the second sequenced strain, S. avermitilis, which 
could be correlated to secondary metabolism, corresponding to 6.5% of the genome. Although 
antibiotic production by the Streptomcyes has been studied intensively over the last century, 
mathematical models predict that only 3% of antibacterial compounds synthesized by these 
bacteria have been discovered to date [24]. These facts indicate that the genomic capacity of 
these microorganisms to synthesise natural products is much higher then originally 
anticipated, a hypothesis which is supported by the available genome sequencing data. In 
order to identify, isolate and evaluate these as yet uncharacterized biosynthetic gene clusters 
and exploit them for analogue production, techniques must be developed to allow the 
straightforward genetic manipulation of the strains. Genetic manipulation in natural producer 
strains is straightforward in some model organisms (for example S. coelicolor) but for many 
other Streptomyces strains it remains more challenging, although there has been some 
progress [10]. Many of these strains are slow-growing or not yet culturable, which further 
hinders the genetic manipulation of the biosynthetic pathways. 
One very useful approach is to express entire gene clusters in genetically more tractable 
production hosts, which facilitates the genetic manipulation of the secondary metabolite 
pathways. This so-called ‘heterologous expression’ technique represents a promising tool for 
both obtaining deeper insights into the biosynthetic pathways, and for generating novel 
derivatives of natural compounds for evaluation as drug leads. 
 
1.3 Heterologous expression of natural product pathways 
There has been considerable recent interest in both the natural product research and drug 
discovery communities, in developing heterologous expression techniques for complete 
secondary metabolite pathways. Furthermore, heterologous expression can also be used to 
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screen genomic DNA obtained from microbial niches (metagenomes) for the production of 
novel secondary metabolites [25;26].  
Efforts towards achieving heterologous expression have met with considerable success 
during the last decade [27-29]. However, in most cases, only small biosynthetic gene clusters 
were expressed in hosts which were closely-related to the producing strains [30]. To date, the 
heterologous expression of secondary metabolite pathways from Streptomyces has mainly 
been achieved in related actinomycete species, and the relatively small biosynthetic gene 
clusters (less than 30 kbp) were often located on a single cosmid or bacterial artificial 
chromosome (BAC) within a genomic library [31-33]. Expression of larger and more complex 
pathways remains more demanding, but can be facilitated by constructing several plasmids 
that harbor subsets of the biosynthetic genes [34].  
As this approach requires time consuming classical cloning steps, however, a new 
method for the expression and engineering of large biosynthetic pathways was developed in 
our working group by Wenzel et al. [35]. In this case, Red/ET (λ-mediated) recombineering 
technology [36-38] was used to reconstitute the hybrid nonribosomal peptide 
synthetase/polyketide synthase (NRPS/PKS) myxochromide S pathway from the 
myxobacterium Stigmatella aurantiaca on one expression construct and to integrate genetic 
elements for expression in Pseudomonas putida. Heterologous expression was successful, and 
the construct yielded higher amounts of myxochromide in P. putida than in the natural 
producer Stigmatella  aurantiaca [35;39;40].  
Red/ET is a novel technique for DNA manipulation, which is precise and independent 
of the presence of restriction sites and the size of the DNA molecule. These features make it 
ideal for the manipulation of large DNA fragments. DNA molecules targeted by Red/ET 
recombineering are precisely altered by homologous recombination in strains of E. coli which 
express phage-derived protein pairs, either RecE/RecT from the Rac prophage, or Redα/Redβ 
from λ phage. These protein pairs are functionally and operationally equivalent. RecE and 
Redα are 5'→3' exonucleases, while RecT and Redβ are DNA annealing proteins (Figure 1.5). 
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Figure 1.5: Mechanism of Red/ET recombineering. 
The target double strand DNA is digested by a 5′→3′ exonuclease (RecE or Redα), after which 
the single-strand binding protein (RecT or Redβ) can bind to the DNA to stabilize the single 
strand. Homologous recombination can then take place. Diagram reproduced from 
www.genebridges.com.  
 
 
 
A functional interaction between RecE and RecT, or between Redα and Redβ, is also required 
in order to catalyze the homologous recombination reaction. Recombination is mediated by 
homology regions, which are stretches of identical DNA sequences found on both molecules 
to be recombined (Figure 1.6). As the sequence of the homology regions can be generated in a 
chemically synthesized oligonucleotide, any position on a target molecule can be specifically 
altered. Red/ET recombination thus allows, at least in principle, every type of possible DNA 
modification (insertions, deletions, substitutions, fusions, point mutations, direct cloning and 
subcloning) regardless of the size of the target molecule (e.g. cosmids or BACs) [41].  
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Figure 1.6: Red/ET recombineering. 
The central step in Red/ET recombineering is the crossover between a targeting construct 
containing homology arms (hm) and the target, which can be a gene locus on the E. coli 
chromosome or any other stretch of DNA in a BAC or plasmid vector contained within the 
cell. Diagram reproduced from www.genebridges.com. 
 
Perlova, et al. [42] also used Red/ET to stitch together a myxobacterial biosynthetic pathway. 
Here, Red/ET recombineering was employed to modify two cosmids containing the entire 
myxothiazol pathway. In a final ligation step, the whole pathway was reconstituted on one 
expression construct, which was subsequently expressed in Myxococcus xanthus. Production 
of myxothiazol was comparable to that of the natural producer Stigmatella aurantiaca 
[42].The same pathway was also expressed in Pseudomonas putida [43]. These and 
subsequent examples [44;45] demonstrate how this promising technique can now be used for 
the reconstitution of large and complex biosynthetic pathways in E. coli and their subsequent 
heterologous expression in related or non-related heterologous hosts. Figure 1.7 gives a 
general overview of the strategy for cloning and heterologous expression of large natural 
product assembly lines [35;39] 
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Figure 1.7: General strategy for the heterologous expression of large biosynthetic pathways. 
After screening of a BAC or cosmid library for constructs containing parts of the investigated 
natural product biosynthetic gene cluster, overlapping fragments can be stitched together in E. 
coli using Red/ET recombineering. The resulting construct harboring the complete natural 
product assembly line can be further modified in E. coli by recombineering, e.g., by inserting 
genes needed for transformation into the heterologous host and/or insertion of promoter 
region(s). The final construct can be transferred into a suitable heterologous host for expression 
of the biosynthetic pathway. Natural product formation can ultimately be analyzed by 
conventional techniques, e.g., HPLC-MS and/or TLC [35].  
 
 
The successful heterologous expression of several classes of natural products, including the 
polyketides (PKs) and non-ribosomal polypeptides (NRPs) and their hybrids, presented a 
special challenge, because the biosynthesis of these complex structures typically requires 
large gene sets [46;47]. The core structures in each case are assembled by gigantic 
multienzymes called polyketide synthases (PKSs) and non-ribosomal peptide synthetases 
(NRPSs), respectively. In both systems, the proteins have to be posttranslationally modified in 
order to be active [48]. These multifunctional enzymes can reach remarkable sizes, for 
example mycolactone A and B from the the bacterium Mycobacterium ulcerans are 
synthezised by PKS multienzymes housing eight and seven extension modules containing 
16990 amino acids and 14130 amino acids, respectively [49].  
Once the proteins are expressed as functional proteins within the cell, they require a 
specific pool of substrates, including but not limited to short-chain fatty acids, proteinogenic 
and non-proteinogenic amino acids, mevalonate, shikimate pathway intermediates, and sugars 
to enable natural product formation. Therefore, the required substrates must be available in 
the heterologous hosts in adequate amounts, at the correct time point.  
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1.4 The biosynthetic logic of nonribosomal peptide synthetases  
NRPS multienzymes are composed of repetitive, multicatalytic units called modules which 
carry out several reactions in a coordinated manner. Typically, each module in the assembly 
line performs one cycle of chain extension (incorporation of one amino acid into the growing 
peptide chain). One cycle of chain extension comprises three essential enzymatic reactions: 1) 
recognition of an amino acid as substrate and its activation as its aminoacyl-adenylate; 2) 
covalent binding of the amino acid as a thioester to the multienzyme; and 3) condensation 
with the amino acyl or peptidyl group tethered to the neighbouring module [50]. This process 
is schematized in Figure 1.8. Overall, peptide synthesis proceeds in an N- to C-terminal 
direction.  
Each of the steps in chain extension is carried out by a specific domain within the 
module. A typical module consists minimally of an adenylation (A) domain, a peptidyl carrier 
protein (PCP) domain (also referred to as a thiolation (T) domain) and a condensation (C) 
domain [47]. The A domain is responsible for recognizing and activating the starter/extender 
unit, which is then covalently linked to the PCP. The attachment point is the terminal 
sulfhydryl of a phosphopantetheine arm attached to a highly conserved serine residue [51]. 
This ‘swing arm’ is added post-translationally to the PCP by a phosphopantetheinyl 
transferase (PPTase). The Ppant arm (20 Ǻ in length) is characterized by its flexibility, which 
presumably facilitates the transport of the intermediates to the reaction centers [51]. The 
condensation domain then catalyses peptide bond formation between the aminoacyl-S-PCP 
and the incoming aminoacyl or peptidyl-S-PCP (see Figure 1.8). The release of the 
intermediates in a linear or cyclic form is normally performed by a thiosterase domain, which 
is located at the end of the last module of the assembly line [52;53] 
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Figure 1.8: Reactions catalyzed by the essential domains in NRPS multimodular assembly lines.  
 
Domains that are involved in the particular reactions are highlighted in grey. A: activation 
domain ; PCP: peptidyl carrier domain; C: condensation domain.  
 
A variety of optional domains increase the structural diversity of the products, including 
methyl transferase (MT), epimerase (E), oxidation (Ox) and heterocyclization (HC) activities 
[54]. These tailoring enzymes are embedded in the NRPS assembly lines and modify the 
elongating chains while they are still covalently tethered to the proteins as peptidyl-S-enzyme 
intermediates. Other tailoring enzymes act in trans, recognizing either or both the peptidyl 
chains or the PCP domains. A third group of tailoring enzymes act after the assembly-line 
stage of the biosynthesis, and further transform the released peptides (e.g., by introducing 
cross-linking or addition of glycosyl groups) [55].  
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In general, nonribosomal peptide synthesis is a linear process in which each module is 
responsible for one particular chain elongation step and the specific order of the modules 
defines the sequence of the incorporated amino acids. However, recent characterization of 
many NRPS systems has revealed several examples where the arrangement of modules and 
domains within the enzyme is not co-linear with the sequence of transformations required to 
generate the observed product. Therefore, Mootz et al. proposed a classification of NRPS 
systems into three groups, according to their biosynthetic logic [56]: linear NRPSs, iterative 
NRPSs and nonlinear NRPSs. Representative examples for each type of biosynthesis are 
shown in Figures 1.9–1.11.  
 
 
Figure 1.9: The multiple carrier thiotemplate mechanism illustrated with the example of tyrocidine A 
synthesis.  
Three peptide synthetases encoded by the genes tycA, tycB and tycC act together to assemble 
the cyclic decapeptide. Diagram reproduced from [57].  
 
Figure 1.9 illustrates a linear NRPS, which is involved in the biosynthesis of the decapeptide 
tyrocidine [58]. In a linear NRPS, the core domains are arranged in the order C-A-PCP. The 
initiation module, which lacks the C domain, is responsible for the incorporation of the first 
amino acid. The terminal module normally contains a TE domain for release of the full-length 
peptide chain. Other examples of linear NRPSs are those responsible for biosynthesis of 
surfactin [59] and pristinamycin [60]. 
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Figure 1.10: The enterobactin assembly line as example for iterative NRPSs.  
 Three dihydroxybenzoylserine-S-PCP intermediates are generated on the two modules which 
are oligomerized and cyclized to the final product on the TE domain. Diagram reproduced 
from [56]. 
 
In iterative NRPSs, modules or domains are used more than once for the assembly of a 
particular product. This strategy is employed to construct peptide chains that consist of 
repeated smaller units. The key step is then the oligomerization and cyclization of the 
monomers by the thioesterase domain. For example, in enterobactin biosynthesis (Figure 
1.10), the complete NRPS assembly line acts iteratively to generate a common structural unit 
(trimer of dihydroxybenzoylserine units) [61], which is then oligomerized to the final product. 
Bacillibactin of B. subtilis, a cyclotrimerized dihydroxybenzoyl-glycyl-threonine-peptide, is 
structurally very similar [62]. An iterative NRPS is also involved in the assembly of 
gramicidin [63].  
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Figure 1.11: The non-linear yersiniabactin NRPS.  
Yersiniabactin biosynthesis proceeds on a mixed NRPS/PKS system. Cy: cyclization domain, 
MT: methylation domain. Diagram reproduced from [56]. 
 
Over the last several years, it has become clear that a number of biosynthetic gene clusters 
deviate in their domain organization from the standard C-A-PCP architecture. In fact, these 
nonlinear NRPS clusters comprise a major proportion of the NRPS systems found in nature 
[64]. The main characteristics of these systems are the unusual arrangement of the core 
domains C, A and PCP. Such a non-linear NRPS is depicted in Figure 1.11. The NRPS 
responsible for the siderophore yersiniabactin is a striking example of nonlinear NRPS 
assembly, where one A domain is used to load three different PCPs [65]. Due to the unusual 
domain organization of nonlinear NRPS biosynthetic gene clusters, it is very difficult to 
predict the product structures with any confidence. Therefore, detailed biochemical studies are 
needed to understand the function and the interplay between the enzymes, which makes 
research with nonlinear NRPS very challenging.  
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1.5 Outline of the dissertation  
Studies on the biosynthesis and the heterologous expression of complex secondary 
metabolites from streptomycetes 
 
The present thesis deals with experiments to heterologously express the phenalinolactone 
biosynthetic gene cluster from Streptomyces Tü6071, and to investigate the biosynthesis of 
the GE81112s from Streptomyces 14386. Figure 1.12 shows the GE81112 family and the 
phenalinoactones, of which the main metabolites are PL A and PL D.  
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Figure 1.12: Structures of the GE81112 metabolites and the phenalinolactones. 
 
The phenalinolactones are structurally intriguing tricyclic terpene glycosides which are 
produced by Streptomyces sp. Tü6071. The compounds exhibit promising antibacterial 
activity [66]. In addition to a highly oxidized γ-butyrolactone ring, which is most likely 
derived from pyruvate, the oxidatively functionalized terpenoid backbone is decorated with a 
5-methylpyrrole-2-carboxylic acid as well as the rare deoxyhexose, 4-O-methyl-L-amicetose. 
The recent cloning and sequence analysis of the pla biosynthetic gene cluster from 
Streptomyces Tü6071 [66] revealed a highly complex genetic architecture that consists of 35 
orfs, which are organized into 11 putative operons. 
Our goal was to heterologously express the cluster using Red/ET recombineering, as 
the technique had already been shown to be suitable for the reconstitution and expression of 
natural product pathways. However, at the outset of this work, the approach had not been 
applied to non-PKS/NRPS gene clusters from streptomycetes. Initially the PL cluster was 
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located on two different cosmids. Therefore, the first aim of the work was to collect the 
biosynthetic genes together onto one expression construct, and then to introduce genetic 
elements for expression in different heterologous hosts. The established expression system 
was then expected to provide a convenient platform for functional investigations of the 
biosynthetic genes and the generation of novel analogues, by genetic engineering of the 
pathway in E. coli.  
The second part of this thesis describes work on a second class of secondary 
metabolites, the GE81112 tetrapeptide family. The GE81112 compounds were isolated from a 
Streptomyces sp., and to date, three variant GE factors have been identified (GE81112 factors 
A, B1 and B). The metabolites were found in the course of microbial product screening 
experiments aimed at discovering novel antibiotics acting on bacterial protein synthesis. 
Extensive NMR and MS studies revealed that the GEs incorporate 4 uncommon amino acids: 
the nonproteinogenic amino acids hydroxypipecolic acid and hydroxypentanoic acid, as well 
as an (amino)histidine and a hydroxychlorohistidine [67] (Figure 1.12). Although the core 
structure of the GEs could be predicted straightforwardly to arise from a nonribosomal 
peptide synthetase (NRPS) multienzyme, the origin of several amino acids and functional 
groups, including the aminohistidine as well as the chlorination and carbamoylation, was not 
obvious from considerations of classical assembly-line biosynthesis. As the biosynthetic gene 
cluster had not been identified, the first objective was to clone the GE81112 biosynthetic gene 
cluster in order to allow studies of the underlying biosynthesis. Once the cluster was 
identified, it would then be annotated, as the first step towards deciphering the biosynthetic 
pathway. In parallel, we aimed to develop methods to genetically manipulate the strain, as 
they were not available. A final goal was to investigate GE biosynthesis by heterologous 
expression. 
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2 Material and Methods 
2.1 Chemicals 
All chemicals used in this work were obtained from the manufacturers, at analytical grade. 
 
Table 2.1: Chemicals used and their sources 
Chemical product Manufacturer 
Acetone 
Acetonitrile 
Chloroform 
Ethanol 
Ethyl acetate 
Hexane 
Methanol 
Magnesium sulfate 
2-Propanol 
Succinic acid 
Sigma Aldrich 
Bacto agar 
Casitone 
Casaminoacids 
Malt extract 
Tryptone 
Peptone  
Yeast extract 
Becton Dickinson and 
Co., USA 
Ammonium acetate 
Sodium-EDTA 
Potassium hydroxide 
Fluka 
Acetic acid 
Boric acid 
Bromphenolblue 
Calcium chloride-di-hydrate 
Glucose monohydrate 
Glycerin 
Magnesium chloride 
Magnesium sulfate hepta-hydrate 
Potassium acetate 
Potassium hydrogen phosphate 
Potassium sulfhate 
Sodium chloride 
Sodium citrate-di-hydrate 
Sodium hydroxide 
Merck 
BSA (Bovine Serum Albumin) New England Biolabs 
Ammonium persulfate 
5-Bromo-4-chloro-3-indolyl--D-galactopyranoside 
Coomassie Brilliantblue 250R 
Dithiothreitol  
Ethidium bromide solution (1%) 
Formamide 
Maleic acid 
Sodium dodecyl sulfate (SDS) 
Rotiphorese®Gel 30 
TEMED 
Triton X-100 
ROTH 
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2.2 Enzymes, Kits and Markers 
All enzymes used in this work are listed in Table 2.2 and were used according to the 
manufacturers’ protocols. 
 
Table 2.2: Enzymes, kits and markers and their manufacturers 
Product Manufacturer 
Page RulerTM Prestained Protein Ladder 
Page RulerTM Protein Ladder 
1 kb DNA ladder 
T4 DNA ligase 
Shrimp alkaline phosphatase 
Restriction endonucleases 
Plasmid purification kit 
Nucleotides 
MBI Fermentas 
Cre recombinase New England Biolabs 
Phusion DNA Polymerase Finnzymes 
Triple Master Polymerase Eppendorf 
HotStarTaq Ploymerase Quiagen 
Topo TA Cloning® Kit 
Gel-Dry™ Drying Kit 
Invitrogen 
Nucleospin® Extract Macherey & Nagel 
Ribonuclease A 
Proteinase K 
Lysozyme 
Roth 
DIG labeleld DNA Molecular Weight Marker III 
DIG-Labeling and Detection Kit 
DIG-Blocking solution 
DIG EasyHyb 
DIG PCR Labeling Mix 
Roche 
BugBuster® Protein Extraction Reagent Novagen 
Gigapack® III Gold Packaging Extract Stratagene 
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2.3 Buffers and stock solutions 
2.3.1 Solutions and buffers for molecular biology applications 
Table 2.3: Solutions and buffers for molecular biology  
Buffer Constituents 
Cell Lysis buffer (P1) NaOH 
10% SDS 
H2O 
20 mM 
10 ml 
to 100 ml 
Cell suspension buffer (P2) Glucose 
Tris 
EDTA 
H2O 
5 mM 
2.5 mM 
1 mM 
to 100 ml 
DNA Loading buffer (6×) Glycerin (87%) 
Bromphenol blue 
Xylene cyanol 
H2O 
3 ml 
25 mg 
25 mg 
to 10 ml 
0.5 M EDTA  EDTA 
NaOH 
H2O 
186 g 
20 g 
to 1L 
Glycerol (50%) Glycerol 
H2O 
115 ml 
to 1L 
Glycerol (20%) Glycerol 
H2O 
57.5 ml 
to 100 ml 
0.1 M IPTG IPTG 
H2O 
240 mg 
to 10 ml 
5 M Sodium chloride 
 
NaCl 
H2O 
580 g 
to 100 ml 
Neutralisation buffer (P 3) 3 M Potassium acetate  
Acetic acid 
H2O 
60 ml 
11.5 ml 
to 100 ml 
10% SDS solution SDS 
H2O 
10 g 
to100 ml 
SET buffer 
 
Tris-HCl (pH 7.5) 
NaCl 
EDTA (pH 8) 
20 mM 
75 mM 
25 mM 
To 100 ml 
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Buffer Constituents 
TBE buffer  (1x) TRIZMA base 
Boric acid 
Na-EDTA 
H2O 
242 g 
57.1 ml 
100 ml 
to 1L  
SM-buffer Tris-HCl (1 M, pH 7.4) 
NaCl 
MgSO4.7 H2O 
Gelatine-solution (2%) 
H2O 
50 ml 
5.4 g 
2 g 
5 ml 
to 1 L 
1 M Tris-HCl TRIZMA Base 
H2O 
60.5 g 
to 500 ml 
P (protoplast) buffer Sucrose  
K2SO4 
MgCl2.6 H2O 
Trace element solution 
H2O 
Add after autoclaving: 
KH2PO4 (0.5%) 
CaCl.2H2O (3.68%) 
TES buffer (5.73%, pH 7.2) 
103 g 
0.25 g 
2.02 g 
2 ml 
to 800 ml 
 
1 ml 
10 ml 
10 ml 
 
2.3.2 Solutions and buffers for Southern Blot and colony hybridization 
Table 2.4: Solution and buffers for Southern Blot and colony hybridization 
Buffer Constituents 
Depurination buffer HCl (1 M) 
H2O 
250 ml 
to 1L 
Denaturation buffer 
 
NaOH 
NaCl (5 M) 
H2O 
20 g 
333 ml 
to 1 L 
Neutralisation buffer 
 
Tris HCl (1 M, pH 7.4) 
NaCl 
H2O 
500 ml 
175.5 g 
to 1L 
SSC (20×) 
 
NaCl 
Sodium citrate.2 H2O 
H2O 
155.3 g 
88.2 g 
to 1L 
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Buffer  Constituents  
Hybridization buffer 
 
DIG Easy Hyb Granules 
H2O 
 
to 64 ml 
2× wash solution SSC (20×) 
10% SDS 
H2O 
100 ml 
10 ml 
to 1L 
1× wash solution 
 
SSC (20× ) 50 ml 
10 ml 
to 1 L 
Maleic acid buffer Maleic acid 
NaCl 
H2O 
11.61 g 
8.8 g 
to 1L 
Blocking solution DIG blocking reagent 
Maleic acid buffer 
50 g 
to 500 ml 
Detection buffer Tris-HCl  (1 M) 
NaCl 
H2O 
100 ml 
5.8g 
to 1 L 
Stripping buffer NaOH 
SDS (10%) 
H2O 
8 g 
10 ml 
to 1L 
 
 
2.3.3 Solutions and buffers for enzymatic applications 
Table 2.5: Solution and buffers for enzymatic applications 
Buffer Constituents 
10x buffer Tris-HCl 
NaCl 
MgCl2 
H2O 
750 mM 
1 M 
100 mM 
to 50 ml 
Binding buffer Tris-HCl (pH 7.8) 
NaCl 
Glycerol 
Imidazole 
H2O 
20 mM 
200 mM 
100 ml 
60 mM 
to 1L 
Borate buffer Boric acid 
H2O 
200 mM 
to 1L 
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Buffer  Constituents  
 
Elution buffer 
 
Tris-HCl (pH 7.8) 
NaCl 
Glycerol 
Imidazole 
H2O 
 
20 mM 
200 mM 
100 ml 
500 mM 
to 1 L 
Stop-mix Activated charcoal 
Tetrasodium pyrophosphate 
Perchloric acid 
H2O 
6 g 
50 ml 
19.2 ml 
to 500 ml 
Stripping buffer 
 
Sodium phosphate (pH 7.4) 
NaCl 
EDTA 
H2O 
20 mM 
500 mM 
50 mM 
to 1 L 
Nickel solution NiSO4 100 mM 
Coomassie Brilliant Blue Brilliant Blue 250 
H2O 
Methanol 
Acetic Acid 
2 g 
450 ml 
450 ml 
100 ml  
4× Protein loading buffer Tris (1 M, pH 6.8) 
87% Glycerol   
Bromophenol blue  
SDS    
H2O   
DTT 500 mM   
The DTT is added directly 
before use. 
5 ml  
4 ml 
10 mg 
1 g  
to 10 ml 
800 μl 
 
PBS buffer 1 PBS tablet 
H2O 
 
to 500 ml 
Wash buffer Tetrasodium pyrophosphate 
Perchloric acid 
H2O 
50 ml 
19.2 ml 
to 500 ml 
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2.4 Media 
2.4.1 Media for E. coli cultivation 
Table 2.6: Media for E. coli cultivation (for agar plates 16 g/L agar were added to the medium) 
Medium Constituents 
LB medium Tryptone 
Yeast extract 
NaCl 
H2O 
10 g 
5 g 
5 g 
to 1 L 
2YT medium Tryptone 
Yeast extract 
NaCl 
H2O 
16 g 
10 g 
5 g 
to 1L 
Freezing solution MgSO4 x 7 H2O 
Na-Citrat x 2 H2O 
NH42 SO4 
Glycerol 
H2O 
Add after autoclaving: 
K2HPO4 
KH2HPO4 
H2O 
760 mg 
4.5 g 
9 g 
440 g 
to 800 ml 
 
47 g 
18  g 
to 200ml 
 
 
2.4.2 Media for cultivation of pseudomonads  
Table 2.7: Media for cultivation of pseudomonads 
Medium Constituents 
LB medium Tryptone 
Yeast extract 
NaCl 
H2O 
10 g 
5 g 
5 g 
to 1 L 
PMC medium K2HPO4 
KH2PO4 
NH4(SO4)2 
Na-Citrate 
MgSO4 
H2O 
6 g 
5 g 
1 g 
8.8 g 
800 mM 
to 1 L 
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2.4.3 Media for cultivation of streptomycetes 
Table 2.8: Media for cultivation of streptomycetes 
Medium Constituents 
Tryptone soy broth medium 
(TSB) 
Tryptone soy broth 
H2O 
30 g 
to 1L 
Yeast extract-malt extract medium 
(YEME) 
Yeast extract 
Peptone 
Malt extract 
Glucose 
Sucrose 
H2O 
3 g 
5 g 
3 g 
10 g 
340 g 
to 1L 
Soya mannitol medium 
(SM) 
Mannitol 
Soya flour 
H2O 
20 g 
20 g 
to 1L 
INA5 medium Glycerol 
Soya flour 
CaCO3 
NaCl 
H2O 
30 g 
15 g 
5 g 
2 g 
to 1L 
T6 medium Glycerol 
Soya flour 
CaCO3 
H2O 
45 g 
25 g 
2g 
to 1 L 
R2YE medium Sucrose 
K2SO4 
MgCl2.6 H2O 
Glucose 
Casaminoacids 
H2O 
Add after autoclaving: 
KH2PO4 (0.5%) 
CaCl2.2H2O (3.68%) 
L-Proline (2 %) 
TES-Puffer (5.73 %, pH 7.2) 
Trace element solution  [10] 
1 N NaOH 
Yeast extract (10%) 
51.1 g 
0.125 g 
5.06 g 
5 g 
0.05 g 
to 400 ml 
 
5 ml 
40 ml 
7.5 ml 
50 ml 
1 ml 
2.5 ml 
25 ml 
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Medium  Constituents  
V6 medium Glucose 
Meat extract 
Yeast extract 
Peptone 
Casein 
NaCl 
 
pH 7.5 
20 g 
5 g 
5 g 
5 g 
3 g 
1.5 g 
to 1L 
NBG Peptone 
Meat extract 
Glucose 
NaCl 
H2O 
10 g 
3 g 
10 g 
5 g 
to 1L 
NL111 Meat extract 
CaCO3 
Malt extract 
H2O 
pH 7.2 
20 g 
10 g 
100 g 
to 1L 
 
2.5 Antibiotics 
Table 2.9: Antibiotics used in this work 
Antibiotic Stock solution End concentration 
Ampicillin 100 mg/ml 100 µg/ml 
Chloramphenicol 34 mg/ml 34 µg/ml 
Kanamycin 60 mg/ml 60 µg/ml 
Tetracyline 12.5 mg/ml 12.5 µg/ml 
Zeocin 100 mg/ml 25µg/ml 
Apramycin 60 mg/ml 60 µg/ml 
Nalidixic acid 25 mg/ml 25 µg/ml 
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2.6 Instruments and materials 
• Agarose gel electrophoresis  
Electrophoresis chamber SUB-CELL® GT   (Biorad)  
Electrophoresis chamber MINI-SUB-CELL® GT  (Biorad)  
• Centrifuges  
Cool centrifugee 5805R     (Eppendorf)  
Tabletop centrifuge 5415D     (Eppendorf)  
Centrifuge Avanti JE      (Beckmann Coulter) 
Biofuge Pico      (Heraeus) 
• Electroporator 
Gene pulser XCell     (Biorad)  
Electroporation cuvette 0.1 cm    (Biorad)  
• Electro blotter 
Trans-Blot SD Semi Dry Transfer Cell   (Biorad)  
• French Press      (SLM Aminco)  
• HPLC  
DAD-coupled HPLC      (Dionex)  
• HPLC-MS  
Agilent 110 series HPLC system    (Agilent)  
Bruker HCTplus      (Bruker)  
Bruker micrOTOF      (Bruker)  
LTQ-Orbitrap      (Thermo Finnigan)  
• Image documentation  
N-1000 Darkroom      (Peqlab) 
Camera biovision      (Peqlab) 
• Incubators  
Incubators       (Binder)  
Hybridization oven APT Line Series BFED  (Binder)  
Multitron Shakers      (Infors)  
• Laminar flow  
HeraeusLaminAir®      (Kendro)  
Hera Safe       (Kendro)  
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• NMR  
Bruker Advance 500      (Bruker)  
• PCR  
Mastercycler Gradient     (Eppendorf) 
PCR Sprint Thermocycler     (Thermo Electron Corp) 
• pH-measurements 
pH-Meter 766 Calimatic     (Knick)  
• Photometer  
Helios Epsilon Spectrophotometer   (Thermo) 
• Protein purification 
Äkta Prime system     (GEHealthcare) 
• TLC 
Alugram®SL G/UV
254 
TLC Platten    (Macherey & Nagel)  
• Thermomixer 
Thermomixer compact    (Eppendorf) 
Thermomixer comfort    (Eppendorf) 
• Sterilisation  
Systec VX-150      (Systec)  
• Ultrasonic bath 
Sonarex       (Bandelin)  
• Water processing 
Milli-Q water purification system    (Millipore)  
PURELAB ultra      (ELGA)  
• Others materials  
Membrane filter 0.22 μm     (Millipore)  
Nylon membrane, positively charged   (Roche)  
Microspin Columns      (Amersham Pharmacia)  
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2.7 Bacterial strains, oligonucleotides and plasmids 
2.7.1 Bacterial strains 
Table 2.10: Bacterial strains used in this work  
Strain Genotype/characteristics Reference 
E.coli DH10B F-mcrA∆(mrr-hdsRMS-mcrBC) 
Ø80dlacZ∆M15∆lacX74 deoR recA1 endA1 
araD 139∆ (ara,leu) 7696 galU galK rpsL 
nupG  
[68] 
E. coli HS 996 F-mcrA∆(mrr-hdsRMS-mcrBC) 
Ø80dlacZ∆M15∆lacX74 deoR recA1 endA1 
araD 139∆ (ara,leu) 7696 galU galK rpsL 
nupG fhuA::IS 
Invitrogen 
E. coli ET 12567/pUZ8002 dam13::Tn9 dcm-6 hsdM hsdR recF143 zjj-
201::Tn10 galK2 galT22 ara14 lacY1 xyl-5 
leuB6 thi-1 tonA31 rpsL136 hisG4 tsx-78 mtlI 
glnV44, carrying the oriT mobilisating plasmid  
pUZ8002 
[10] 
E. coli GB2005 HS996 ΔrecT and redα Genebridges 
E. coli GB2005 red GB2005 insertion of the pBAD recE recT γ 
recA operon 
Genebridges 
E. coli SCS110 rpsL (Strr) thr leu endA thi-1 lacY galK galT 
ara tonA tsx dam dcm supE44 Δ(lac-proAB) [F´ 
traD36 proAB lacIqZΔM15] 
Stratagene 
E. coli BL21(DE3) F– ompT gal dcm lon hsdSB(rB– mB–) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
[69] 
E. coli Rosetta BL21 (DE3) 
pLysS/RARE 
 
F- ompT hsd SB(RB– mB–) gal dcm λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) 
pLysSRARE (CmR) 
Novagen 
 [69] 
 
E.coli SURE endA1 glnV44 thi-1 gyrA96 relA1 lac recB recJ 
sbcC umuC::Tn5 uvrC e14- Δ(mcrCB-hsdSMR-
mrr)171 F'[proAB+ lacIq lacZΔM15 Tn10(tetR)] 
Stratagene 
[70] 
P. putida KT2440 wild type [71] 
S. lividans TK24 Derived from S. lividans TK66 [72] 
S. coelicolor A3(2) wild type [73] 
S. coelicolor M512 ΔredD, ΔactII-ORF4 SCP1–SCP2– [74] 
S. Tü6071 phenalinolactone producer [66] 
S. 14386 GE81112 producer [75] 
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2.7.2 Oligonucleotides  
2.7.2.1 Primers used in the phenalinolactone project 
Table 2.11: Primers used in the phenalinolactone project, DST= desalted 
Primer Sequence (5′→3′) Purification 
PhlET6 CGAGCGGGGATGCGCCAACTTCGCCCGTTCTTCTTCCTAA
GGGCGAATTCGGATCTGATCAGCACGTGTT 
HPLC 
PhlET7 GTAGAGGATCTCTAGATTAATTGGGAGTGATTTCCCTTGTT
TAAAGGATCTCAGTCCTGCTCCTCGGCCA 
HPLC 
PhlET10 
 
GTAGAGGATCTCTAGATTAATTGGGAGTGATTTCCCTTGTT
TAAAGGATCAGTACTCCACTAGTGTGAATTGTAATACGAC
TCACTATAGGGCGATTTAAAGGATCCGGCCAGCCTCGCAG 
AGCAG 
HPLC 
PhlET11 
 
GGGCGCTCTGGTTGTGGAGCAGGTGCTCGTACCAGTGGCC
GACGACGTACTTACTTGGCGGAAGTCTGCT 
HPLC 
PhlET18 
 
CAGCGCGATGGTGTACGAGAGGCGGTCGTCCGCCCATGCG
TGAGCTGAAGGCTGCTCTA GTACACCTGA 
HPLC 
PhlET19 
 
CGGGGGATGGGATTGCGTAGGTCTTGGGTTGCTGCCGTCT
CGGCATGCACGTCGTTGCTGTATCTCCAG 
HPLC 
PhlET20 
 
TCTCGGATCTGGTCGTGCGAAGGCGCTCCGACAACGCCGT
TTGAAAAGGGGCTGCTCTA GTACACCTGA 
HPLC 
PhlET21 
 
CGAATGCGCCGGATCCGTTGTTGCTGTTCCTCGGTGAGGTC
AAACTCCACGTCGTTGCTGTATCTCCAG 
HPLC 
PhlET22 
 
GAGGCCACGCTGGGGGCCCACCGCCACATCTGCTGAAGAG
AATGGTCGGGGAAGTTCCTATTCTCTAGAAAGTATAGGAA
CTTCTGCAGCAGCACGTGTTGAC 
HPLC 
PhlET23 
 
TCCGGCTGCACGACGGCCTCGTCGGCGTGGCGGACGCGCT
CTCTTCTTGAGAAGTTCCTATACTTTCTAGAGAATAGGAAC
TTCAAGCGCCGGTTCGTACGGCG 
HPLC 
PhlET28 
 
CGGCCCCCAGAAGTGAGGGTACTGCCCGGCGAACAGGGG
TGATTTAAATCCTGGTGTCCCTG 
HPLC 
PhlET29 
 
AGAACGCCAACGGGATCGACTGGCTCTGAATTCTCCGTGA
CCATGCCCATCAGAACCTTCCTACCAACCGGCACGATTGT
GCCCACAACAGCATCTTACGCCCCGCCCTGCCACTC 
HPLC 
Apra_for GTGCAATACGAATGGCGAAA DST 
Apra_rev TCAGCCAATCGACTGGCGAG DST 
ermE 
CPhl19_for 
GCCAGGCTTCTTGCCCATCT DST 
ermE 
CPhl19_rev 
ACGTGCGGCGTCCGCGCCGA 
 
DST 
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2.7.2.2 Primers used in the GE81112 project 
Table 2.12: Primers used in the GE81112 project 
Primer Sequence (5′→3′)  Purification 
Cyclo_14386_for AGCGCCAGGAGAGACCCTTG DST 
Cyclo_14386_rev GCGTGCAACTGGGTGACGGC DST 
Cyclo Probe_for CCCCGGGCCGGAACGCCATG DST 
Cyclo Probe_rev GAACGCCATGACCATGCGGG DST 
Tubz_up GGAGGTGGCCGTGCAGAGGATGTC DST 
TubZ_down CTGCACGCGCTGATGGATGAGGTC DST 
RapL_up GCGCGTCGGGCATCGGTGTG DST 
RapL_down CCTTGGGCAGCTCGGTCTTG DST 
Cyclo KO_for ACTGCAGAATTCGCGACGAACGCCCGCACCG DST 
CycloKO_rev TACTGAGAATTCGGTGCCTACGCCGGGCTC DST 
NRPS-A1-up CGGCTCCACCGGCACNCCNAARGGNG DST 
NRPS-H1-dn CGGCCGAGGTCGCCNGTNCKRTA DST 
RevA3 CCTCCGGSCCSACCGGSMCGCCSAAGG DST 
PSLGG 2000 GCCGCCSAGSCYGAAGAA DST 
BI11-T7end-2-for TGGAGCGTCAGGCGCATCCC DST 
BI11-T7end-2-rev GGACCGTCTTCACCGAGGCC DST  
pGEX_Cyclo_for_EcoRI CCTTGGGAATTCACAAGCCCTAACACTGAGCG DST 
pGEX_Cyclo_for_NotI GCCCGTGCGGCCGCTCACCGCCGCGCTCCCTG DST 
pET28_Cyclo_for_NdeI CCTTGGCATATGACAAGCCCTAACACTGAGCG DST 
pET28_Cyclo_for_BamHI GCCCGTGGATCCTCACCGCCGCGCTCCCTG DST 
BI11A1_pip_for CCGTACATATGCTCGTTCCTGCCGGAACCGG DST 
BI11A1_pip_rev CGCGGGGATCCCTACCGCGAGGCGTTCGAGT DST 
BI11A2_for GCCGCCATATGTCTCCCCGGCACCCGGTCGC DST 
BI11A2_rev GGTCAGGATCCCCGGCGCGGGGCGGGGTGCC DST 
BI11A3_for CCGACCATATGCCCTCGGTCCCGGTCGGCAG DST 
BI11A3_rev ACCGGGGATCCACGATCGAGCACCCGCGACC DST 
FD10_KO_for 
 
GCCAGTCAGCGACGGCCAGTGCGAGCGCGGC
GAGCAGCACGTCGTTGACAATTTAAATCCTGG
TGTCCCT 
HPLC 
FD10_KO_rev 
 
GCGTATGTGATTTATACGTCGGGTTCGACGGG
GCGGCCGAAGGGTGTGGTTTACGCCCCGCCCT
GCCACT 
HPLC 
Sonde BI11 SEQ1 CATGTTCGAGCTGTCCTTCC DST 
Sonde BI11 SEQ2     CAGGTCGGCCACCTCCAACG DST 
Sonde BI11 SEQ3    GCTGGACGCGAACCTGACGG DST 
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Primer Sequence (5′→3′)  Purification 
Sonde BI11 SEQ4 GCGCCCTGATCTCCTCCACGG DST 
Sonde BI11 SEQ5    TCGGGCAGTGCGTCGAGCATG DST 
Sonde BI11 SEQ6        GCCGTCCGCCGGAGACCTTG DST 
Sonde BI11 SEQ7 CATCAGCTCCCGGGTCGTGGT DST 
Sonde BI11 SEQ7_rev GTCAGCGCCACGACCGACGAC DST 
Sonde BI11 SEQ6_rev        ATGATCGCGAAGCGCGGCTGA DST 
Sonde BI11 SEQ5_rev    TCGGCGCGAGCGGCACCGGCC DST 
Sonde BI11 SEQ4_rev AGTTCTGGCGGGCCACCGAGG DST 
Sonde BI11 SEQ 3_rev  CCGCGTGCTGCAACTGCCTTC DST 
Sonde BI11 SEQ 2_rev  GGCGCGGGCGTTCGTCGCCGA DST 
T7 TAATACGACTCACTATAGGGC DST 
T4 CACCTGTGGCGCCGGTGATG DST 
LacZ1 CTTGGGCTGCAGGTCGAC DST 
LacZ2 GTGTGGAATTGTGAGCGG DST 
 
2.7.3 Plasmids 
2.7.3.1 General plasmids 
Table 2.13: General plasmids used in this work 
Plasmids Relevant characteristics Reference 
pSC101-BAD-γβαA-Apra ET cloning vector Genebridges 
pSC101-BAD-γβαA-Amp ET cloning vector Genebridges 
pCR2.1-TOPO 
Cloning vector, lacZα, t7 , f1ori, neoR, 
bla, pUC origin 
Invitrogen 
pKC1132 
Knockout vector for Streptomyces, oriT 
RK2, lacZα, aac(3)IV 
[10] 
pKC1139 
Knockout vector for Streptomyces, oriT 
RK2 lacZα, aac(3)IV,  ori psG5 
[10] 
pRK2013 Tn903, RK2   [76] 
pGEX-6-P-1 
Expression vector, for expression with N-
terminal GST Tag 
GE Healthcare 
pET28b(+) 
Expression vector, for expression with N-
terminal His Tag 
Novagen 
pOJ436 
Cosmid vector, oriT RK2 aac(3)IV,  λcos 
attP ØC31 
[10] 
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2.7.3.2 Plasmids used in the phenalinolactone project 
Table 2.14: Plasmids used in the phenalinolactone project 
Plasmids Vector Relevant characteristics 
CPhl7 pOJ436 ET cloning product, Cos 3-1O12 + zeocin resistance gene, apraR, zeoR 
CPhl8 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster 
containing the zeocin resistance gene and the oriT-tet-trpE 
cassette, apraR ,tetR, zeoR 
CPhl9 pOJ436 
ET cloning product, Cos 10-4D08 + oriT-tet-trpE cassette, 
tetR, apraR 
CPhl10 pOJ436 
ET cloning product, CPhl8 + Pm-promotor in front of the gene 
plaM2, tetR, apraR,cmR 
CPhl13 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster 
containing  loxP-kan-cassette, apraR, tetR, zero, kanR 
CPhl14 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster, 
knockout of plaP5, apraR, tetR, zero, kanR 
CPhl15 pOJ436 
ET cloning product, complete Phl biosynthetic gene cluster 
containing  loxP-kan-cassette, apraR, tetR, zero, kanR 
CPhl16 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster, 
knockout of plaP2, apraR, tetR, zero, kanR 
CPhl17 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster 
containing  frt-kan-cassette, apraR, tetR, zero, kanR 
CPhl18 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster, 
knockout of plaA6, apraR, tetR, zero, kanR 
CPhl19 pOJ436 
ET cloning product, complete PL biosynthetic gene cluster 
containing bidirectional ermE promoter in front of the genes 
plaM2 and plaO2 
Cos3-1O12 pOJ436 
Cosmid containing part of the PL biosynthetic gene cluster, 
apraR 
Cos10-4D08 pOJ436 
Cosmid containing part of the PL biosynthetic gene cluster,  
apraR 
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2.7.3.3 Plasmids used in the GE81112 project 
Table 2.15: Plasmids used in the GE81112 project 
Plasmids Vector  Relevant characteristics 
Cos FD10 pOJ436 
 Cosmid from Streptomyces 14386 cosmid library, 
pOJ436 backbone, apraR   
Cos AI6 pOJ436 
 Cosmid from Streptomyces 14386 cosmid library, 
pOJ436 backbone, apraR 
Cos BI11 pOJ436 
 Cosmid from Streptomyces 14386 cosmid library, 
pOJ436 backbone, apraR 
Cos BA23 pOJ436 
 Cosmid from Streptomyces 14386 cosmid library, 
pOJ436 backbone, apraR 
Cos EB22 pOJ436 
 Cosmid from Streptomyces 14386 cosmid library, 
pOJ436 backbone, apraR 
pKC1132_FD10 pKC1132 
 pKC1132 derivative containing an internal 1.3 kb 
fragment of NRPS from FD10, apraR 
pKC1132_AI6 pKC1132 
 pKC1132 derivative containing an internal 1.3 kb 
fragment of NRPS from AI6, apraR 
pKC1132_BI11
_PipA 
pKC1132 
 pKC1139 derivative containing an internal 0.6 kb 
fragment of  pipecolic acid incorporating A-
domain from BI11, apraR 
pKC1139_FD10 pKC1139 
 pKC1132 derivative containing an internal 1.3 kb 
fragment of NRPS FD10, apraR 
pKC1139_AI6 pKC1139 
 pKC1132 derivative containing an internal 1.3 kb 
fragment of NRPS AI6, apraR 
pKC1139_ 
BI11_PipA 
pKC1139 
 pKC1132 derivative containing an internal 0.6 kb 
fragment of  pipecolic acid incorporating A-
domain from BI11, apraR 
BI11-PipA-
Topo 
pCR2.1-TOPO 
 Topo derivative containing an internal 0.6 kb 
fragment of  pipecolic acid incorporating A-
domain from BI11, apraR 
Cyclo-pGEX pGEX6-P-1 
 pGEX-6P-1 derivative for expression of the 
cyclodeaminase gene with N-terminal GST Tag, 
ampR 
BI11A1 pET28b(+) 
 pET28b derivative for expression of  BI11 A1 
with N-terminal His tag, kanR 
BI11A2 pET28b(+) 
 pET28b derivative for expression of  BI11 A2 
with N-terminal His tag, kanR 
BI11A3 pET28b(+) 
 pET28b derivative for expression of  BI11 A3 
with N-terminal His tag, kanR 
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2.8 Streptomycetes 
2.8.1 Mutants of S. lividans TK24 
Table 2.16: Mutants of S. lividans TK24 generated in this work 
Mutant Relevant characteristics 
S. lividans TK24::CPhl8  
Integration of CPhl8 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::CPhl14 
Integration of CPhl14 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::CPhl16 
Integration of CPhl16 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::CPhl18 
Integration of CPhl18at the attP site for heterologous 
expression, apraR 
S. lividans TK24::CPhl19 
Integration of CPhl19 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::FD10 
Integration of FD10 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::BI11 
Integration of BI11 at the attP site for heterologous 
expression, apraR 
S. lividans TK24::BA23 
Integration of BA23 at the attP site for heterologous 
expression, apraR 
 
 
2.8.2 Mutants of S. coelicolor A3(2) 
Table 2.17: Mutants of S. coelicolor A3(2) generated in this work 
Mutant Relevant characteristics 
S .coelicolor A3(2)::CPhl8  
Integration of CPhl8 at the attP site for heterologous 
expression, apraR 
S .coelicolor A3(2)::CPhl14 
Integration of CPhl14 at the attP site for heterologous 
expression, apraR 
S .coelicolor A3(2)::CPhl16 
Integration of CPhl16 at the attP site for heterologous 
expression, apraR 
S .coelicolor A3(2)::CPhl18 
Integration of CPhl18 at the attP site for heterologous 
expression, apraR 
S .coelicolor A3(2)::CPhl19 
Integration of CPhl19 at the attP site for heterologous 
expression, apraR 
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2.8.3 Mutants of S. coelicolor M512 
Table 2.18: Mutants of S. coelicolor M512 generated in this work 
Mutant Relevant characteristics 
S .coelicolor M512::CPhl8 
Integration of CPhl8 at the attP site for heterologous expression, 
apraR 
S .coelicolor M512::CPhl14 
Integration of CPhl14 at the attP site for heterologous 
expression, apraR 
S .coelicolor M512::CPhl16 
Integration of CPhl16 at the attP site for heterologous 
expression, apraR 
S .coelicolor M512::CPhl18 
Integration of CPhl18 at the attP site for heterologous 
expression, apraR 
S .coelicolor M512::CPhl19 
Integration of CPhl19 at the attP site for heterologous 
expression, apraR 
 
2.8.4 Mutants of S. 14386 
Table 2.19: Mutants of S. 14386 generated in this work 
Mutant Relevant characteristics 
S. 14386::pKC1132_BI11_PipA Insertion of pKC1132_BI11_PipA in S. 14386 to create a knockout of the GE81112 cluster 
 
 
2.9 Cultivation and conservation of strains 
2.9.1 E. coli/Pseudomonas putida 
3 ml of sterile LB medium were inoculated with a few cells from a single colony and 
cultivated at 30 °C (Pseudomonas) or 37 °C (E. coli) at 180 rpm overnight. For storage at –80 
°C, 1 ml of the culture was mixed with 1 ml of 50% glycerol. To restart cultivation, a few 
cells from the frozen cultures were inoculated into fresh LB medium with an inoculating loop. 
Antibiotics were added to the growth medium as appropriate.  
 
2.9.2 Streptomycetes  
2.9.2.1 Spores 
1 ml of sterile 20% glycerol was added to a fresh well-sporulating plate. The surface of the 
culture was scraped vigorously with an inoculating loop to resuspend the spores. The crude 
suspension was then poured into a sterile falcon tube and diluted with 20% glycerol to obtain 
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a homogenous suspension. 1 ml of this spore suspension was then aliquoted into 1.5 ml 
eppendorf tubes and frozen at –20 °C.  
 
2.9.2.2 Mycelia 
A square from a well-sporulating plate was used for inoculation of 30 or 50 ml medium 
(typically TSB) as preculture. The primary growth cultures were inoculated 1:100 with the 
preculture, and incubated at 28 °C or 30 °C at 180 rpm. For storage at –80 °C, 1 ml of the 
culture was mixed with 1 ml of 50% glycerol. To restart cultivation, a few cells were 
inoculated on fresh agar plates.  
 
2.10 Isolation of prokaryotic DNA 
2.10.1  Isolation of genomic DNA 
Genomic streptomycetes DNA was isolated using the salting out procedure [10]. Mycelia 
from a 30 ml culture were harvested at 3000 rpm for 10 min. The mycelia were resuspended 
in 5 ml SET buffer, and then 100 µl lysozyme solution (1 mg/ml lysozyme in P-buffer) was 
added. The mixture was incubated at 37 °C for 30–60 min. 140 µl proteinase K solution (20 
mg/ml in H2O) was then added, and then the solution was mixed by inversion. 600 µl of 10% 
SDS was added and again the sample was mixed by inversion. The mixture was incubated at 
55 °C for 2 h. 2 ml 5M NaCl were added, and again mixed by inversion. After cooling to 37 
°C, 5 ml chloroform were added, and the sample was mixed by inversion for 30 min at 20 °C. 
The sample was then centrifuged for 15 min at 3000 rpm at room temperature. The 
supernatant was transferred to a fresh tube, 0.6 vol isopropanol were added, and then the 
sample was mixed by inversion. After ca. 3 min, the DNA could be spooled onto a sealed 
Pasteur pipette. The DNA was rinsed in ca. 2 ml 70% ethanol, air dryed and dissolved in 200 
µl H2O by heating at 55 °C.  
 
2.10.2  Isolation of plasmid and cosmid DNA by alkaline lysis 
An overnight culture of 1–3 ml of E. coli was harvested by centrifugation in 1.5 ml eppendorf 
tubes. The supernatant was removed and the pellet was resuspended in 250 µl buffer P1 + 
RNAse (100µg/ml). The cells were then lysed in 250 µl P2 (NaOH/SDS). The lysate was then 
neutralised by adding 250 µl potassium acetate. The samples were then centrifuged for 10 min 
at 13000 rpm. The plasmid DNA remained in the supernatant was precipitated with 600 µl 
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isopropanol. After 10 min of centrifugation at 13000 rpm, the DNA pellets were washed with 
700 µl 70% EtOH, air dryed, and then dissolved in 20 µl H2O. 
 
2.10.3  Isolation of plasmid DNA with the NucleoSpin® Plasmid Kit 
Isolation of plasmid DNA with the NucleoSpin® Plasmid Kit was performed according to the 
manufacturer’s instructions.  
 
2.11 Separation and purification of DNA 
A 0.8% agarose gel containing ethidium bromide (EtBr, ~0.25 μg/ml) was prepared and the 
DNA samples, prepared in 6× DNA loading dye, were loaded into the slots of the gel. A size 
standard (GeneRulerTM 1 kb DNA ladder, Fermentas) was used to determine the length of 
DNA samples from PCR or specific fragments from restrictions. Electrophoresis was 
performed in 1× TBE buffer with a voltage of approximately 10 V per cm gel length until the 
dye front reached the edge of the gel. DNA was visualized under UV light (245 nm) using a 
gel documentation (peqlab). 
 
2.11.1  Extraction of DNA from agarose gels 
After separation by gel electrophoresis, desired DNA fragments were excised from the gel 
under UV light. Extraction from the gel was carried out with the NucleoSpin® Extract Kit, 
according to the manufacturer’s protocol. 
 
2.11.2  DNA precipitation 
DNA dissolved in H2O was mixed with 1/10 vol 3M NaOAc solution. After addition of 1 
volume isopropanol, the sample was incubated 20 min at –20 °C. After centrifugation for 10 
min at 13000 rpm, the pellet was washed with 700 µl 70% EtOH, air dryed and redissolved in 
the desired volume of H2O. 
 
2.11.3  Phenol/chloroform extraction 
An equal volume of phenol/chloroform was added to the DNA sample, followed by vortexing. 
After centrifugation the upper aqueous phase was separated cleanly by decanting. Phenol was 
quantitatively removed by subsequent precipitation with isopropanol (see part 2.10.2). 
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2.12 Polymerase chain reaction  
For polymerase chain reaction or PCR different polymerases were used which are listed in 
Table 2.20. 
 
2.12.1  Composition of standard PCR setup 
Different annealing temperatures were tested for the PCR reactions 
 
Table 2.20: PCR protocols 
 Phusion-
Polymerase 
Triple Master 
Polymerase 
Hot Star Taq 
Polymerase 
Buffers 4  µl  
5× GC buffer or 
5× HF buffer 
5 µl 
10× Tuning buffer 
2.5 µl 
10× HST buffer 
MgCl2 (25 mM) – – 1.5 µl 
dNTPs  
(1.2 mM/dNTP) 
4 µl 8 µl 4 µl 
DMSO 0.6 µl – 0.75 µl 
Glycerol (50%) – – 4 µl 
Primers 1/2   
(50 pmol/µl) 
0.5 µl 0.5 µl 0.5 µl 
Polymerase 0.2 µl 0.3 µl 0.1 µl 
Template 0.5 µl 0.5 µl 0.5 µl 
Sterile water 10.2 µl 32.5 µl 10.65 µl 
Total volume 20 µl 50 µl 25 µl 
Temp. 98 °C 95 °C 95 °C Primary 
denaturation Time 30 min 3 min 15 min 
Temp. 98 °C 95 °C 94 °C Denaturation 
Time 8 s 1 min  20 s 
Temp. 60 °C 58 °C 58 °C Annealing 
Time 30 s 1 min 30 s 
Temp. 72 °C 72 °C 72 °C Extension 
Time 0.25 min/kb 1 min/kb 1 min/kb 
Temp. 72 °C 72 °C 72 °C Final 
extension Time 10 min 10 min 10 min 
Cycles 32 30 30 
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2.12.2  Colony PCR 
Cells were removed from an agar plate with an inoculating loop or 10 µl of cell suspension 
was taken from a liquid culture and transferred into an eppendorf tube containing 10 µl H2O. 
The cell mixture was then boiled at 95 °C for 10 min in an eppendorf thermomixer. 1 µl of 
this mixture was used as template in the PCR reaction. Hot Star Taq Polymerase was used for 
all colony PCRs following the protocol in Table 2.20. 
 
2.13 Enzymatic manipulation of DNA 
2.13.1  Restriction endonucleases 
Reactions were performed in a total volume of 20 µl containing 2 µl 10×buffer, 5 µl DNA, 
0.5µl restriction enzyme and 12.5 µl H2O. The restriction mix was incubated for 2–4 hours or 
overnight at 37 °C (or at other incubation temperatures recommended by the manufacturer). 
All restriction enzymes and corresponding buffers were purchased from Fermentas GmbH.  
 
2.13.2  Ligation 
Ligations were carried out in a total reaction volume of 10 µl, containing 1 µl vector, 7 µl 
insert DNA, 1 μl 10×ligation buffer and 1 µl T4 DNA ligase. The reaction was incubated 
overnight at 16 °C, and then heat-inactivated for 20 min at 65 °C (Thermomixer comfort) 
following verification of the successful ligation by agarose gel electrophoresis. 
 
2.13.3  Dephosphorylation 
Dephosphorylation was carried out within the restriction reaction. 1 µl shrimp alkaline 
phosphatase (SAP) was added to the restriction digestion. Incubation was carried out at 37 °C 
for 1 h. Heat-inactivation of the enzyme was then performed for 15 min at 65 °C.  
 
2.13.4  Cloning with TOPO-TA-Cloning kit 
Direct cloning of PCR products was carried out using the TOPO TA Cloning® kit 
(Invitrogen). TOPO TA Cloning® provides a highly efficient, 5-minute, one-step cloning 
strategy ("TOPO® Cloning") for the direct insertion of Taq polymerase-amplified PCR 
products into a plasmid vector. Taq polymerase has a nontemplate-dependent terminal 
transferase activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. The 
linearized vector supplied in this kit has single, overhanging 3´ deoxythymidine (T) residues. 
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This allows PCR inserts to ligate efficiently with the vector. If PCR reactions were carried out 
with other then Taq polymerase, addition of 3’ A-overhangs is needed. All reactions were 
performed according to the manufacturer’s protocol.  
 
2.14 Red/ET recombination 
For Red/ET recombination the target cosmid/plasmid was first electroporated into competent 
cells containing the Red/ET catalyzing plasmid GB2005/pSC101-BAD-γβαA-amp. Selection 
was carried out using ampicillin (50 µg/ml) and the appropriate antibiotic from the incoming 
target construct. Cells were grown at 30 °C overnight and used as preculture. 1.4 ml LB 
medium were inoculated with 30 µl of the cells and cells grown at 30 °C until an OD600 = 0.2 
was reached. Expression of Red/ET proteins was induced by adding 25 µl of 10% L-
arabinose. Further incubation was carried out at 37 °C until an OD600 = 0.4 was obtained. 
Cells were then harvested by centrifugation for 1 min at 13000 rpm and washed twice with 1 
ml chilled H2O. After the last washing step, the cells were resuspended in 30 µl H2O and 
electroporated with purified PCR product. Electropoartion conditions were as follows: 1350 
V, 10 µF, 600 Ohms. After electroporation, 1 ml pre-warmed LB was added and the cells 
were cultivated for 1 h at 37 °C without antibiotic. The cells were then plated out on LB-agar 
containing the appropriate antibiotics. Recombination products were checked by restriction 
digest with several enzymes (selected on the basis of in silico digests of the expected 
products).  
 
2.15 Transformation of bacteria 
2.15.1  Electroporation of E. coli 
To obtain electrocompetent cells, cells were grown at 37 °C to an OD600 = 0.6–0.8 in 1.5 ml 
Eppendorf tubes. The cell suspension was then centrifuged and washed twice with chilled 
H2O. Cells were then resuspendend in 30 µl H2O and used for electroporation with a 0.1 cm 
cuvette. Electroporation parameters were as follows: 1250 V, 10 µF, 600 Ohms, and the 
expected time constant was 5 ms. After electroporation, 1 ml of pre-warmed LB was added 
and the cells were cultivated for 1 h at 37 °C without antibiotic. The cells were then plated out 
on LB-agar containing the appropriate antibiotics.  
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2.15.2  Conjugation of streptomycetes with E. coli 
Electrocompetent cells of E. coli ET12567/pUZ8002 grown in the presence of kanamycin 
(kan) (25 µg/ml) and chloramphenicol (cm) (25 µg/ml) to maintain selection for pUZ8002, 
were prepared as described previously (2.15.1). The competent cells were transformed with 
the oriT-containing vector, and selected for the incoming plasmid only. A colony was 
inoculated in 1 ml of LB-medium containing cm and kan and the antibiotic used to select for 
the oriT-containing plasmid, and grown overnight. The overnight culture was diluted 1:100 in 
fresh LB containing antibiotics, and grown at 37 °C to an OD600 of 0.4–0.6. The cells were 
washed twice with an equal volume of LB and resuspended in 0.1 volume of LB. During the 
washing of the E. coli cells, for each conjugation approximately 108 Streptomyces spores were 
added to 500 µl 2YT broth, heat shocked at 50 °C for 10 min and then cooled. 500 µl E. coli 
cells were then added to 500 µl of the heat-shocked spores or mycelial fragments. The 
mixture was spun briefly and most of the supernatant was poured off. The pellet was then 
resuspended in the residual liquid. The cells were plated out on SM agar plates without 
antibiotic. After 16–20 h incubation at 30 °C, cells were scraped from the plate and 
resuspended in 500 µl LB medium. The mixture was then plated in different dilutions on SM 
agar plates containing nalidixic acid (25 µg/ml) and apramycin (60 µg/ml). Incubation at 30 
°C was continued until the appearance of potential exconjugants.  
 
2.15.3  Protoplast transformation 
25 ml YEME medium were inoculated with 0.1 ml spore suspension and incubated for 36–40 
h in a 30 °C shaker at 180 rpm. Cultures of S. lividans and S. coelicolor were poured into a 50 
ml falcon tube and centrifuged for 10 min at 1000×g. The supernatant was discarded and the 
pellet was resuspended in 15 ml of 10.3% sucrose. After 10 min of centrifugation, the 
supernatant was again discarded and the washing step was repeated. The mycelia were 
resuspended in 4 ml lysozyme solution (1 mg/ml in P-buffer) and incubated at 30 °C for 15–
60 min. 5 ml P-buffer were added and the protoplasts were sedimented gently by spinning at 
1000×g for 7 min. The supernatant was discarded and the protoplasts were resuspended in 1 
ml P-buffer. 300 µl PEG (sterile filtered) were mixed with 900 µl P-buffer. 400 µl of this 
solution were mixed with 100 µl of the freshly-prepared protoplasts and 10 µl DNA. Dilutions 
of this mixture were plated out on R2YE agar plates, and the plates incubated at 30 °C. After 
16–20 h, the plates were overlaid with 1 ml H2O containing 1 mg/ml apramycin. Resistant 
colonies typically appeared after 3 days. 
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2.16 Construction of a cosmid library from Streptomyces 14386 
This method was used to clone large genomic DNA fragments (35–45 kb) into cosmid vectors 
[77] using phage transfection. 
 
2.16.1  Preparation of the ligation reaction 
Genomic DNA of Streptomyces 14386 (see part 2.10.1) was partially digested with Sau3A. 
After separation by gel electrophoresis, fragments showing an average size between 35 and 45 
kb were pooled and extracted with phenol/chloroform (2.11.3) and precipitated. The DNA 
was subsequently dephosphorylated (2.10.3) and extracted with phenol/chloroform again. The 
aqueous phase was later precipitated together with the vector pOJ436. 
The E. coli/Streptomyces shuttle vector pOJ436 was digested with the restriction 
endonuclease PvuII and subsequently dephosphorylated with SAP. The DNA was extracted 
with phenol/chloroform and precipitated. The vector was subsequently digested with BamHI, 
extracted with phenol/chloroform again and precipitated together with the partially-digested 
genomic DNA.  
 
2.16.2  Ligation and phage infection  
The precipitated DNA pellet from 2.16.1 was resuspended in 15 µl H2O and ligated at 16 °C 
(2.13.2). The DNA was precipitated again and resuspended in 20 µl H2O. 4 µl from the 
ligation reaction were mixed with the GigapackIII Gold Packaging Extract (Stratagene), 
incubated for 1.5 h at room temperature and subsequently mixed with 500 µl SM-buffer and 
50 µl chloroform. The mixture was centrifuged briefly and stored at 4 °C. 
In parallel E. coli SURE was grown in LB medium supplemented with 10 mM Mg2SO4 and 
0.2% maltose, until an OD600 = 0.7 was reached. Various amounts of packaging extract were 
then mixed with E. coli SURE as follows:     
2 µl packaging extract + 23 µl SM buffer + 25 µl E. coli SURE 
5 µl packaging extract + 20 µl SM buffer + 25 µl E. coli SURE 
10 µl packaging extract + 15 µl SM buffer + 25 µl E. coli SURE 
 
The mixtures were incubated for 30 min at 37 °C. 200 µl LB were then added and incubation 
was continued at 37 °C while shaking 2 h at 165 rpm. The cells were plated out on LB agar 
containing 60 µg/ml apramycin. The titer of the packaging extract was determined through 
counting the colonies. Typically, 2 µl of packaging extract yielded 2275 colonies. 
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2.16.3  Generation of the cosmid library  
To obtain a 10-fold coverage from an estimated genome size of 8 Mbp, ca. 2000 cosmid 
clones were needed. In order to ensure that enough clones were obtained, 5 µl packaging 
extract were used and prepared as described in 2.16.2. After incubation, the cells were plated 
on LB agar containing 60 µg/ml apramycin in 22 cm × 22 cm NUNC plates (Nalgene). The 
plates were incubated at 32 °C overnight and the colonies were picked using the Qbot-robot 
(Gentrix) in the Department of Genome Analysis at the Helmholtz-Centre for Infection 
Research in Braunschweig in six 384-well microtiterplates containing 50 µl 2YT medium (60 
µg/ml apramycin).  
 
2.16.4  Robotically produced high-density colony arrays 
The plates were incubated at 37 °C overnight and the growing colonies were spotted with the 
Qbot-robot (Gentrix) on fresh NUNC-LB-agar plates (60 µg/ml apramycin) which were 
covered with a 22 cm × 22 cm nylon membrane. 50 µl freezing solution (Table 2.6) was 
subsequently added to each well of the microtiter plates were subsequently amended with 50 
µl freezing solution (2.4.1) and frozen at -80 °C.  
.  
Altogether 12 membranes were spotted with the complete cosmid library. To enable an 
explicit assignment of the transferred colonies to the six 384er microtiterplates each colony of 
the microtiterplates was spotted twice in a definend 4x4 array (Figure 2.1). 
 
Figure 2.1: Spotting array of the high-density colony filters. 
 
The NUNC-LB-agar plates with the nylon membranes were incubated at 32 °C for 16–20h. 
For the subsequent lysis of the cells, the membranes were processed as follows: Whatman 
paper was soaked with denaturation solution, neutralization solution and 2× SSC solution 
(Table 2.4). The membranes (bottom side) were transferred onto the Whatman paper, initially 
using denaturation solution. After 15 min incubation, the membranes were briefly transferred 
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to dry Whatman paper in order to remove remaining denaturation solution. Subsequent 
incubation in neutralization solution (15 min) and 2× SSC (10 min) was carried out, followed 
by drying of the membranes on fresh Whatman paper. The colonies were fixed on the 
membranes through incubation at 80 °C for 2 h. The membranes were treated with 14 ml 
Proteinase K solution (2 mg/ml) for 1 h at 37 °C. To remove cell debris, the membranes were 
treated with H2O soaked tissues. After drying at room temperature, the processed membranes 
could be used for hybridization. 
 
2.17 DNA Hybridization 
2.17.1  Southern Blot  
5 µg genomic DNA were digested with different restriction enzymes (2.13.1) and separated 
by gel electrophoresis (2.11). After gel documentation, the gel was depurinated for 10 min in 
0.25 M HCl, with gentle shaking. The gel was subsequently incubated twice for 20 min in 
denaturation buffer (Table 2.4) and neutralization buffer (Table 2.4) at room temperature. 
After treatment of the gel, the DNA was blotted onto a membrane by vacuum blot.  
 
2.17.2  Vacuum Blot 
The membrane placed onto Whatman paper soaked with 10× SSC (Table 2.4) on the vacuum 
blotter, in order to prevent the formation of air bubbles. A plastic mask was placed on the 
membrane leaving a window for placing the gel onto it. The gel was placed onto the 
membrane and the vacuum pump was switched on to immobilize the gel onto the membrane. 
The vacuum blot chamber was filled with 10× SSC and blotting was carried out for 90 min, 
with a vacuum of 5 mm Hg.  
 
2.17.3  Generation of DIG-labeled probes 
For the generation of DIG-labeled probes the ‘DIG PCR labeling mix’ from Roche was used. 
Digoxigenin labeled desoxynucleotides were employed in a standard PCR reaction (2.12). 
The obtained probe was stored at –20 °C, until it was used for hybridization.  
 
2.17.4  Hybridization and detection with the DIG labeling system 
The DIG systems protocol from Roche was used. The membrane was pre-hybridized in 
hybridization buffer for 2 h at 42 °C. The DIG labeled probe was denaturated for 10 min at 95 
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°C and directly cooled on ice. The probe was then added to the hybridization buffer to obtain 
a final concentration of DIG labeled probe of 7.5–15 ng/ml. The pre-hybridization solution 
was removed and fresh hybridization buffer containing the DIG-labeled probe was added to 
the membrane. Hybridization was performed at 42 °C overnight. Non stringent hybridization 
(heterologous) was performed at 38–40 °C. After hybridization, the membrane was washed 
twice with 2× SSC washing buffer (Table 2.4) at room temperature, followed by stringent 
washing with 0.5× SSC (Table 2.4) at 68 °C (58 °C for colony hybridization). The membrane 
was subsequently equilibrated in maleic acid buffer (Table 2.4) for 10 min and then incubated 
with blocking solution (Table 2.4) for 30 min at room temperature. DIG antibody (Anti 
digoxigenin-AP conjugate, Fab fragment) was added to fresh blocking solution (1:10000) and 
the membrane was incubated for 30 min in this solution. The membrane was then washed 
twice with maleic acid buffer for 15 min. The membrane was then briefly equilibrated with 
detection buffer (Table 2.4) (5 min) and subsequently covered with CDP-Star solution 
(Roche) (1 ml/100 cm2). After 1 min of incubation, the membrane was shrink-wrapped and 
the chemoluminescence was detected by gel documentation (Peqlab).  
 
2.17.5  Stripping of membranes 
Membranes were treated with stripping buffer (Table 2.4) for 20 min at room temperature. 
After a brief equilibration in 2× SSC, the membranes were either used again for hybridization 
or stored at –20 °C. 
 
2.17.6  Colony Hybridization 
Hybridization of the high-density colony filters from S. 14386 was carried out with the DIG 
system from Roche as described in 2.17.4.  
 
2.17.7  Analysis of DNA- and protein sequences 
Sequence data were analyzed with the program Vector NTI (InforMax). Additional programs 
for sequence analysis were freely accessible via the internet.  
BLAST    http://www.ncbi.nlm.nih.gov/blast/  
Frame  plot    http://www.nih.go.jp/~jun/cgi-bin/frameplot.pl  
PKS/NRPS Analysis   http://www.tigr.org/jravel/nrps/  
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ClustalW    http://www.ebi.ac.uk/clustalw/  
PFAM     http://www.sanger.ac.uk/Software/Pfam/search.shtml 
Npbiogene    http://www.npbiogene.com/ 
NRPS predictor  http://www-ab.informatik.uni-tuebingen.de/toolbox/  
    index.php?view=domainpred 
2.18 Protein and enzymatic analysis 
Different proteins from the GE biosynthetic gene cluster were overexpressed as GST- or His-
tagged fusion proteins for biochemical characterization. The genes were cloned into the 
expression vectors pGEX-6P-1 (N-terminal GST-tag) or pET-28b(+) (N-terminal His-tag) 
(Table 2.13). The genes are expressed under the control of IPTG-inducible promoters (T7 
promoter in the pET system, Ptac promoter in the pGEX system). The pET-28b(+) plasmid 
carries kanamycin resistance, the pGEX-6P-1 plasmid ampicillin resistance. The genes were 
cloned into the expression vectors, sequenced and transformed into E. coli BL21(DE3) or E. 
coli Rosetta BL21 (DE3) pLysS/pRARE. 
 
2.18.1  Cultivation and cell disruption 
A single colony of E. coli BL21 or E. coli Rosetta BL21 (DE3) pLysS/pRARE containing the 
plasmid with the expression vector construct was used for inoculation of a LB culture (with 
the appropriate antibiotic). This preculture was grown overnight and used to inoculate the 
expression culture (1:100 dilution). The culture was then grown until an OD600 = 0.8 at 30 °C 
and 180 rpm, and then induced with IPTG to a final concentration of 0.1 M. Incubation was 
continued at 16 °C overnight, or at 30 °C for additional 2 h. Cells were harvested by 
centrifugation for 10 min at 10000 rpm and were resuspended in an appropriate buffer (e.g. 
PBS buffer or binding buffer for Äkta-purification) (Table 2.5)). All further steps were carried 
out on ice or at 4 °C.  
To check for the presence of soluble protein, 1 ml of the cell culture was centrifuged, 
the pellet was resuspended in 100 µl BugBuster® Protein Extraction Reagent (Novagen) and 
then the mixture was incubated for 20 min at room temperature. The cell lysate was then 
centrifuged for 10 min at 4 °C and 10 µl of the supernatant and the remaining pellet were 
analyzed by SDS-PAGE. If the protein was soluble, the residual culture was used for cell 
disruption at larger scale. For this, the cells were lysed using a French press at 700 psi 
(typically two passages). E. coli Rosetta BL21 (DE3) pLysS/pRARE strains were induced to 
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carry out self-lysis by freezing and thawing, which caused the production of lysozyme. In this 
case, the cell lysate was centrifuged for 45 min at 10000 rpm, and the remaining supernatant 
was used for further purification.  
 
2.18.2  Protein purification 
2.18.2.1 GST-tagged proteins 
GST fusion proteins were purified using GST MicroSpin columns (GE Healthcare). The 
lower caps were removed from the columns, and each column was placed into a clean 2 ml 
eppendorf tube and spun for 1 min at 3500 rpm. The flow-through was discarded and the 
lower caps were replaced. 600 µl of the cell lysate (see part 2.18.1) were applied to the 
column. The columns were recapped at the top and mixed gently by inversion for 20 min at 
room temperature. The top and bottom caps were removed and each column was placed into a 
clean 2 ml eppendorf tube. The tube was centrifuged for 1 min at 3500 rpm to collect the 
flow-through. Each tube was placed into a new eppendorf tube and 600 µl 1× PBS wash 
buffer was applied to each column. This step was repeated once. 150 µl cleavage buffer 
containing 10 µl PreScission (GE Healthcare) protease were then added to the column and the 
top and bottom caps were replaced; the column was then incubated at 4 °C overnight. On the 
following day, the columns were placed into eppendorf tubes and the eluate containing the 
protein without GST tag was collected and checked using SDS-PAGE.  
 
2.18.2.2 His-tagged proteins 
Prepacked HisTrap™ HP columns were used for preparative purification of histidine-tagged 
recombinant proteins by immobilized metal ion affinity chromatography (IMAC) on the Äkta 
prime. 15 ml protein lysate were filtered through a sterile filter and loaded onto the 1 ml 
HisTrap column. Purification was performed as recommended in the GE Healthcare manual 
(HisTrap HP, Instructions 71-5027-68 AF). The following gradient was applied: 
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Table 2.21: Imidazol gradient applied for Äkta system.  
Volume [ml] Eluent A: binding buffer [%] Eluent B: elution  buffer [%] 
20 100  0  
40 100  0  
60 100  0  
70 88  12  
80 80  20  
90 60  40  
100 40  60  
110 0  100 
Pressure limit: 0.55 MPa; Flow 1ml/min 
 
To check the fractions for the presence of protein, 150 µl of each fraction were precipitated 
with an equal volume of acetone at –20 °C for 20 min. After centrifugation, the precipitated 
protein pellet was resuspended in 10 µl of 4× protein loading buffer and analyzed by SDS-
PAGE.  
 
2.18.3  Bradford assay 
Bradford assays were carried out according to the manufacturer’s manual (Biorad). In each 
case, a standard curve was measured with bovine serum albumin (BSA).  
 
2.18.4  Protein concentration by centrifugation 
Concentration of protein extracts was performed using Amicon Ultra-30 K centrifugal filters 
(Millipore), according to the manufacturer’s instructions. The nominal molecular weight limit 
(NMWL) of the filters was 30,000 Da.  
 
2.18.5  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis, is a technique to 
separate proteins according to their molecular weight [78]. The following proteins markers 
were applied for size determination:  
Marker PageRuler™, Fermentas: 10, 15 25, 30, 40, 50, 60, 70, 80, 100, 120, 170 kDa 
Marker PageRuler™ Prestained, Fermentas : 10, 15 25, 35, 40, 55, 70, 120, 170 kDa 
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2.18.5.1 Preparing of SDS gels and electrophoresis 
For detection of proteins, a 10% separating and a 5% stacking polyacrylamide gel were 
prepared. Ca. 20 µg protein was loaded into each lane of the gel. The protein samples were 
mixed with 10 µl of 4× protein loading buffer and boiled for 10 min at 95 °C. After loading 
the protein sample and a prestained protein marker (Fermentas) onto the gel, electrophoresis 
was performed in 1× running buffer at 100 V. Electrophoresis was stopped when the 
bromophenol blue front reached the edge of the gel (approximately 1.5 h).  
 
10% Separating gel: 
H2O     5.9 ml  
30% Bis-/Acrylamide mix  5  ml  
1.5 M Tris (pH 8.8)   3.8 ml  
10% SDS     150 µl 
10% APS    150 μl  
TEMED    6 μl  
The solution was poured between two glass plates, overlaid with isopropanol and allowed to 
polymerize. 
 
5% Stacking gel: 
H2O     7 ml  
30% Bis-/Acrylamide mix  1.7  ml  
1.5 M Tris (pH 6.8)   1 ml  
10% SDS     100 µl 
10% APS    100 μl  
TEMED    10 μl  
 
The solution was poured onto the separating gel and allowed to polymerize. 
 
2.18.5.2  Detection of protein bands 
Protein gels were stained with Coomassie Brilliant Blue. The staining solution contained 
methanol/acetic acid/water (10:10:80) and 1% Coomassie Brilliant Blue R250 (Roth). 
Staining was carried out for 1–2 h, or was accelerated by heating the gel in the microwave for 
Material and Methods 53 
 53
a couple of seconds. Destaining was performed in the same mixture without Coomassie. Gel-
Dry™ Drying Kit (Invitrogen) was used to conserve gels. 
 
2.18.6  Protein identification by MALDI-MS 
The desired protein band was excised from the SDS-PAGE gel and washed three times with 
water. 500 µl of a 50% acetonitrile (ACN) mixture in H2O were added until the gel piece was 
destained. The gel piece was then air dried and 500 µl ACN were added for 10 min. The gel 
piece was air dried again and 20 µl trypsin were added to each sample. After complete 
rehydration of the gel piece, 20 µl 40 mM NH4HCO3 were added and the gel piece was 
incubated overnight. TFA was added to a final concentration of 0.1%. The sample was then 
stored at –20 °C prior to analysis by MALDI-MS.  
 
2.18.7  Cyclodeaminase assay 
To determine the cyclodeaminase acitivity one millimole L-or D-Lysine was incubated at 30 
°C with 10 µM protein, 5 mM Tris (pH 8.0), 1 mg/ml BSA, and 100 µM NAD+. H2O was 
added at a total volume of 100 µl and the reaction was incubated for 16 h. The reaction was 
quenched with two reaction volumes of acetonitrile, stored at -20 °C for at least 10 min and 
spun at 13000 rpm for 10 min. The supernatant was vacuum-dried and solved in 200 µl borate 
buffer and used for derivatization. 
For derivatization, the reactant solution constisted of FMOC-Cl dissolved in acetone (1.5 
mg/ml). Two hundred microliters of FMOC solution was added to the 200 µl of the 
reaction/borate buffer mixture and incubated 10 min at room temperature. Termination of the 
reaction and removal of excess reagent (Fmoc-Cl), its hydrolysis product FMOC-OH, and 
acetone were performed by extraction with 600 µl hexane. After two additional extractions, 
400 µl 25% acetonitrile in 0.1 M borate buffer was added. A 50 µl aliquot of the diluted 
sample was injected into the HPLC system. FMOC-derivatized compounds were separtated 
with a standard gradient (see section 2.10.1.). The peak corresponding to FMOC pipecolic 
acid was detected with a mass of m/z = 571.2 [M-H]–. 
 
2.18.8  ATP-PPi exchange assay 
This assay was carried out in order to determine the substrate specificity of adenylation 
domains. Therefore 2 µM protein, 5 µl dATP (40 mM), 10 µl 10× buffer and 5 µl amino acid 
(40 mM) were mixed together. The reaction was started by addition of 0.1 µCi [32P]-
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pyrophosphate (Perkin Elmer). Incubation was done for 30 min and the reaction was stopped 
by the addition of 500 µl stop-mix. After centrifugation for 1 min at 13000 rpm the pellet was 
washed twice with 1 ml 0.1M wash buffer (Table 2.5). The charcoal pellet was then 
resuspended in 0.5 ml H2O. 3.5 ml scintillation fluid was then added to the mixture and the 
radioactivity was determined by scintillation counting. 
 
2.19 Analysis of secondary metabolites in natural producer strains and 
recombinant Streptomyces strains 
Streptomyces strains used in this work were Streptomyces Tü6071 [66], S. lividans TK24 [72], 
S. coelicolor A3(2) [11], S. coelicolor M512 (ΔredD, ΔactII-ORF4 SCP1–SCP2–) [73] and 
Streptomyces 14386 [67] (Table 2.10). For production and heterologous expression of 
secondary metabolites different cultivation conditions were used for the different strains.  
 
2.19.1  Cultivation in production medium 
2.19.1.1 Phenalinolactones 
For phenalinolactone production, the cultures were cultivated under standard conditions at 28 
°C and 180 rpm on a rotary shaker, and harvested after 6–8 days by centrifugation. NL111 
(Table 2.8) liquid medium was used for production. Precultures were grown in the same 
medium and used to inoculate production cultures (1:100 dilution). Studies on the 
optimization of PL production were performed under standard cultivation conditions in 
NL111 medium, but with growth at 37 °C and also in NBG, SM and INA5 medium.  
Apramycin (60 µg/ml) was used for cultivation of recombinant Streptomyces strains. 
 
2.19.1.2 GE81112 
Precultures were grown in V6 medium and used to inoculate production cultures (1:100 
dilution). INA5 or T6 (Table 2.8) production medium was used for production of GE81112. 
The cultures were maintained at 30 °C and 180 rpm on a rotary shaker and harvested after 6–8 
days. Apramycin (60 µg/ml) was used for cultivation of recombinant Streptomyces strains. 
 
2.19.2  Feeding experiments 
Precultures were grown in V6 medium at 30 °C for 3 days and then used to inoculate a 50 ml 
production culture in T6 medium (1:100 dilution). Stock solutions of deuterium-labeled L- 
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and D-pipecolic acid and uniformely labeled (U13C) L-histidine (500 mM) were prepared and 
introduced into the cultures after 72, 96, 120, 144 and 168 h, to a final concentration of 1 mM. 
Cells were harvested after 196 h. As a control, the same cultivation was performed without 
feeding of labeled substances. 
 
2.19.3  Extraction 
After cultivation in production medium, the cells were harvested by centrifugation at 5000 
rpm for 10 min. The culture supernatant was extracted twice with ethyl acetate. The solvent 
was then removed by evaporation, redissolved in methanol (1% of the original culture 
volume) and centrifuged for 10 min. The supernatant was transferred to a fresh vial. The cell 
pellet was extracted with a mixture of acetone/methanol (1:1). The solvent was then removed 
by evaporation redissolved in methanol (1% of the original culture volume) and centrifuged 
for 10 min. The supernatant was transferred to a fresh vial.  
 
2.19.4  Purification of GE compounds 
The GE81112 producer S. 14386 was cultivated at 30 °C in 5 L baffled shake flasks at 180 
rpm in GE production medium (see part 2.19.1.2). 13 L were harvested after 6 days of 
cultivation. Cells were extracted with acetone/methanol (1:1) and the supernatant was 
extracted with ethyl acetate (1:1), as described in 2.19.3. HPLC-MS analysis revealed that the 
desired compounds could only be found in the supernatant. 13 L of supernatant were then 
extracted twice with ethyl acetate (1:1). After evaporation of the solvent, the extract was 
resuspended in methanol and extracted with heptane (1:1). The extract was then fractionated 
by preparative RP-HPLC (Dionex P680 HPLC equipped with a PDA-100 Photodiode Array 
Detector; Waters xBridge™ Prep C18  column (5µm OBD™ 19 × 100 mm)) using a stepwise 
gradient, (0–2 min, 10% acetonitrile; 2–30 min, 10–95% acetonitrile; 10 ml/min; detection at 
280 nm; injection volume, 250 µl) coupled to a mass spectrometer (Bruker HCTplus ion trap, 
operating in positive-ionization mode at a scan range of m/z 100–1100).  
Fractions were checked by HPLC-MS analysis, and combined when they contained the 
desired compounds. The solvent was evaporated, and the compounds were further enriched by 
gel permeation chromatography (Sephadex LH-20 in methanol). Pure compound was obtained 
by sequential RP-HPLC using a stepwise gradient (solvent B: acetonitrile containing 0.01% 
formic acid, 0–10 min, 30% B; 10–20 min, 30–50%; 20–25 min, 50–95% B; 25–27 min, 
95%B, injection volume 200 µl).  
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2.19.5 Analysis of the secondary metabolites 
2.19.5.1  HPLC-UV/Vis, HPLC-MS, HPLC-MS/MS, LTQ-Orbitrap-MS 
10 μl of the extracts (see part 2.19.3) were analyzed by HPLC-MS analysis. Analysis was 
carried out using an Agilent 1100 series solvent delivery system equipped with a photodiode 
array detector and coupled to a Bruker HCTplus ion trap mass spectrometer. Chromatographic 
separation was carried out on a Nucleodur C18/3 µm RP column (125 × 2 mm; Macherey & 
Nagel) equipped with an C18/5 precolumn (8 × 3 mm) using a mobile phase system 
consisting of H2O (A) and acetonitrile (B), each containing 0.1% formic acid. The following 
gradient was applied: 0–2 min, 25% B; 2–22 min linear from 25–95 %B; 22–24 min isocratic 
at 95% B. Detection was carried out in negative or positive ionization mode at a scan range of 
m/z = 100–1100.  
 Phenalinolactones were identified by comparison to the retention times (rt) and the MS 
data of authentic standards (phenalinolactone A: rt = 13.5 min, [M–H]– = 714.5; 
phenalinolactone D: rt = 18.1 min, [M–H]– = 698.3) in negative ionization mode. 
Phenalinolactone E was identified by comparison to the retention times and the MS data of 
phenalinolactone D (phenalinolactone E: rt = 13.0 min, [M–H]–  = 570.3). LC-coupled FT-
Orbitrap-MS analysis was carried out with an Accella UPLC system (Thermo Electron 
Corporation) coupled to a LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific) 
operating in negative or positive ionization mode at a scan range of m/z 100–2000. A Hypersil 
Gold column (2.1 × 50 mm; Thermo Fisher Scientific) was used for separation with a solvent 
system consisting of H2O (A) and acetonitrile (B), each containing 0.1% formic acid. A 
gradient of 5–95 % B was applied over 10 min. Measurements were carried out in single ion 
mode (SIM). GE8112 compounds were identified by comparison to the retention times (rt) 
and the MS data of authentic standards (GE factor A: [M+H]+ = 644.21858; GE B: [M+H]+ = 
659.22953 and GE factor B1: [M+H]+ = 658.2458760) in the negative ionization mode. 
 
2.19.5.2 NMR 
The structure of the isolated compounds 631, 645 and 659 were elucidated by using 1D (1H-, 
13C-NMR) and 2D NMR analysis (1H-1H-COSY, HSQC heteronuclear sequential quantum 
coherence, HMBC heteronuclear multiple bond correlation) on Bruker DRX 500 or Bruker 
Advance 500 spectrometers using several solvents ([d6]DMSO and CD3OD). Calculation of 
theoretical NMR-spectra was performed with ACD/Labs 7.00 software. 
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3 Results 
3.1 Heterologous expression and genetic engineering of the phenalinolactone 
biosynthetic gene cluster using Red/ET recombineering  
3.1.1 Goals 
The aim of the thesis was the development of heterologous expression techniques for complex 
secondary metabolite pathways from streptomycetes using Red/ET recombineering. The 
biosynthetic gene cluster which was chosen for this work was the phenalinolactone 
biosynthetic gene cluster from Streptomyces Tü6071. The gene cluster was already cloned and 
sequenced in the group of Andreas Bechthold from Freiburg University, from whom the strain 
was obtained. As the complete gene cluster was located on two different cosmids, we aimed 
in the first step to reconstitute the complete PL biosynthetic pathway on one expression 
construct using Red/ET recombineering. After the successful cloning, we planned to express 
the pathway in different heterologous host strains such as pseudomonads and streptomycetes. 
The successful heterologous expression would then open the door for generation of novel 
analogues by genetic engineering. 
 
3.1.2 Reconstitution of the complete pla biosynthetic gene cluster 
We employed Red/ET recombineering in E. coli [36-38] to rebuild the entire pla biosynthetic 
pathway on an integrative E. coli-Streptomyces shuttle vector (pOJ436), and to introduce 
additional genetic elements for heterologous expression in pseudomonads and streptomycetes. 
 
3.1.2.1 Cloning strategy 
The biosynthetic gene cluster comprises 11 transcriptional units harboring 35 genes. Two 
pOJ436-derived cosmids (Cos3-1O12 and Cos10-4D08 [66]) containing overlapping regions 
of the pla gene cluster were used as starting points. The cloning strategy is described in Figure 
3.1, and consists of three different cloning steps that are each discussed in detail below.  
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Figure 3.1: Description of the cloning strategy. 
The phenalinolactone biosynthetic gene cluster consists of 35 orfs, and was located on two 
overlapping cosmids (Cos3-1O12 and Cos10-4D08) carrying the pOJ436 backbone. In the first 
step, a ScaI-oriT-tet-trpE cassette was inserted via Red/ET recombineering into Cos10-4D08 at 
the upstream end of the gene cluster, generating the construct CPhl9. In the next step, 
introduction of the zeocin resistance gene at the downstream end of the cluster led to the 
construct CPhl7. After restriction digest of CPhl9 with ScaI, the resulting 15 kb fragment was 
used to reassemble the whole cluster using Red/ET recombineering. The final expression 
construct containing the whole cluster was designated CPhl8.  
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3.1.2.2 Cloning step 1:  introduction of the ScaI-oriT-tet-trpE box at the 5′-end of the 
pla biosynthetic gene cluster 
Cos10-4D08 was modified by insertion of a gene cassette into the upstream end of the pla 
gene cluster, to generate construct CPhl9. In addition to a ScaI restriction site and a 
tetracycline (tet) resistance gene, the introduced cassette also contained an oriT as well as a 
portion of the trpE gene from Pseudomonas putida which should in future enable the transfer 
of the expression construct into pseudomonads. The oriT was needed for conjugation and the 
trpE gene for integration into the Pseudomonas putida genome. This step also resulted in the 
deletion of orfs 1–3, which we expected not to be involved in PL biosynthesis. The ca. 4 kb 
gene cassette was amplified by PCR from template CMch37 [35] which contained the oriT-
tet-trpE box. The primers PhlET10 and PhlET11 that were used in the PCR contained three 
homology arms in total (H1, H2 and H3). Homology arms 1 and 2 were used to enable the 
integration of the oriT-tet-trpE box into Cos10-4D08, via double homologous recombination 
(Figure 3.2) 
 
Figure 3.2: Red/ET Cloning step 1. 
Integration of oriT-tet-trpE box into cosmid 10-4D08 via double homologous recombination 
resulted in the construct CPhl9. H1, H2 and H3: homology arms 1, 2, and 3 
 
Homology arm 3 and the ScaI restriction site were needed for the subsequent cloning steps. 
Selection for correct recombinant mutants was carried out on LB-agar containing tetracycline 
(12.5 µg/ml) and apramycin (60 µg/ml). To confirm the individual cloning steps, each of the 
constructs generated by recombination was digested with a diagnostic set of restriction 
enzymes (Figure 3.5). 
Results 60 
 60
3.1.2.3 Cloning step 2:  introduction of the zeocin resistance gene at the 3′ end 
In the next cloning step we aimed to reconstruct the whole phenalinolactone biosynthetic gene 
cluster on one expression construct. Therefore, construct CPhl9 was digested with ScaI to 
generate a linear fragment which could then be recombined with the target construct Cos3-
1O12 containing the remaining part of the cluster. As the whole ScaI restriction digest was to 
be used for transformation, it was formally possible that there could be still some undigested 
construct CPhl9 in the transformation mixture. Selection on tetracycline (oriT-tet-trpE box) 
and apramycin (target molecule) would then result in mutants carrying the constructs CPhl9 
and Cos3-1O12, without any recombination taking place. To avoid this problem, we inserted 
the zeocin resistance gene in Cos3-1O12 to create CPhl7. The introduction of a new resistance 
gene enabled selection on tetracycline and zeocin, forcing homologous recombination and 
avoiding replication of the undigested construct CPhl9 in the mutants. The zeocin resistance 
gene was inserted into Cos3-1O12 at the opposite end of the gene cluster (downstream of 
plaZ), an alteration which simultaneously deleted orf6 which was not needed for 
phenalinolactone biosynthesis.  
 
Figure 3.3: Red/ET Cloning step 2.  
Integration of the zeocin resistance gene into cosmid 3-1O12 via double homologous 
recombination resulted in the construct CPhl7. H4, H5: homology arms 4 and 5. 
 
The ca. 600 kb zeocin cassette was amplified by PCR, again using MCh37 as template. Two 
homology arms (H4 and H5) were introduced with primers PhlET6 and PhlET7. Double 
homologous recombination via these homology arms enabled the insertion of the zeocin 
cassette into Cos3-1O12. Selection for correct recombinant mutants was carried out on LB-
agar containing zeocin (25 µg/ml) and apramycin (60 µg/ml). To confirm the cloning step, the 
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construct CPhl7 generated by recombination was digested with a diagnostic set of restriction 
enzymes (Figure 3.5). 
 
3.1.2.4 Cloning step 3:  stitching of the pla biosynthetic gene cluster 
Construct CPhl9 was digested with ScaI to generate a linear 15 kb fragment. A ScaI site had 
been inserted into the construct with the primer PhlET10 in the first cloning step described in 
chapter 3.1.2.2. A second ScaI restriction site was already present in the overlapping region of 
the cosmids (Figure 3.4).  
 
Figure 3.4:   Red/ET Cloning step 3.  
Digestion of CPhl9 with ScaI and recombination of the 15 kb linear fragment with CPhl7, 
resulted in the final construct CPhl8 containing the complete pla biosynthetic pathway. 
  
This 15 kb fragment was then transformed into E. coli GB2005/pSC101-BAD-γβαA-amp in 
order to achieve recombination with CPhl7. Recombination of the linear fragment with CPhl7 
containing the missing end of the gene cluster resulted in the final construct CPhl8 containing 
the complete phenalinolactone pathway flanked by the oriT-tet-trpE box at the 5′-end and the 
zeocin resistance gene at the 3′-end of the cluster (Figure 3.4). Selection for correct 
recombinant mutants was carried out on LB-agar containing zeocin (25 µg/ml) and 
tetracycline (12.5 µg/ml). The individual cloning steps were confirmed by restriction analysis 
with the enzymes EcoRI, BglII and PvuII, as shown in Figure 3.5.  
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Figure 3.5: Restriction analysis of the Red/ET recombination constructs. 
Lane 1: Cos3-1O12, 2: CPhl7, 3: CPhl8, 4: CPhl10, 5: CPhl9, 6: Cos10-4D08. Lanes 1 and 6 
show the restriction pattern of the starting constructs Cos3-1O12 and Cos10-4D08. Lane 2 
shows the restriction fragments of CPhl7 into which the zeocin resistance gene was inserted, 
and lane 5 shows the restriction pattern of CPhl9 with the introduced oriT-tet-trpE box. 
Comparing the recombination constructs with the starting constructs enabled us to confirm the 
identity all of the constructs. Lane 8 shows the final construct CPhl8 containing all the 
fragments combined from CPhl7 and CPhl9. Lane 4 shows the restriction pattern of the 
construct CPhl10, which contains a promoter exchange. All restriction patterns showed the 
expected fragments. 
 
In summary, using this cloning strategy, we were able to reconstitute the complete 
phenalinolactone biosynthetic pathway on one expression construct containing the pOJ436 
backbone. At this point, the expression construct was ready for transformation into various 
heterologous host strains.  
 
3.1.3 Transformation of the biosynthetic gene cluster into heterologous host strains 
Two genera of bacteria, Pseudomonas and Streptomyces, were selected as hosts, as they had 
already been proven as suitable for heterologous expression of natural products [79]. 
 
3.1.3.1 Triparental conjugation of the expression construct CPhl8 into pseudomonads 
The final expression construct CPhl8 was transferred into Pseudomonas putida KT2240 by 
triparental mating. Exconjugants were screened on PMM agar containing tetracycline (12.5 
µg/ml) for the selection of P. putida::CPhl8 mutants. The transformation efficiency was very 
high, yielding several thousand tetracycline-resistant exconjugants. Single colonies were used 
for inoculation of liquid cultures. 
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3.1.3.2 Conjugation of the expression construct CPhl8 into streptomycetes 
The expression construct CPhl8 carried the vector backbone of the E. coli/Streptomyces 
shuttle vector pOJ436, enabling integration at the chromosomal attP site in streptomycetes 
genomes. Three different Streptomyces strains were used for transformation: Streptomyces 
lividans TK24, Streptomyces coelicolor A3(2) and Streptomyces coelicolor M512. The 
construct was transformed using biparental conjugation, and selection was carried out at 30 
°C on SM agar plates containing apramycin (60 µg/ml) and nalidixic acid (25 µg/ml). In all 
cases, the transformation efficiency was very high, yielding several thousands apramycin-
resistant exconjugants. After 3–5 days, single colonies were transferred to fresh SM agar 
plates containing apramycin and nalidixic acid. When sporulation was observed, the colonies 
were used to inoculate liquid cultures. 
 
3.1.3.3 Verification of the mutants  
After transformation of the expression construct CPhl8 into pseudomonads and 
streptomycetes, many antibiotic-resistant colonies were obtained in all cases. To verify the 
integration of the constructs into the genome of the different strains, primers apra_for and 
apra_rev were designed to amplify the apramycin resistance gene from the vector backbone of 
CPhl8. For the verification of the Pseudomonas mutants, a colony PCR was performed with 2 
randomly chosen colonies. 1 µl of an overnight culture was used as template for the PCR 
reaction. The Pseudomonas putida KT2240 wild type strain was used as a negative control, 
while DNA from the expression construct CPhl8 was used as a positive control. PCR products 
with the expected size (777 bp) were obtained for all mutants and for the positive control, 
whereas the negative control did not yield a PCR product (Figure 3.6). These result indicated 
the successful integration of the expression construct into the Pseudomonas putida genome. 
 
 
Figure 3.6: Verification of P. putida KT2240::CPhl8 mutants by colony PCR. 
Amplification of the apramycin resistance gene. Lane 1: P. putida KT2240::CPhl8#1; Lane 2: 
P. putida KT2240::CPhl8#2; Lane 3: P. putida WT; Lane 4: CPhl8 DNA. 
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For the verification of the Streptomyces mutants, genomic DNA was isolated from the 
mutants and from the wild type strain. A PCR was then performed using the apramycin 
primers to amplify the apramycin resistance gene from the vector backbone. Figure 3.7 
exemplifies one PCR reaction using four randomly chosen S. lividans TK24 mutants and wild 
type as template. The expected PCR product with a size of 777 bp was present in all mutants 
and in the positive control (CPhl8 DNA), but not in the wild type. PCR reactions were 
performed for all mutants. Integration of the expression construct into the genome of the 
different Streptomyces strains was confirmed in all mutants. 
 
 
 
 
Figure 3.7: Verification of S. lividans TK24::CPhl8 mutants by PCR. 
Amplification of the apramycin resistance gene. Lane 1: S. lividans TK24 WT; Lanes 2–5: S. 
lividans TK24::CPhl8 mutants #1–4; Lane 6: CPhl8 DNA. 
 
3.1.4 Heterologous expression of the phenalinolactone biosynthetic gene cluster 
In order to heterologously express the phenalinolactone pathway in pseudomonads and 
streptomycetes, cultivation conditions had to be established. Different media and temperatures 
were tested, as described below. 
 
3.1.4.1 Cultivation of pseudomonads 
Two mutants of P. putida KT2240::CPhl8 were inoculated into a 50 ml culture LB medium 
containing 1 ml XAD and tetracycline (12.5 µg/ml). In parallel, the wild type P. putida 
KT2240 was inoculated into a 50 ml culture LB containing 1 ml XAD without antibiotic. 
Cultivation was carried out at 16 °C and 30 °C for 3 days. The cultures were then harvested 
by centrifugation and the XAD was extracted with MeOH/acetone and submitted to HPLC-
MS analysis. 
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3.1.4.2 Cultivation of streptomycetes 
Streptomyces lividans TK24::CPhl8, S. coelicolor A3(2)::CPhl8 and S. coelicolor 
M512::CPhl8 were grown in 100 ml NL111 production medium containing apramycin (60 
µg/ml) at 28 °C for 6–8 days. In parallel, the corresponding wild type strains as well as the 
natural phenalinolactone producer Tü6071 were grown in production medium without 
antibiotic. The cultures were harvested by centrifugation and the supernatant was extracted 
with ethyl acetate and submitted to HPLC-MS analysis.  
 
3.1.4.3 HPLC-MS analysis  
3.1.4.3.1 Production profile of the natural producer Streptomyces TÜ6071 
Initially the production profile of an extract of the natural producer Tü6071 was analyzed by 
HPLC-MS to establish HPLC conditions for the detection of phenalinolactones. Dürr et al. 
[80] demonstrated previously that production of phenalinolactones in NL111 production 
medium produced the highest yields. The primary metabolites produced during cultivation in 
NL111 medium were phenalinolactones (PLs) A and D, whereas PLs B and C were not 
detected [80] (Figure 3.8). 
 
Figure 3.8:  Chemical structures of phenalinolactones A, B, C and D. 
 
Figure 3.9 shows the typical production profile of the natural producer Streptomyces Tü6071. 
Phenalinolactones were identified by comparison to the retention times (rt) and the MS data 
of authentic standards. Analysis was performed in negative ionization mode enabling 
detection of the phenalinolactone A and D parent ions (m/z [M–H]– = 714.3 (RT: 13.8 min) 
and m/z [M–H]– = 698.3 (18.1 min), respectively).  
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Figure 3.9: HPLC-MS analysis of the natural producer Streptomyces Tü6071.  
a) Base peak chromatogram (BPC) in negative ionization mode within a mass range of 100–
1100 B) Extracted ion chromatogram (EIC) of PL A with a mass of m/z [M–H]– = 714.3 c) 
Extracted ion chromatogram (EIC) of PL D with a mass of m/z [M–H]– = 698.3.  
 
Fragmentation of the parent ions leads to a characteristic fragmentation pattern (MS/MS 
fingerprint) that could be used to unambiguously identify PL A and PL D. Figure 3.10 shows 
the detected parent ions of PL A and PL D, and the corresponding MS/MS fragmentation 
patterns. The MS/MS fragmentation pattern of PL A exhibited characteristic fragmentation 
ions with masses m/z [M–H]– = 582.7, 600.5, 642.4, 670.4 and 686.4. The corresponding 
fragments for PL D were m/z [M–H]– = 584.7, 626.6, 654.4, 670.4. On the basis of these 
fragmentation patterns, it was possible to clearly identify phenalinolactones in the extracts of 
the heterologous host strains.  
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Figure 3.10: ESI-MS/MS fragmentation patterns of PL A and PL D.  
a) Parent ion of PL A with a mass of m/z [M–H]– = 714.3 detected at a retention time of 13.5 
min. b) MS/MS fragmentation pattern of PL A showing characteristic fragmentation ions. c) 
Parent ion of PL D with a mass of m/z [M–H]– = 698.3  detected at a retention time of 18.3 
min. d) MS/MS fragmentation pattern of PL D showing characteristic fragmentation ions. 
 
3.1.4.3.2 Production profile of the Pseudomonas mutants 
The basepeak chromatograms were analyzed for the presence of masses corresponding to PL 
A and PL D, but neither compound was detected in the extracts. Therefore, a new, higher 
selectivity and sensitivity HPLC-MS method was used (developed by Daniel Krug). This 
method detected the CID (collision-induced dissociation) fragmentation of compounds with 
masses 714.5 and 698.3 eluting between retention times of 12–14 min and 18–20 min, and 
was validated by analysis of the phenalinolactone A and D standards. However, analysis using 
this new method still failed to reveal the presence of phenalinolactones A and D.  
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3.1.4.3.3 Production profile of the Streptomyces mutants  
We next investigated the extracts of the Streptomyces mutants, using the previously-described 
method. Phenalinolactones A and D were detected in extracts of the natural producer 
Streptomyces Tü6071, and in the recombinant S. lividans and S. coelicolor strains harboring 
the pla gene cluster. As expected no phenalinolactones were present in extracts of the 
corresponding wild type S. lividans and S. coelicolor strains. This result clearly demonstrated 
the successful heterologous production of the terpene glycosides (Figure 3.11). 
 
 
 
Figure 3.11: HPLC/MS analysis of streptomycetes mutants carrying the PL pathway. 
 
A) BPC of natural phenalinolactone producer strain S. sp. Tü6071, S. lividans TK24 WT and S. 
lividans::CPhl8. B) Natural producer strain S. sp. Tü6071, S. coelicolor A3(2) WT and S. 
coelicolor::CPhl8. C) Natural producer strain S. sp. Tü6071, S. coelicolor M512 WT and S. 
coelicolor::CPhl8. The chromatograms show the negative ions within a mass range of 100–
1100 in auto MSn mode. CID fragmentation between retention times of 12–14 min and 16–18 
min was monitored for the masses 714.5 and 698.3, corresponding to the phenalinolactone A 
and D standards. The section in each chromatogram between 12–18 min is shown in expanded 
form on the right. PL A and/or D were detected in the extracts of the recombinant strains.  
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3.1.4.4 Optimization of heterologous PL production in Pseudomonas 
3.1.4.4.1 Promoter exchange 
As there was no PL detected in extracts of the Pseudomonas mutants harboring the pla 
biosynthetic pathway, we decided to exchange one of the native Streptomyces promoters 
against the inducible Pm-promoter. Importantly, the Pm-promoter had already been validated 
during the heterologous expression of the myxochromide biosynthetic pathway [35]. As the 
cluster is composed of 11 different transcription units (operons), we intended to introduce the 
Pm-promoter at a position which would drive transcription of the genes for the core 
biosynthetic machinery. Based on biosynthetic considerations, enzymes PlaT1–T6 comprise 
the machinery to biosynthesize the phenalinolactones scaffold [66]. The first precursor of PL 
biosynthesis is geranylgeranyl diphosphate (GGDP), which is generated by PlaT4 from 4 
monomers of isopentenyl pyrophosphate (IPP) (see Discussion Figure 4.2). PlaT6 and PlaT5 
are expected to be involved in IPP production. So these first three enzymes should be able to 
catalyze the formation of GGDP. PlaT1-PlaT3 then catalyze the formation of PL precursor 1 
and 2 (shown in Figure 4.2, Discussion part). Unfortunately, the corresponding genes (plaT1–
3 and plaT4–6) are located in different transcription units and exhibit different orientations 
(Figure 3.12). Therefore, we introduced the promoter in front of the gene plaM2 where the 
initial genes for biosynthesis are located (plaT4-6), expecting that overexpression of the early 
genes in the pathway would lead to the initiation of PL production or to the production of 
GGDP or PL precursors. For this, a cassette containing the Pm-promoter was amplified by 
PCR using CMch37 [35] as template, the xylS gene and the chloramphenicol resistance gene, 
as well as 50 bp homology arms to enable double homologous recombination. This cassette 
was introduced by Red/ET recombineering and exconjugants were selected on LB agar 
containing chloramphenicol (cm) (34 µg/ml) and apramycin (60 µg/ml).  
 
Figure 3.12: Introduction of the inducible Pm-promoter in front of plaM2 by Red/ET 
recombineeering. 
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The new construct CPhl10 was verified by restriction analysis (Figure 3.5) and subsequently 
transformed into the P. putida KT2240 by triparental conjugation. Integration of the construct 
into the chromosome was confirmed by colony PCR analysis, amplifying the apramycin 
resistance gene as described above (3.1.2.3.). Expression was induced by adding 1 mM toluic 
acid to the cultures after 2 h of cultivation. We expected at least that GGDP would be 
expressed when the core biosynthetic genes (plaT4-6) were under the control of the Pm-
promoter. However, HPLC-MS analysis still did not reveal production of PL precursors or PL 
production in extracts of the Pseudomonas mutants.  
 
3.1.4.5 Optimization of heterologous PL production in Streptomyces 
3.1.4.5.1 Changing cultivation conditions 
Production of PL in the heterologous Streptomyces strains was quantified using authentic PL 
standards. Production under standard conditions (NL111 medium at 28 °C; underlined in 
grey, Table 3.1) was much lower in the heterologous host strains (maximum 0.13 µg/L in S. 
lividans TK24) than in the native host S. Tü6071 (Table 3.1). In an attempt to optimize 
production in the heterologous hosts, different cultivation conditions (additional media and 
temperatures) were tested (Table 3.1), with growth at 28 °C. Production was highest under 
standard conditions in NL111 production medium (Table 3.1). In INA5 and SM medium, PL 
production was typically lower in the heterologous host strains then in the natural producer, 
while the same media yielded less phenalinolactones from the native host relative to 
cultivation in NL111 medium. Growth in NBG medium completely abolished production by 
all strains. These results indicated that PL production in NL111 medium was optimal relative 
to cultivation in INA5, SM and NBG media. 
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Table 3.1: Phenalinolactone production by Streptomyces Tü6071, S. lividans TK24, S. coelicolor 
A3(2) and S. coelicolor M512 during cultivation in different media at 28 °C. Highest 
production yield underlined in grey. 
 
Strain 
Production of 
phenalinolactone (µg/L) 
 NL111 INA5 SM NBG 
     
S.  Tü6071 500 200 200 - 
S. lividans TK24::CPhl8 0.13 0.10 0.05 - 
S. coelicolor A3(2)::CPhl8 0.01 0.01   - 
S. coelicolor M512::CPhl8 0.5 0.03 0.01 - 
     
 
We also evaluated cultivation at 37 °C. Under these conditions, phenalinolactone production 
by S. lividans was increased 100-fold compared to growth at 28 °C (Table 3.2). However PL 
production by the S. coelicolor mutants was completely abolished at this higher temperature.  
 
Table 3.2: Phenalinolactone production by Streptomyces Tü6071, S. lividans TK24, S. coelicolor 
A3(2) and S. coelicolor M512 during cultivation in NL111 medium at 28 °C and 37 °C.  
 
Strain 
Production of 
phenalinolactone (µg/L) 
 28 °C 37 °C 
   
S. Tü6071 500 200 
S. lividans TK24::CPhl8 0.13 10 
S. coelicolor A3(2)::CPhl8 0.01 - 
S. coelicolor M512::CPhl8 0.5 - 
   
 
3.1.4.5.2 Precursor feeding 
We also attempted to improve production by supplementation with a putative biosynthetic 
precursor. Because the core terpenoid backbone in phenalinolactone biosynthesis is derived 
from isoprenoid building blocks [66], we administered mevalonolactone to the culture 
medium. Mevalonolactone is the lactonized form of mevalonate, a direct precursor in the 
mevalonate pathway for the construction of isoprenoid units [74]. Most Streptomyces strains 
employ the non-mevalonate pathway for the formation of isoprenoids, but some strains 
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additionally utilize the mevalonate pathway to produce terpenoid antibiotics [74]. However, 
feeding of 1 mM mevalonolactone did not increase phenalinolactone production in 
Streptomyces sp. Tü6071 nor in the heterologous host strains  
 
3.1.4.5.3 Promoter exchange 
We also evaluated the effect of exchanging a number of the native promoters against the 
strong constitutive ermE promoter [81]. We intended to introduce the promoter at the same 
position (between plaO2 and plaM2) as in the construct for the PL expression in the 
pseudomonads (3.1.4.4.1), as this transcriptional unit contained the genes for the core 
biosynthetic gene cluster. We expected that at least GGDP or precursor 1 or 2 should be 
expressed (Figure 4.2, Discussion part). For this, we constructed a bidirectional promoter so 
that transcription in both transcription units containing the core genes would be driven (Figure 
3.13). We therefore amplified the ampicillin (amp) resistance gene with primers containing 50 
bp homology arms to enable homologous recombination. The ermE promoter was also 
introduced using the primers, as it is only ca. 60 bp in size. The amplified cassette was 
introduced by Red/ET recombineering, and recombinant mutants were selected on LB agar 
containing amp (100 µg/ml) and apra (60 µg/ml). The new construct CPhl19 was verified by 
restriction analysis, and subsequently transformed into the three heterologous host strains. In 
each case, integration of construct CPhl19 into the genome was verified by PCR, as described 
earlier (3.1.3.3.). 
 
Figure 3.13: Introduction of two ermE promoters between plaO2 and plaM2 by Red/ET 
recombineering. 
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HPLC-MS analysis of the extracts from the mutants revealed that neither PL nor any PL 
precursors were produced in the mutants. Instead PL production was completely abolished.  
 
3.1.5 Genetic modification of the pla biosynthetic gene cluster 
The established heterologous expression system enabled attempts to engineer the PL 
biosynthetic pathway to generate novel analogs. In theory, using Red/ET recombineering, we 
could perform single or multiple in-frame deletions at any desired position within the 
expression construct. As proof-of-principle, we aimed to modify PL biosynthesis by deletion 
of selected genes from the CPhl8 expression construct. 
 
3.1.5.1 Deletion of plaA6 
The first aim was to modify the pla gene cluster by deletion of the glycosyl transferase-
encoding gene plaA6 from the CPhl8 expression construct, to generate a phenalinolactone 
derivative lacking the L-amicetose moiety. For this, a kanamycin resistance cassette was 
amplified by PCR to incorporate flanking flippase (FLP) recombinase target sites (FRT sites), 
as well as 50 bp homology arms to enable double homologous recombination (Figure 3.14). 
After replacement of the target gene (plaA6) by the selection marker (kan) using Red/ET 
recombineering, the kan gene was excised from the expression construct by FLP-
recombinase-catalyzed site-specific recombination, to create a markerless in-frame deletion. 
The modified pla gene cluster was again verified by restriction analysis. The construct 
CPhl18 was subsequently transformed into the three heterologous Streptomyces strains by 
conjugation, and integration of the construct into the chromosome was confirmed by PCR 
analysis by amplifying the apramycin resistance gene, as described earlier. 
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Figure 3.14: Deletion of the glycosyl transferase encoding gene plaA6. 
Red/ET recombineering was used to replace plaA6 with the kanamycin resistance 
cassettewhich was flanked by FRT recognition sites. Incubation with FLP recombinase at 37 
°C led to a markerless deletion of plaA6 in the pla cluster.  
 
3.1.5.2 Deletion of plaP2 and plaP5 
By deletion of the acyltransferase encoding gene plaP2, we aimed to generate a derivative 
lacking the 5-methylpyrrole-2-carboxylic acid moiety. The gene plaP5 is proposed to be 
responsible for the methylation of the pyrrole carboxylic acid [66], and thus deletion of this 
gene was expected to give an unmethylated PL derivative. To create these deletions, we 
exploited the Cre/lox system instead of the FLP/FRT system. Using the Cre system would 
enable us to do two deletions in parallel using the FRT system too. Therefore a kanamycin 
resistance cassette was amplified by PCR to incorporate Cre recombinase target sites (loxP 
sites), as well as 50 bp homology arms to enable double homologous recombination 
(analogous to Figure 3.14). After replacement of the target gene (plaP2 or plaP5) by the 
selection marker (kan) using Red/ET recombineering, the kan gene was excised from the 
expression construct by Cre-recombinase-catalyzed site-specific recombination, to create a 
markerless in-frame deletion. The modified pla gene cluster was subsequently transformed 
into three heterologous host strains by conjugation, and integration of the construct (CPhl14 
(Δplap2) and CPhl16 (Δplap5) into the chromosome was confirmed by PCR analysis by 
amplifying the ampramycin resistance gene, as described earlier.  
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3.1.5.3 Verification of the new PL derivatives by high-resolution Orbitrap MS analysis 
Nine mutant strains were obtained after conjugation with the different constructs listed in 
Table 3.3. The production profiles of the mutant strains were analyzed by HPLC-MS, and 
compared to that of the respective wild type strains, and the natural phenalinolactone producer 
Streptomyces  Tü6071. The expected masses of the new derivatives are also listed in Table 
3.3.  
 
Table 3.3: Streptomyces mutants obtained after conjugation with the modified constructs 
Construct Modification in the biosynthetic pathway Heterologous host 
Sum 
formula of 
expected PL 
derivatives 
Expected  
mass [M–H] – 
CPhl14 ΔplaP2 S. lividans TK24 C37H50NO11 684.3 
CPhl14 ΔplaP2 S. coelicolor A3(2) C37H50NO11 684.3 
CPhl14 ΔplaP2 S. coelicolor M512 C37H50NO11 684.3 
CPhl16 ΔplaP5 S. lividans TK24 C25H35O8 463.3 
CPhl16 ΔplaP5 S. coelicolor A3(2) C25H35O8 463.3 
CPhl16 ΔplaP5 S. coelicolor M512 C25H35O8 463.3 
CPhl18 ΔplaA6 S. lividans TK24 C31H40NO9 570.3 
CPhl18 ΔplaA6 S. coelicolor A3(2) C31H40NO9 570.3 
CPhl18 ΔplaA6 S. coelicolor M512 C31H40NO9 570.3 
 
As expected, phenalinolactones A and D (m/z [M–H]– = 714.5 at retention time 13.8 min and 
m/z [M–H]– = 698.5 at 18.1 min) were detected in the extract of the natural producer, but not 
in extracts of the wild type heterologous hosts. In the extract of the strain S. coelicolor 
M512::CPhl18, we detected a new compound designated as PL E (m/z [M–H]– = 570.3 at 13.0 
min) which differed from PL D by 128 atomic mass units, consistent with the anticipated loss 
of the 4-O-methyl-L-amicetose moiety (Figure 3.15). MS2 analysis confirmed that the new 
compound had a similar fragmentation pattern to the PLs (shown in Figure 3.16). 
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Figure 3.15: HPLC/MS analysis of S. coelicolor::CPhl18. 
A) BPC of parental strain S. coelicolor M512 and B) S. coelicolor M512::CPhl18 (plaA6 
deletion). A new compound, designated PL E, was detected in the extract of S. coelicolor 
M512::CPhl18 at a retention time of 13.0 min. C) Fragmentation pattern of PL E (molecular 
ion, m/z [M–H]– = 570.3).  
  
The compound was not detected in extracts of the S. lividans::CPhl18 and S. 
coelicolor::CPhl18 mutants, nor in the extracts of the other heterologous host strains carrying 
the constructs CPhl14 and CPhl16. No expected derivatives could be detected in the extracts 
of the mutants carrying constructs CPhl14 and CPhl16 instead PL production was completely 
abolished in these mutants. 
 
To verify the identity of PL E from S. coelicolor M512::CPhl18, we analyzed the compound 
by high resolution LC-coupled Fourier transform-Orbitrap MS. This analysis confirmed the 
expected elemental composition of C31H40O9N1 (measured m/z [M–H]– = 570.26733; 
calculated m/z [M–H]– = 570.27086; Δ = –3.52166 amu). Additional structural information 
was obtained using tandem-MS and subsequent comparison of the MS2 fingerprints with 
those obtained for the glycosylated compound PL D. The principal collision induced 
dissociation (CID)-fragmentations for the standard substance PL D and the new derivative PL 
E were assigned as summarized in Table 3.4. Fragmentation of the terpenoid backbone as 
well as of the sugar and the pyrrole-carboxylic acid groups was not observed in the MS2 
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spectra of PL D, indicating that despite the loss of the sugar group, the fragmentation pattern 
of phenalinolactones D and E should be very similar. Indeed, comparison of the fragmentation 
pattern of both molecules showed that they exhibited the same set of peaks, but offset by a 
constant mass difference corresponding to L-amicetose (Table 3.5 and Figure 3.16). The 
peaks are derived from the parent molecules by expulsion of CO, CO2 and H2O, although the 
precise locations of these losses remain to be elucidated. The expulsion of C4H2O4, which 
occurred from both compounds, can be attributed to the γ-butyrolactone. These data strongly 
suggest that the PL E is the desired unglycosylated derivative of PL D. 
 
 
 
Figure 3.16: Verification of the unglycosylated derivative PL E by LTQ-Orbitrap MS analysis. 
Accurate mass determination of the standard substance PL D (A) and the unglycosylated 
compound PL E (B) with high resolution LC-coupled Orbitrap-MS yielded molecular ions of 
m/z [M–H]– = 698.35504 and m/z [M–H]–  = 570.26733, respectively, suggestive of the 
elemental formulas C38H52O11N1 and C31H40O9N1. Additional support for structure assignment 
was provided by MS2 studies, which showed that PL D and PL E have the same fragmentation 
patterns, but with the peaks offset by a constant mass corresponding to the L-amicetose moiety 
missing in PL E. 
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Table 3.4 
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3.2 Identification of the GE81112 biosynthetic gene cluster 
3.2.1 Goals 
As the GE81112 biosynthetic gene cluster had not been identified, the first objective was to 
clone the cluster in order to allow studies of the underlying biosynthesis. (For this, we aimed 
to generate a cosmid library based on the E. coli/Streptomyces shuttle vector pOJ436 [10]). 
We then hoped to use in vitro protein expression and targeted gene inactivation to obtain 
deeper insights into the biosynthesis. To support this work, we aimed to establish genetic 
manipulation methods for the strain, starting with optimization of production and cultivation 
conditions for the GE81112 compounds.  
 
3.2.2 Production profile of Streptomyces 14386 
The GE81112 producing Streptomyces strain 14386 was provided by the company KtedoGen 
(Italy). Initial experiments for cultivation optimization to produce GE compounds in shake 
flasks were carried out by Margherita Sosio (KtedoGen). Sosio tested two different media, 
INA5 and T6, for both cultivation of the strain and GE production. Precultures were grown in 
V6 medium for 96 h, and then used to inoculate INA 5 and T6 production medium (1:100). 
The GE81112 production results are shown in Table 3.5.  
 
Table 3.5: GE81112 compounds produced under different cultivation conditions.  
 
Medium/cultivation 
time 
LC/MS 
[M+H]+ 
 INA 5 (96 h) ND 
 INA 5 (140 h) ND 
 T6 (96 h) ND 
 T6 (140 h) 644, 659 
ND: Not Detected 
 
Detection of GE81112 factor A and B by LC/MS was only possible after cultivation in T6 
medium for 140 h. These results showed that T6 (cultivation time: 140 h) is the best medium 
identified to date for production of GE compounds. To reproduce these results in our lab, we 
cultivated the strain under the same conditions and analyzed the extracts for the presence of 
the GE metabolites. Overall, our results were nearly identical to those obtained by KtedoGen. 
For example, during cultivation in INA5 medium, GE compounds could never detected by 
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MS. During cultivation in T6 medium for 140 h, low amounts of the main GE compound B 
(m/z [M+H]+ = 659.22953) were detected by high resolution MS analysis on an Orbitrap LTQ 
mass spectrometer with the sum formula C24H36O10N10Cl1 (see Figure 3.17).  
 
Figure 3.17: Analysis of the extracts of strain S. 14386 by high-resolution MS on an LTQ Orbitrap 
mass spectrometer.  
A) Base peak chromatogram (BPC) with B) extracted ion chromatogram (EIC) showing a 
molecular ion of m/z [M+H]+ = 659.23254, as well as C) the elemental formula. 
 
Despite trying several different cultivation conditions, production of the GE compounds 
remained low or even undetectable by MS. Due to the poor yields, it was not possible to 
obtain an MS/MS spectrum of the substances from the culture extract. These findings are in 
full agreement with the results obtained by KdetoGen. Although production was low in T6 
medium detection of the GE81112 B compound was reliable so that we used these cultivation 
conditions for future experiments. 
 
During analysis of the culture extracts from S. 14386, it became apparent that the strain was 
producing additional metabolites. These substances first attracted attention because one of 
them (659) had nearly the same mass by HPLC-MS analysis as the corresponding GE81112 
compound B and also incorporated chlorine as shown by the isotopic pattern (Figure 3.18).  
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Figure 3.18: HPLC/MS analysis of an extract of strain S. 14386. 
A) Base peak chromatogram (BPC) with extracted ion chromatograms (EIC) showing 
molecular ions of m/z [M+H]+ = 631.3, 645.3 and 659.3. B) Mass spectrum of the three 
substances showing isotopic patterns characteristic of chlorinated compounds. 
 
A detailed analysis of the extract revealed three likely related substances with masses of m/z 
[M+H]+ = 631.3, 645.3, and 659.3, which all showed an isotopic pattern which is typical for 
chlorinated substances (Figure 3.18 B)). To obtain accurate mass information, the compounds 
were analyzed at high resolution using an Orbitrap LTQ mass spectrometer. Determination of 
the exact masses and the corresponding elemental formulae (Figure 3.19) confirmed that the 
compounds differed by 14 mass units from each other. Correspondingly, they share the same 
overall fragmentation patterns, but with peaks offset from each other by 14 mass units. 
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Figure 3.19: Analysis by high resolution MS of the substances with molecular masses 631, 645, 659.  
The determined accurate masses and molecular formulae are shown. A) Pseudo-molecular ion 
of [M+H]+=631.3, B) fragmentation pattern of molecular ion [M+H]+=631.3, C) Pseudo-
molecular ion of [M+H]+=645.3, D) fragmentation pattern of molecular ion [M+H]+=645.3, E) 
Pseudo-molecular ion of [M+H]+=659.3 F) fragmentation pattern of molecular ion 
[M+H]+=659.3  
 
This analysis suggested that the substances are related to the known GE series of compounds, 
as they are chlorinated and have similar elemental formulas; however, as the fragmentation 
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patterns differed, the compounds are not identical but remain interesting to investigate. 
Finally the MS analysis of the production profile revealed that we could now detect the main 
GE81112 factor B compound. In the next step we aimed to generate a cosmid library to allow 
us to identify the corresponding biosynthetic gene cluster. 
 
3.2.3 Generation of a cosmid DNA library 
One strategy for cloning and identifying a gene cluster is to generate a gene library in E. coli. 
A gene library is a population of organisms, each of which carries a DNA molecule that was 
inserted into a cloning (e.g. cosmid) vector. Ideally, all of the cloned DNA molecules 
represent the entire genome of the organism meaning that the desired biosynthetic gene 
cluster should be also present there. Knowing the size of the genome of the organisms from 
which one would generate the library one can calculate the approximately number of cosmids 
containing the gene cluster. When we assume that the average size of a Streptomyces genome 
is 9 Mbp and a cosmid vector can carry ca. 40 kb of insert DNA then we need to generate ca. 
225 cosmid clones to clone the whole genome. To get a 10-fold coverage of the genome 2250 
cosmid clones need to be obtained. As biosynthetic gene clusters are normally between 30 and 
60 kb approximately 30-60 cosmids are expected to harbor parts of the gene cluster. The 
cosmids containing the desired gene cluster can then be identified by screening of the cosmid 
library with labeled probes (Figure 3.20).  
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Figure 3.20: General overview of the strategy for generation of a cosmid library. 
Genomic DNA of the desired organism is isolated and cloned into cosmid vectors. The desired 
cosmid(s) containing the whole biosynthetic gene cluster or portions of it can then be identified 
with a labeled probe. A common cosmid vector is the E. coli/Streptomyces shuttle vector 
pOJ436 [10]. 
 
As a cosmid vector, we used the E. coli/Streptomyces shuttle vector pOJ436 [10]. Genomic 
DNA from the GE81112 producing strain was isolated using the salting out procedure 
(described in section 2.10.1). The isolated DNA was then partially digested with Sau3A to 
obtain fragments 30–35 kb in size. Fragments of the correct size were pooled and used for 
ligation into the PvuII/BamHI-digested vector pOJ436. Figure 3.21 shows partially-digested 
DNA generated by using different amounts of enzymes. Fractions 6 and 7 were chosen for the 
ligation, as they contained the greatest proportion of fragments between 35–40 kb. The two 
fractions were pooled together and ligation was carried out as described in section 2.16.1. To 
determine the phage titer different amounts of infected E. coli were plated out yielding 
different amounts of cosmid clones (see section 2.16.1).  
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Figure 3.21: Digestion of genomic DNA from S. 14386 with Sau3A. 
Lane 1: Ladder; Lane 2–7: variable digestion of genomic DNA obtained by 
using different amounts of enzyme.  
 
We investigated whether 19 randomly choosen cosmid clones 
contained the correct insert size by digestion with BamHI 
(Figure 3.22). In Figure 3.22 one can see that most of the clones 
showed different fragments larger then 10 kb indicating that 
most of the analyzed clones contained an insert with an average 
size of 30–40 kb. Based on this information, we created the 
cosmid library containing 2304 cosmid clones in order to reach 
a 10-fold coverage of the genome of S. 14386 (section 2.16.2).  
The cosmid library was then ready for hybridization with a suitable probe to identify the 
GE81112 biosynthetic gene cluster.  
 
 
Figure 3.22: Analysis of 19 randomly chosen cosmid clones. 
 
The clones were digested with BamHI to determine whether they contained different inserts 
and inserts of the correct size.  
 
 
3.2.3.1 Retrobiosynthetic analysis of GE81112 to design suitable probes 
To find suitable probes for the hybridization of the cosmid library, we applied a 
“retrobiosynthetic” strategy which allowed us to predict some aspects of the genetic 
composition of the gene cluster from the structure of the natural product. As described 
previously, GE81112s were assumed to derive from a non-ribosomal peptide synthetase. It is 
known that for these systems there is a strong correlation between compound structure and 
biosynthetic organization (even for some domains in non-linear systems) [64]. For example, it 
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is possible to predict with some degree of confidence, the building blocks incorporated into 
the structure and therefore the number of modules and the complement of domains in the 
NRPS, as well as which functionalities are likely to arise by  post assembly-line processing. 
Thus, according to the molecular structure of GE81112, we were able to propose a hypothesis 
for the complement of genes that was likely to be present in the GE81112 gene cluster. 
Assuming that the pathway will be co-linear (see section 1.4), the biosynthetic gene cluster 
should incorporate four NRPS chain extension modules which are responsible for activating 
and introducing the four observed amino acids (Figure 3.23). Each of the modules was 
expected to incorporate the three standard NRPS domains, C, A and PCP. We also anticipated 
that a halogenase would be involved in the chlorination of all three GE81112 compounds.  
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Figure.3.23: Structures of GE81112 metabolites.  
The different building blocks were expected to be derived from different amino acids and are 
marked in different colors. Red: pipecolic acid, green: ornithine/glutamine, blue: histidine, 
purple: histidine  
 
We also hypothesized that the starter unit for GE81112 biosynthesis would be pipecolic acid, 
or its hydroxylated derivative (shown in red in Figure 3.23). As the stereochemistry of the 
GE81112 compounds has not been solved yet, we did not know if L-or D-pipecolic acid would 
be incorporated. On the basis of published precedent [82], however, we assumed that the 
pipecolic acid would be formed from lysine via the action of a lysine cyclodeaminase (Figure 
3.24).  
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Figure 3.24: Example of conversion of L-lysine to L-pipecolic acid by the action of a lysine 
cyclodeaminase as it is known from rapamycin.  
 
This proposal is in accordance with the in vitro characterization of RapL, a cyclodeaminase, 
which has been found in the rapamycin biosynthetic gene cluster cluster [82]. Other 
cyclodeaminases have been identified in the friulimicin [83], the virginiamycin S [84] and in 
the tubulysin biosynthetic gene clusters [85]. The in vitro reaction has also been reconstituted 
for LipE from the friulimicin gene cluster [83] and TubZ from the tubulysin biosynthetic gene 
cluster (Y. Chai, A. Sandmann, unpublished results). The pipecolate moiety in GE81112 
differs from those in rapamycin and tubulysin, in that it is hydroxylated at position 3. This 
step was anticipated to be catalyzed by a β-hydroxylase, but the timing (i.e. before or after 
incorporation) could not be predicted. Another interesting feature of the structures is the 
amino acid which is incorporated second – aminohydroxypentanoic acid (building block 2, 
marked in green) – which we expected to derive from glutamine/glutamate or ornithine. We 
also hypothesized that the third and fourth amino acid building blocks (indicated in blue and 
purple) are likely to derive from histidine.  
 
3.2.4 Design of the probes 
On the basis of these predictions, we were able to design suitable probes for the screening of 
the cosmid library. For this, it is desirable to design a probe which is specific for an unusual 
feature of the cluster; as such a probe is likely to improve the chances of finding the correct 
cosmid. As described above, we predicted that a cyclodeaminase should be present in the 
genome. As such cyclodeaminases are relatively rare in biosynthetic pathways [86], this gene 
was judged to be a good candidate for trying to locate the GE81112 biosynthesis gene cluster 
in the genome of S. 14386. We therefore designed a probe based on cyclodeaminase 
sequences. To create the probe, we used specific primers to amplify two known 
cyclodeaminase genes – tubZ [85] (primers: TubZ_up and TubZ_down (section 2.7.2.2.)) 
from the tubulysin cluster and rapL [87] from the rapamycin cluster (primers: RapL_up and 
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RapL_down (2.7.2.2.)). The amplificates were pooled and used to probe the cosmid library at 
low stringency. To check if the probe worked, we hybridized the genomic DNA of S. 14386 
(digested with different enzymes) with the probe which yielded several distinct hybridization 
signals, indicating that the cosmids containing cyclodeaminase genes were likely present, and 
therefore that the library was likely to contain the desired cluster. 
As an alternative approach, we designed an additional probe to identify NRPS genes. For this, 
we used degenerate NRPS primers (RevA3 and PSLGG) (2.7.2.2.) which had already been 
employed successfully to identify NRPS genes in myxobacteria [88-90]. These primers 
amplify A domains between the structural regions A3 and A6 [91], where the amino acid 
binding pocket is located, giving a 1.3 kb PCR fragment. The PCR was carried out using a 
step-wise gradient with different annealing temperatures (46–52 °C) using the S. 14386 DNA 
as template. Several of the obtained PCR fragments were cloned into PCR 2.1 TOPO and 
sequenced. Different A domain binding pockets were obtained after sequencing (presumably 
specific for the incorporation of valine, threonine, glutamine) indicating that the probes had 
successfully amplified various A domains. As it was not possible to correlate the substrate 
specificities of the A domains to the GE81112 structure, we were unable to select a single A 
domain as a probe, and therefore decided to use the whole PCR reaction containing all of the 
amplified A domains. This approach was expected to ensure a high diversity of A domain 
hybridization so that as many as possible A domains would hybridize.  
 
3.2.5 Identification of an unknown NRPS biosynthetic gene cluster 
3.2.5.1 Identification of two cosmids containing NRPS genes 
Using both the cyclodeaminase and A domain probes at low stringency, we identified several 
cosmids which hybridized with one or both of the probes (Figure 3.25). Ten of these cosmids 
were then chosen for a more detailed analysis. A PCR with the degenerate NRPS primers was 
performed to verify the hybridization results, yielding the expected 1.3 kb fragment in each 
case. PCR with the cyclodeaminase primers was not successful; this result was expected, 
however, as the primers used were not degenerate, and so would not have been expected to 
target the particular cyclodeaminase gene(s) present in the S. 14386 genome. The DNA of the 
ten cosmids was isolated, and digestion with different enzymes was performed to evaluate the 
restriction patterns and to check if similar restriction fragments for different cosmids were 
obtained. This result would indicate that the same DNA sequence (biosynthetic gene cluster) 
was present on the cosmids.  
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Figure 3.25: High density colonies filters. 
A) Hybridization with the cyclodeaminase probe. B) Hybridization with the NRPS probe. 
 
Two of the cosmids showed similar restriction patterns, indicating that they contained 
overlapping sequence. End sequencing (Primers T4 and T7 (Table 2.12)) revealed that one of 
the cosmids (AI6) contained NRPS sequences (Table 3.6), and so this cosmid and the 
overlapping one were sequenced in their entirety. 
 
Table 3.6: End sequencing results for cosmids FD10 and AI6 with T4 and T7 primers 
Cosmid Homology (Name, Strain, Database no.) Identity Score 
E-
Value 
FD10_T4 Polyketide synthase type I, Streptomyces aizunensis, 
gi/62737770/AAX98186186.1 
40% 37.4 bits 0.26 
FD10_T7 Glutamate synthase, small subunit, Streptomyces 
avermitilis,gi/29832732/ref/NP827366.1 
89% 228 bits 2e-79 
AI6_T4 Hypothetical protein SAV2451, Streptomyces 
avermitilis MA-4680, gi/29828993/ref/NP823627.1 
83% 268 bits 3e-70 
AI6_T7 Peptide synthetase 2, Streptomyces filamentosus 
gi/60650533/gb/AAX31558.1 
51% 304 bits 6e-81 
 
3.2.5.2 Annotation of the unknown biosynthetic gene cluster 
The two cosmids were sequenced at the HZI (Helmholtz Center for Infection Research) in 
Braunschweig, in the Department of Genome Analysis. The obtained sequence was then 
analyzed for the presence of putative open reading frames (orfs) with FramePlot 2.3.2 [92], 
and preliminary functional assignments of individual orfs were made by comparison of the 
deduced gene products with proteins of known function in the BLAST database. Sequence 
analysis of cosmids AI6 and FD10 revealed three orfs for NRPS biosynthesis each containing 
four modules, which are all transcribed in the same direction (Figure 3.26 and Table 3.7). The 
modules include typical NRPS domains C, A and PCP domains, as well as E domains. 
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Figure 3.26: Sequencing results from cosmids FD10 and AI6.  
Key:  orange, NRPS and PKS genes; brown, regions which are shared between cosmids AI6 
and FD10. 
 
 
Table 3.7: List of NRPS genes from cosmids FD10 and AI6 
Orf Proposed function Identity/similarity to protein/origin 
Cosmid FD10   
nrps1_FD10 NRPS: A1 PCP1 C2 A2 PCP2 
E2 
52%, 64%: SACE4288, 
Saccharopolyspora erythraea 
nrps2_FD10 NRPS: C3 A3 PCP3 C4 A4 
PCP4 E4 
47%, 58%: CDA peptide synthetase I, 
Streptomyces coelicolor A3(2) 
nrps3_FD10 NRPS: C5 54%, 70%: pstC, Actinoplanes friuliensis 
Cosmid AI6   
nrps1_AI6 NRPS: A1 PCP1 E1 51%, 63%: SACE4288, 
Saccharopolyspora erythraea 
nrps2_AI6 NRPS: C2 A2 PCP2 C3 A3 
PCP3 E3 
47%, 58%: CDA peptide synthetase I, 
Streptomyces coelicolor A3(2) 
nrps3_AI6 NRPS: C4 A4 50%, 65%: pstC, Actinoplanes friuliensis 
 
The nrps1_FD10 gene from cosmid FD10 most likely starts with an ATG which is located 9 
bp downstream of a putative ribosome binding site (RBS) GAGG. nrps1_FD10 appears to be 
part of an operon with nrps_FD10_2-3. nrps2_FD10 represents another NRPS with a putative 
RBS (GGAG) upstream from the start codon ATG. The subsequent gene nrps3_FD10 
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encodes a NRPS protein, which only contains a C-domain. nrps3_FD10 starts with GTG, and 
a RBS (GGAG) is located 8 bp upstream. On the basis of sequence analysis and restriction 
mapping, it was expected that the two cosmids would contain portions of the same 
biosynthetic gene cluster, and would therefore share an overlapping region. However, 
annotation of cosmid AI6 revealed that only the nrps2_AI6 gene showed exactly the same 
sequence as nrps2_FD10. The other two genes, nrps1_AI6 and nrps3_AI6, exhibited some 
sequence identity to the corresponding FD10 genes, but were not identical along their full 
lengths. Specifically, nrps1_AI6 is only half the size of nrps1_FD10, while only a portion of 
nrps3_AI6 is present in nrps3_FD10. Additionally gene nrps3_AI6 is interrupted at the end of 
the cosmid, so it is not clear how large this gene cluster actually is. Taken together, these 
observations indicate that the clusters might have arisen from gene duplication, as they are 
overall highly similar, though not identical.  
 
At this point, it remained to establish which of the two clusters, if either, was responsible for 
the biosynthesis of GE81112. The presence of four modules in each gene cluster was 
consistent with the incorporation of four amino acids into the corresponding products, so no 
decision could be made on that basis. We therefore performed a detailed sequence analysis of 
the NRPS domains from each module.  
 
3.2.5.3 Analysis of the NRPS domains 
3.2.5.3.1 A domains 
NRPS include a specific adenylation domain to select each amino to be incorporated into the 
peptide product; the sequence of A domains in the NRPS dictates the primary structure of the 
peptide product. A domains contain 10 highly-conserved core motifs (A1─A10), where the 
region between motifs A3 and A6 forms the amino acid binding pocket [91]. To determine the 
substrate specificity of the A domains in the putative GE81112 clusters, each of the A 
domains was aligned with A domains from the gramicidin, rapamycin and tubulysin 
synthetases. All ten core motifs were identified in each A domain from both cosmids, 
indicating that all A domains are functional.  
Results 92 
 92
 
Figure.3.27: Consensus core motifs of A domains from cosmid FD10. 
The ten core motifs A1–A10 of the NRPS A domains are shown. The A domains from cosmid 
FD10 were compared with known A domains from NRPSs of gramicidin (GrsA), rapamycin 
(RapP) and tubulysin (TubB). The amino acids marked in green match the consensus motif for 
each region. “x” can be any amino acid. 
 
The substrate specificity of A domains can be predicted using the specificity-conferring code 
of adenylation domains [93;94]. The code was developed by two different groups [93;94] 
using the crystal structure of the phenylalanine-activating A domain PheA from the 
gramicidin synthetase (GrsA) from Bacillus brevis. The crystal structure led to the 
identification of the 8 residues that form the substrate binding pocket. By comparing the 
sequence of PheA, the structure of which was known, with the sequence of 160 other 
adenylation domains, eight residues that (putatively) form the amino acid binding pockets 
were identified. The signature sequences for different substrate specificities were then 
determined from groups of domains activating the same substrate. This code now allows the 
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substrates of uncharacterized or unknown A domains to be predicted from the primary 
sequences. Nevertheless some limitations of the code should be noted. First, there is only a 
limited amount of sequence information available for A domains, and thus it is currently 
impossible to discern with confidence consensus specificity sequences for all amino acids. 
Furthermore, NRPS are not restricted to proteinogenic substrates and more then 300 are 
known to be incorporated but the codes currently available are mostly restricted to 
proteinogenic amino acids. A clear shortcoming of the available biochemical data is that it is 
limited mostly to A domains from E. coli, Bacillus sp. and Pseudomonas sp. Actinomycetes, 
including notably Streptomyces, are largely missing from the essential database. 
 
In order to predict the substrate specificity of the FD10 and AI6 A domains from the 
sequenced cosmids, the A domains were aligned against the A domain from the gramicidin A 
synthetase (GrsA), and the 8 residues that form the amino acid binding pocket were identified 
(Figure 3.28; shown for A domains from cosmid FD10).  
 
Figure.3.28: Alignment of A domains from cosmid FD10 with the A domain of GrsA. 
grey: core motifs of A domain; black: 8 residues that form the amino acid binding pocket 
 
Additionally the sequence was cross-checked with the bioinformatics programs 
(http://www.tigr.org/jravel/nrps/ and http://www-ab.informatik.uni-tuebingen. de/ 
toolbox/index.php?view=domainpred) which also allow substrate specificities to be predicted. 
Sequence analysis of the code residues from all of the A domains from both clusters allowed 
the prediction of substrate specificity in several cases (Table 3.8).  
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Table 3.8: Putative A domain ‘code residues’ within A domains from both clusters  
 
                        Position of the amino acid within the A domain 
 235 236 239 278 299 301 322 330 
Activated 
amino acid 
prediction 
 
Identitiy 
to 
protein 
FD10_A1 D A V D F G T I No hit  
FD10_A2 D A L L I G A V Phe/Trp 75% 
FD10_A3 D F W S V G M V Thr 87% 
FD10_A4 D A A Q L G V I No hit  
AI6_A1 D A L L I G A V Phe/Trp 75% 
AI6_A2 D F W S V G M V Thr 87% 
AI6_A3 D A A Q L G V I No hit  
AI6_A4 D V F S V A V V No hit  
 
When identity to known A domains could not be found in the database for the 8 amino acid 
residues, no hit was predicted from the bioinformatics program. We also compared the A 
domains manually with the known A domains which were published by Challis et al. [94]. 
Despite the use of multiple methods no substrate specificity could be predicted for FD10_A1, 
FD10_A4, AI6_A3 and AI6_A4. 
 
Consistent with the observation that both clusters exhibited an overall high level of sequence 
similarity, three of the A domains from each cluster showed the same apparent substrate 
specificity (FD10_A2 and AI6_A1, FD10_A3 and AI6_A2 and FD10_A4 and AI6A3). 
FD10_A2 (which showed the same specificity as AI6_A1) exhibited 75% identity to the 
specificity pocket of the TycB-M2 A domain in Bacillus brevis, which selects and activates L-
phenylalanine or L-tryptophan. Sequence analysis of FD10_A3 (same specificity as AI6_A2) 
revealed 87% identity to the specificity pocket of the SyrE-M7 A domain in Pseudomonas 
syringae, which is involved in selection and activation of L-threonine. Analysis of FD10_A1, 
FD10_A4 and AI6_A3 and AI6_A4 A-domains revealed that the identified code residues did 
not allow a prediction of the specificity.  
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3.2.5.3.2 PCP, C and E domains 
The PCP, C and E-domains were analyzed to determine whether or not they were likely to be 
functional, which would support the hypothesis that the clusters act to biosyntheize a 
tetrapeptide. The peptidyl carrier protein (PCP) (or thiolation (T) domain) is the site of 
substrate attachment during chain elongation [95]. These proteins show a conserved signature 
sequence LGx(HD)S(LI), where the central S is the point of covalent attachment of the Ppant 
prosthetic group. The signature sequence including the active serine was found in all PCP 
domains from both cosmids FD10 and AI6, indicating that the domains should be activated to 
participate in chain extension.  
 
Figure 3.29: PCP consensus motif.  
The PCP domains from cosmid FD10 were compared with known PCP domains from the 
gramicidin (GrsA), surfactin (SrfA), tyrocidine (TycA) and calcium-dependent antibiotic 
(CDA) NRPSs. The amino acids marked in grey match the consensus motif. “x” can be any 
amino acid. The highly conserved serine residue (site of Ppant attachment) is indicated in 
black. 
 
C domains are responsible for the condensation of two amino acids activated on adjacent 
modules. These domains incorporate seven highly-conserved core regions, all of which were 
found in the C domains in both cosmids FD10 and AI6. We also analyzed the epimerase 
domains, which are responsible for substrate epimerization (formation of D-amino acids). 
Again, the seven characteristic conserved motifs for all E domains could be identified in the E 
domains on both cosmids. These results demonstrate that, in principle, all modules are active 
and so each system should be able to generate a tetrapeptide. Thus, these results did not allow 
us to prove or exclude that one or both of the clusters are responsible for the biosynthesis of 
GE81112 and further experiments/analysis had to be done. Therefore we continued our 
analysis, by investigating the cyclodeaminase from FD10.  
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3.2.6 Analysis of the cyclodeaminase from cosmid FD10 
We also expected that the GE81112 cluster would include a cyclodeaminase, providing L-
pipecolic acid from L-lysine. BLAST sequence analysis of both cosmids revealed that only 
cosmid FD10 contained a cyclodeaminase sequence (The protein showed 62% identity to the 
TubZ protein from Angiococcus disciformis). To analyse the conserved regions of the protein 
which would indicate whether it was functional, we performed an alignment with three 
different cyclodeaminases TubZ [85], LipE [83] and RapL [87] (Figure 3.30). 
 
 
Figure.3.30: Alignment of the cylodeaminase from cosmid FD10 with LipE, RapL and TubZ. 
 
No color: Non-similar amino acid residues, blue: conservative, green: block of similar, yellow: 
identical 
 
Cyclodeaminases are typically 1000–1100 kb in size (corresponding to approximately 350 
amino acid residues). However, the cyclodeaminase present on cosmid FD10 was only 465 kb 
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in size, corresponding to 155 amino acid residues. Thus, more than half of the protein was 
apparently missing, relative to previously-characterized cyclodeaminases.  
   
3.2.6.1 Heterologous expression of cosmids FD10 and AI6 
In principle, the most straightforward method to verify the identity of the gene clusters would 
have been to knockout one of the NRPS genes, and then to determine if production of 
GE81112 was abolished. We attempted to generate this knockout by amplifying an internal 
region from the nrps_2 gene, which was then cloned into the knockout vector pKC1132 [10], 
and introduced the vector into strain S. 14386  by conjugation. However, to date, the knockout 
has not been successful.  
 
We therefore decided to use an alternative strategy to determine the identities of the cluster – 
heterologous expression of the biosynthetic gene clusters from both cosmids. The two 
cosmids were transformed into S. lividans TK24 and S. coelicolor A3(2) by conjugation. 
Exconjugants were verified by PCR (amplification of the apramycin resistance gene) and 
extracts were analyzed by high resolution Orbitrap-MS analysis (data not shown). We did not 
observe production of GE81112 in the extracts of the mutants harboring either cosmid AI6 or 
FD10. Instead, three new peaks with masses 631.2242 (retention time 3.86 min), 645.2389 
(retention time 4.70 min) and 659.2545 (retention time 4.94 min) were detected in the extract 
of S. lividans TK24::FD10 (Figure 3.31), although the compounds were not present in S. 
lividans TK24 wild type or in S. lividans TK24::AI6.  
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Figure 3.31: Analysis of S. lividans::FD10 extract by high-resolution MS.  
  
A) Base peak chromatogram (BPC) of S. lividans::FD10 extract and extracted ion 
chromatograms (EICs), showing molecular ions and elemental formulas of B) m/z= 631.2242 
[M+H]+, C) m/z = 645.2389 [M+H]+  and D) m/z = 659.2545 [M+H]+ . E), F) and G) show the 
exact masses and elemental formulas of GE81112 factor A, B1 and B for comparison. 
 
Detailed MS/MS analysis revealed that all 3 of the substances exhibited exactly the same 
fragmentation pattern as the new chlorinated substances found during analysis of the GE 
producer strain (section 3.2.2). This result led us to conclude that the three substances 631, 
645 and 659, had been heterologously expressed in S. lividans from cosmid FD10. No 
production of the same metabolites was observed from cosmid AI6, which is likely explained 
by the fact that the cluster is incomplete. In addition, no other new metabolites were detected 
in the extract of S. lividans TK24::AI6.  
These results indicated that the biosynthetic gene cluster from cosmid FD10 is not responsible 
for biosynthesis of GE81112, but for the new substances which might be related to the GE 
compounds. Therefore we aimed to purify the novel substances and to elucidate their 
structures.  
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3.2.7 Isolation and attempted structure elucidation of three chlorinated substances 
In previous experiments, we observed that the desired compounds were mostly localized to 
the culture supernatant, while only traces of the metabolites were present in the cell pellets. 
Cultivation with XAD resin did not lead to an increase of production, and only small amounts 
of the compounds were detected in the extract of the XAD. Therefore the strain was grown 
without XAD, and the compounds were isolated from the supernatant. S. 14386 was grown in 
GE production medium for 6 days and harvested by centrifugation. 
 
 
Figure.3.32: Purification procedure for substances 631, 645 and 659. 
 
The purification scheme is outlined in Figure 3.32. First, 13 L of the supernatant were 
extracted twice with the same volume of ethyl acetate. After the solvent was removed by 
evaporation, the extract was resuspended in 50 ml methanol and extracted with heptane for 
degreasing. The heptane and MeOH phases were subsequently analyzed by HPLC-MS.  
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Figure 3.33: HPLC-MS analysis of heptane and MeOH fractions. 
Base peak chromatogram of heptane A) and MeOH B) phases, and extracted ion 
chromatograms of MeOH fraction showing molecular ions of C) m/z [M+H]+ = 631.3, D) 645.3 
and E) 659.3.  
 
Only traces of the compounds could be detected in the heptane phase, while all three 
compounds were present in the MeOH phase (Figure 3.33). The methanol phase was therefore 
evaporated and resuspended in a smaller volume of methanol (2 ml). This sample was then 
fractionated by semi-preparative HPLC using a stepwise gradient (solvent A: H2O containing 
0.01 % formic acid; solvent B: methanol containing 0.01% formic acid, 25%–90% B over 35 
min, injection volume 250 µl). As the substances did not exhibit a significant UV signal, the 
HPLC was coupled to a mass spectrometer (Bruker HCT equipped with an ion trap mass 
spectrometer) for online monitoring of the masses. Using this method, the exact retention 
times of the compounds could be measured, allowing straightforward collection of the 
substances. Five fractions were collected and analyzed for the presence of the compounds 
(representative results are shown in Figure 3.34).  
Results 101 
 101
 
Figure 3.34: HPLC/MS analysis of different purified fractions after preparative HPLC. 
 
Base peak chromatogram showing molecular ions with the masses m/z [M+H]+ = 631.3, 645.3 
and 659.3.  
 
Fractions 2, 4 and 5 contained the compounds 631, 645 and 659, respectively. However, 
contaminants remained in all of the fractions, so it was necessary to carry out a further 
purification step. MS analysis revealed that only substances with relatively low masses (< m/z 
= 300) were present in fraction 2 (containing 631). Fractions 4 (645) and 5 (659) also 
contained substances with masses similar to the desired compounds (in a range of m/z = 600). 
These observations prompted us to use size-exclusion chromatography for fraction 2 (631), 
followed by purification by isocratic preparative HPLC, while fractions 4 (645) and 5 (659) 
were directly submitted to separation by isocratic preparative HPLC. All 30 samples from 
each fraction were combined and the solvent evaporated. The extracts of fractions 4 (645) and 
5 (659) were resuspended in 500 µl methanol.  
 
The extract of fraction 2 (631) was resuspended in 1 ml of methanol and subsequently 
separated on a Sephadex LH20 column (28 h), yielding 48 fractions. Every second fraction 
was analyzed by HPLC/MS. Fractions 9–11 contained the compound and were combined. 
The solvent was evaporated and the extract was resuspended in 500 µl methanol. All three 
extracts were then purified by isocratic preparative HPLC (solvent A: H2O containing 0.01 % 
formic acid; solvent B: acetonitrile containing 0.01% formic acid, 0–10 min 30% B isocratic, 
10–20 min 30%–50% B, 20–25 min 50%–95% B, 25–27min 95% B, injection volume 200 
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µl). Monitoring was again carried out by mass spectrometry. After this separation step, 
essentially pure compound was obtained in each case (Figure 3.35)  
 
Figure 3.35: HPLC-MS analysis of different fractions after preparative HPLC. 
Base peak chromatograms and UV chromatograms after preparative HPLC showing molecular 
ions of A) m/z [M+H]+ = 631.3, B) m/z [M+H]+ = 645.3, and C) m/z [M+H]+ = 659.3.  
 
The extracts were vacuum-dried by lyophilization and weighed. Compound 631 was obtained 
at a yield of 4.8 mg, compound 645 at 2.3 mg and compound 659, 1.2 mg. Structure 
elucidation of all three substances was then performed by NMR.  
 
3.2.8 NMR structure elucidation 
NMR structure elucidation was started with the compound 631 because purification yielded 
the highest amount (4.8 mg) of this compound. NMR was carried out using 1D (1H, 13C) and 
2D (1H-1H-COSY, HMBC and HSQC) NMR analysis in [D6]DMSO as well as in CD3OD. 
Although several structural elements have been elucidated to date for compound 631 (Figure 
3.36), it has not yet been possible to solve the complete structure. 
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Figure 3.36: Postulated structural elements of compound 631 identified by NMR spectroscopy.  
N/O means that N or O might be present at that specific position. R indicates that the 
functionality could not be identified. 
 
(NMR interpretation was done by H. B. Bode) and is not discussed in detail here. The 
structure is likely to contain four amino acid-derived structural elements (nos. 1–4) including 
two ornithine moieties (3 and 4) which are probably acylated (H. B. Bode, personal 
communication). However, these structural elements could not be connected together due to 
missing correlations in the 2D-NMR experiments (HMBC, COSY). The three compounds 
631, 645 and 659 differ in 14 atomic mass units each. To date, it is not clear at which 
positions these variations occur. Therefore, further experiments will be necessary to complete 
the structure elucidation.  
 
3.2.9 Identification of the GE81112 biosynthetic gene cluster 
3.2.9.1 Identification of a cosmid containing GE81112 biosynthetic genes 
As the results described in section 3.2.5 led us to conclude that the identified gene clusters 
were not involved in the biosynthesis of GE81112, we developed a new strategy to identify 
the GE81112 gene cluster. The previous cyclodeaminase probe successfully identified a 
cyclodeaminase, but it was truncated, and therefore presumed to be inactive. However, as 
such pseudo-genes often arise by gene duplication of an original active copy; we reasoned 
that there might be a second, complete cyclodeaminase gene in the genome, which should be 
functional. We therefore decided to generate a new specific cyclodeaminase probe based on 
the cyclodeaminase sequence found on cosmid FD10. In order to amplify the cyclodeaminase 
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gene, a PCR reaction was carried out using specific primers (Table 2.12, Cyclo Probe_for and 
Cyclo Probe_rev). The resulting 400 bp PCR product was labeled with digoxigenin and used 
to re-probe the cosmid library. To evaluate the likely success of this strategy, we first carried 
out a Southern Blot to check if the probe hybridized to more than one gene in the genome. 
Digestion of cosmid FD10 with PvuII produced a 2.5 kb fragment which encompasses the 
cyclodeaminase sequence. Thus, if the FD10 cyclodeaminase were the only cyclodeaminase 
in the genome, we would have observed a single 2.5 kb band by Southern Blot. 
 
Figure.3.37: Southern Blot analysis of genomic DNA from S. 14386.  
1: Ladder; 2–4: varying concentrations of genomic DNA from S. 14386 digested with PvuII. 
 
For the Southern, genomic DNA of S. 14386 was isolated and digested with PvuII. 
Hybridization was carried out at 42 °C under stringent conditions using the new 
cyclodeaminase probe. Southern Blot analysis showed the expected 2.5 kb band (Figure 3.37). 
However, two additional signals were detected at approximately 1 kb and 13 kb (Figure 3.37), 
suggesting that the probe hybridized a total of three times with genes in the genome (1 kb, 2.5 
kb and 13 kb band). We assumed that the hybridization had been successful, as non-specific 
hybridization would likley have resulted in more signals. Thus, we concluded that the genome 
was likely to contain a second or even a third copy of the cyclodeaminase gene. As the new 
probe seemed to function well, we aimed to screen the cosmid library again with this probe to 
identify cosmids that had not hybridized with the old cylodeaminase probe. Hybridization was 
again carried out at 42 °C (Figure 3.38).  
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Figure 3.38: Screening of S. 14386 cosmid library with the specific cyclodeaminase probe.  
 
The hybridization was successful, as only nine distinct signals were obtained, in addition to 
that with cosmid FD 10 (positive control). To verify the presence of cyclodeaminase sequence 
on these nine cosmids, we performed a PCR analysis on the cosmids using the primers 
employed to generate the probe. PCR products of ca. 400 bp were obtained for all cosmids 
and the control FD10, confirming in each case that the cyclodeaminase sequence was present. 
As we expected that NRPS sequence must also be present on the cosmid, we additionally 
performed a PCR using the degenerate NRPS primers RevA3 and PSLGG [88]. 
Unfortunately, no PCR products were obtained with these primers. One possible explanation 
for this result, however, is that the NRPS degenerate primers RevA3 and PSLGG were not 
optimal. Indeed, attempts by other members of the laboratory to use these primers to amplify 
A domains from Streptomcyes genomes have not been successful, perhaps because they were 
originally designed for use with myxobacterial DNA.  
 
We therefore designed new primers based on Streptomyces A domains using the CODEHOP 
software [96]; priming was targeted against the core A3 and A6 motifs. The new primers were 
then used to amplify A domains from the nine cosmids that produced products of the correct 
size in the cyclodeaminase PCR. This reaction resulted in PCR products from four of the nine 
cosmids. These fragments were cloned into pCR2.1-TOPO and sequenced. BLAST analysis 
revealed that all of the sequences showed high homology to A domains. We then analyzed the 
A domain sequences as described earlier, to predict the substrate specificity of each A domain 
(Table 3.9).  
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Table 3.9: Putative A domain ‘code residues’ within A domains from cosmids  
 
                            Position of the amino acid within the A domain 
 235 236 239 278 299 301 322 330 
Activate
d amino 
acid 
Identity 
to 
protein 
Topo BG23 D A S Q V G E V Asp/Asn 75% 
Topo DB20 D A V D F G T I No hit  
Topo DK18 D A V D F G T I No hit  
Topo BI11 D V Q D I A H M Pro/Pip 70% 
 
This analysis led to a prediction that the A domain in cosmid BI11 would be specific for 
proline/pipecolic acid. This result was supported by BLAST analysis of the A domain which 
predicted homology to a “NRPS for pipecolate incorporation, Streptomyces sp. NRRL 
30748”. We also directly compared the nonribosomal code of this A domain to those of 
known pipecolic acid-incorporating A domains from the rapamycin and tubulysin systems 
(Table 3.10). The code residues in each case were similar, supporting the probable specificity 
for pipecolic acid.  
 
Table 3.10: Substrate specificity pocket of pipecolic acid incorporating A domains  
                                Position of the amino acid within the A domain 
 235 236 239 278 299 301 322 330 
Activated 
amino 
acid 
 
A domain RapP D Y Q Y C G H L Pip  
A domain BI11 D V Q D I A H M   
A domain TubB D I Q Y I A Q V Pip  
 
Taken together, these data strongly suggested that cosmid BI11 contained the biosynthetic 
pathway for GE81112. Furthermore, as we anticipated that the NRPS would contain four 
modules (30–40 kb), it was possible that entire gene cluster would be located on a single 
cosmid. To verify this, we end sequenced the cosmid using primers T4 and T7 (Table 2.12.). 
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Table 3.11:  End sequencing results of cosmid BI11 with T7 and T4 primers 
Cosmid Homology Identity Score 
E-
Value 
BI11_T4 DNA binding protein, Streptomyces coelicolor 36% 143 1e-32 
BI11_T7 L-arginine beta-hydroxylase, Streptomyces 
vinaceus 
44% 
 
331 4e-89 
 
The T4 end exhibited homology to a DNA binding protein, while sequence at the T7 showed 
similarity to an arginine β-hydroxylase (Table 3.11). The DNA binding protein was not 
expected to have any function in the biosynthesis, and thus cosmid BI11 contained at least 
one end of the gene cluster. However, it was possible that the β-hydroxylase was involved in 
the biosynthesis, so we could not conclude that the entire cluster was located on the cosmid. 
Nonetheless, we sequenced BI11, as at least a significant portion of the cluster was likely to 
be present.  
 
3.2.9.2 Identification of overlapping cosmids 
To find a cosmid which overlapped with the 3′ (T7) end of the GE81112 biosynthetic gene 
cluster, we amplified a 1 kb fragment from the T7 end of cosmid BI11 to serve as a probe. 
The sequenced PCR product was then used as a template to carry out a PCR reaction using 
digoxigenin-labeled nucleotides. The cosmid library was then screened with the new probe, 
with hybridization at 42 °C.  
 
 
Figure.3.39: Screening of the cosmid library to identify cosmids which overlapped the T7 end of 
cosmid BI11. Cosmid BI11is labeled. 
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Seven new cosmids were identified, in addition to cosmid BI11 (marked in Figure 3.39). We 
initially investigated the cosmids by PCR analysis by amplifying an 800 bp fragment with the 
primers used to generate the probe (cyclo probe_for and cyclo probe_rev). All of the cosmids 
produced a positive signal. However, as some of the cosmids gave a similar restriction pattern 
to that of BI11, we excluded them from further analysis. We chose one cosmid (BA23) which 
showed the least similar fragmentation pattern and analyzed it further. To ensure that both 
cosmids (BI11 and BA23) contained similar portions of the cluster, and to determine whether 
the cloned DNA was co-linear with the S. 14386 chromosome, we performed a Southern Blot 
with both the cosmids and the wild type genomic DNA. In theory, the probe that derives from 
the T7 end of cosmid BI11 should produce identical signals when hybridized to the cosmids 
and the wild type DNA. As hybridization was observed to the same fragments in all cases 
(Figure 3.40), the cosmids were verified to be co-linear with the genome. 
.  
Figure 3.40: Southern Blot analysis of cosmid BI11 and the overlapping cosmid.  
Schematic arrangement of cosmids BI11 and BA23. To verify the colinearity between the 
cosmids and the genome, the cosmids and the genomic DNA were digested with the same 
enzymes (NotI, SalI and PvuII). The probe was designed against the T7 end of cosmid BI11, as 
shown. 1: Cosmid BI11, 2: cosmid BA23, 3: genomic DNA, L: Ladder 
 
3.2.9.3 Annotation  
The two cosmids BI11 and BA23 were sequenced in the HZI. The obtained sequence was 
analyzed for the presence of putative open reading frames (orfs) with FramePlot 2.3.2 [92], 
and preliminary functional assignments of individual orfs were made by comparison of the 
deduced gene products with proteins of known function in the BLAST database (Table 3.12).  
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Table 3.12: BLAST results for genes on the cosmids BI11 and BA23 
Gene Homology Identity Score E-Value 
orf1 
putative partitioning protein ParA, Nocardia 
farcinica IFM 10152 
 
63/222 
(29%) 
 
77.0 
 
8e-13 
 
orf2 
hypothetical protein SAV_5443 
Streptomyces avermitilis MA-4680 
 
263/478 
(55%) 
 
470 
 
1e-130 
 
orf3 
FtsK/SpoIIIE family protein 
Streptomyces avermitilis MA-4680 
 
802/1099 
(72%) 
 
1565) 
 
0 
 
orf4 
hypothetical protein SAV_6995 
Streptomyces avermitilis MA-4680 
 
118/142 
(83%) 
 
244 
 
2e-63 
 
orf5 
serine/threonine protein kinase 
Streptomyces avermitilis MA-4680 
 
249/381 
(65%) 
 
395 
 
5e-108 
 
geA 
thioesterase type II 
Streptomyces atroolivaceus 
 
89/230 
(38%) 
 
142 
 
4e-32 
 
geB 
putative ABC-type multidrug transport 
system ATPase and permease 
component, Streptomyces griseus 
 
269/563 
(47%) 
 
449 
 
4e-124 
 
geC 
putative ABC transporter ATPase and 
permease component, Streptomyces griseus 
 
291/575 
(50%) 
 
533 
 
1e-149 
 
geD 
TubZ protein 
Angiococcus disciformis 
 
182/346 
(52%) 
 
337 
 
1e-90 
 
geE 
syringopeptin synthetase 
Pseudomonas syringae 
 
209/522 
(40%) 
 
325 
 
7e-87 
 
geF putative L-proline 3-hydroxylase protein Ralstonia solanacearum GMI1000 
81/253 
(32%) 
 
123 
 
2e-6 
 
geG 
 
peptide synthetase protein, Ralstonia 
solanacearum GMI1000 
765/2401 
(31%) 
 
857 
 
0 
 
geH 
non-ribosomal peptide synthetase 
Myxococcus xanthus DK 1622 
 
168/530 
(31%) 
 
194  
 
2e-47 
 
geI 
L-arginine β-hydroxylase 
Streptomyces vinaceus 
 
144/322 
(44%) 
 
238 
 
6e-61 
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Table 3.12: Continuation of Table 3.12 
Gene Homology Identity Score E-Value 
geJ 
bacitracin synthetase 3; BacC, 
Bacillus licheniformis 
 
223/598 
(37%) 
 
368  
 
1e-99 
 
geK 
ribosome-associated GTPase 
Streptomyces sviceus ATCC 29083 
 
209/368 
(56%) 
 
395 
 
3e-108 
 
geL 
halogenase, 
Microcystis aeruginosa 
 
199/500 
(39%) 
 
376 
 
2e-102 
 
geM bacitracin synthetase 3; BacC,Bacillus 
licheniformis 
199/500 
(39%) 
 
397  2e-108 
geN ChlK, thioesterase type I, 
 Streptomyces antibioticus 
44/112 
(39%), 
80.5 4e-14 
orf6 
3-oxoacid CoA-transferase subunit B 
Streptomyces avermitilis, MA-4680 
 
177/215 
(82%) 
 
359  
 
1e-97 
 
orf7 
protocatechuate 3,4-dioxygenase α 
subunit, Streptomyces avermitilis MA-
4680 
 
185/253 
(73%) 
 
375  
 
2e-102 
 
orf8 
protocatechuate 3,4-dioxygenase β 
subunit, Streptomyces avermitilis MA-
4680 
 
129/182 
(70%) 
 
253  
 
5e-66 
 
orf9 
3-carboxymuconate cycloisomerase 
Streptomyces sviceus ATCC 29083 
 
319/447 
(71%) 
 
570 
 
8e-161 
 
orf10 
deoxyribose-phosphate aldolase 
Streptomyces avermitilis MA-4680 
 
 
150/205 
(73%) 
 
285  
 
4e-75 
 
orf11 
arthrofactin synthetase/syringopeptin 
synthetase C-related non-ribosomal 
peptide synthetase module, 
Bradyrhizobium sp. BTAi1 
 
513/1186 
(43%) 
 
777  
 
0.0 
 
orf12 
peptide synthetase protein, Ralstonia 
solanacearum GMI1000 
 
221/656 
(33%) 
 
244  
 
3e-62 
 
orf13 
putative ATP/GTP binding protein 
Streptomyces coelicolor A3(2) 
 
178/193 
(92%) 
 
338 
 
3e-91 
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Table 3.12: Continuation of Table 3.12 
Gene Homology Identity Score E-Value 
orf14 
integrin-like protein, Streptomyces 
avermitilis MA-4680 
 
200/468 
(42%) 
 
299 
 
3e-79 
 
orf15 
two-component system sensor kinase, 
Streptomyces coelicolor A3(2) 
 
107/218 
(49%) 
 
179 
 
2e-43 
 
orf16 
polyketide synthase type I, Streptomyces 
aizunensis 
 
228/435 
(52%) 
 
359 
 
4e-97 
 
 
Based on the chemical structure of GE81112 we expected a NRPS pathway involving a 
cyclodeaminase and a halogenase. Annotation of the two cosmids revealed 30 orfs of which 
14, designated geA–N, are postulated to be involved in the GE81112 biosynthetic pathway 
(Figure 3.41). The genes marked in black indicate NRPS encoding enzymes.  
 
The sequenced region starts with the gene orf1, which shows homology to a putative 
partitioning protein ParA from Nocardia farcinica IFM 10152. This protein is not expected to 
be involved in the biosynthesis, as these proteins are known to be involved in bacterial mitosis 
[97]. Similarly, we excluded orfs 2 and 3, as they do not show homology to proteins 
postulated to be involved in the biosynthesis. orf2 is a hypothetical protein with no assigned 
function, and orf3 encodes for a FtsK/SpoIIIE family protein which belongs to the family of 
DNA translocases [98]. It is not possible, however, to conclusively identify the boundaries of 
a gene cluster based solely on the deduced functions of the gene products. Therefore, in 
future, it will be necessary to carry out gene knockouts to confirm the proposed cluster ends. 
 
Figure 3.41: GE81112 biosynthetic gene cluster on cosmids BI11 and BA23. 
 
Key: black, NRPS biosynthetic genes; light grey, modification genes; dark grey, orfs not 
involved in the biosynthesis. 
 
The first gene that we predicted to be involved in the biosynthesis is gene geA, which encodes 
a type II thioesterase (TEII). TEIIs are present in many NRPS and PKS systems, where they 
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perform crucial proof-reading functions by hydrolyzing aberrant substrates from the 
respective carrier protein domains. In modular PKS, type II TEs are proposed to release from 
the ACP domains acyl groups that have been produced by aberrant decarboxylation of chain 
extender units [99]. In NRPS systems, they are proposed to play two functions: removal of 
acyl groups added to the PCP domains during post-translational priming of the apo proteins, 
and release of amino acids that have been loaded by mistake [100].  
 
geA appears to be in an operon with genes geB–E. geB and geC encode proteins which show 
homology to ABC transporter systems. Many antibiotic-producing actinomycetes posses at 
least one ABC (ATP-binding cassette) transporter which forms part of the antibiotic 
biosynthetic pathway, and in most cases confers resistance to the drug in a heterologous host. 
In Type I ABC transporters, two genes are involved, one encoding a hydrophilic ATP-binding 
protein with one nucleotide-binding domain, and the other encoding a hydrophobic membrane 
protein. The same type of proteins have been found in the GE81112 cluster [101]. geD 
encodes the cyclodeaminase gene that was targeted in our second probing strategy. It shows 
52% identity to TubZ, the cyclodeaminase from Angiococcus disciformis. This time the 
protein was not truncated as in cosmid FD10 and was proposed to be functional. The 
sequence of the truncated cyclodeaminase gene on cosmid FD10 is identical to a region 
within geD, consistent with the idea that the truncated form arose from gene duplication.  
 
geE is the first gene that encodes for a NRPS protein, and most likely starts with a GTG. A 
putative RBS (GGAG) was found 7 bp upstream of the gene. The next gene geF is oriented in 
the opposite direction, and encodes a protein with homology to a putative L-proline 3-
hydroxylase. This enzyme is expected to be responsible for the hydroxylation of the pipecolic 
acid. The following gene, geG, encodes another NRPS protein, and is the likely starting point 
of a new operon which includes genes geH and geI. geG has an ATG start codon and a 
putative RBS (GAAGG) is located 19 bp upstream from the start codon. geH encodes a third 
protein with homology to NRPSs, and again starts with a GTG. The last gene in this operon is 
geI, which exhibits homology to an L-arginine β-hydroxylase, which might be responsible for 
the hydroxylation of one of the incorporated histidines in GE81112. The last operon contains 
5 genes (geJ–geN). This operon starts with a change in the transcription direction again. The 
operon begins with the gene geJ which encodes a NRPS enzyme. The next two genes, geK 
and geL, encode a GTPase protein and a halogenase, respectively; GeL may be responsible 
for the chlorination of the GE81112 histidine. The NRPS-enconding gene geM starts with a 
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TTG, and a RBS (AGGG) is located 6 bp upstream of the gene. The last gene of the operon is 
geN, which encodes a protein with homology to a type I thioesterase. A RBS (GAAA) is 
located 8 bp upstream of the gene which starts with an ATG. The involvement of orfs 6–16 
can not yet be excluded. 
 
3.2.9.4 Analysis of NRPS domains 
The sequence analysis revealed 14 open reading frames that we predicted to be part of the 
gene cluster. Five of them showed homology to NRPS genes (Figure 3.41). The constituent 
domains were assigned using the PKS/NRPS predictor (http://www.tigr.org/jravel/nrps/) and 
confirmed by manual inspection with BLAST, as the prediction programs can omit some 
domains.  
 
 
Figure 3.42: The GE81112 biosynthetic gene cluster.  
 
In order to incorporate 4 amino acids into the GE81112 structure, we expected the synthetases 
to contain 4 modules for the biosynthesis of a tetrapeptide including a loading module 
followed by three condensation module with the standard C-A-PCP arrangement. However, 
the sequence analysis revealed that the cluster exhibits a highly nonlinear arrangement that 
did not fit to what we expected. Altough the domain complement for the biosynthesis of a 
tetrapeptide could be identified one extra module consisting of an A-PCP didomain could be 
identified. Furthermore the modules showed a highly split arrangement (Figure 3.42). Thus, 
from the domain assignment alone, the overall order of subunits could not be discerned, and 
so we carried out further analysis of the domains themselves. We started with the analysis of 
the A domains, as we hoped that the predicted substrate specificities would give us a first hint 
about the order of the domains. 
 
3.2.9.4.1 Analysis of the A domains  
To determine the order of the A domains in the GE81112 cluster, we analyzed the substrate 
specificity of the A domains. The eight conserved motifs were identified for each A domain, 
and the specificity-conferring code (bioinformatics and manual prediction) was then used to 
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predict the substrate specificity. The first A domain, encoded by gene geE (GeEA1) as a 
discrete protein, showed specificity for the incorporation of proline/pipecolic acid (see section 
3.2.9.1). This observation made it a candidate for selection of the GE81112 starter unit. The 
second A-domain located on gene geG (GeGA2) showed homology to 
ornithine/glutamine/asparagine-incorporating A domains. The third A domain on gene geG 
(GeGA3) was predicted to be specific for the incorporation of tyrosine/tryptophane, and the 
two latter domains on geJ (GeJA4) and on geM (GeMA5) for histidine (Table 3.13).  
 
Table 3.13: Putative A domain ‘code residues’ within A domains in the GE81112 cluster 
                        Position of the amino acid within the A domain 
 235 236 239 278 299 301 322 330 Predicted 
amino acid 
Identity 
to 
protein 
GeEA1  D V Q Y I A Q V Pro/Pip 70% 
GeGA2 D A Y N L G L I Orn/Gln/Asp 70% 
GeGA3 D A V G V G E V Tyr/Trp 70% 
GeJA4 D S A S T A E V His 70% 
GeMA5 D S A L T A E V His 70% 
 
These results correlated well with our prediction that an ornithine and two histidines are 
incorporated in the the GE81112 metabolites, in addition to the pipecolic acid. However, it 
remained unclear why two PCP-A didomains (geM and geJ) are located within the cluster, 
although only one is required to give a total of four active modules. To check if any of the 
domains were inactive in order to account for the prescence of the apparently superfluous 
module, we continued by analyzing the C and PCP domains.  
 
3.2.9.4.2 Analysis of the C and PCP domains 
The GE81112 cluster contains three C domains which were aligned with C domains from the 
rapamycin [102], the gramicidin [103] and the calcium-dependent antibiotic [104] clusters. 
The seven conserved regions were identified in all of the C domains. The same analysis was 
carried out for the PCP domains, revealing the signature sequence and active Ser residue, in 
all cases. These results demonstrate that in principle, all modules are active, so that it is 
unlikely that one of the modules is skipped.  
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3.2.9.4.3 Analysis of the TE domains 
TE domains are characterized by a conserved signature sequence GxSxG [91]. There are two 
classes of TE domains known in NRPS systems. TEI domains are normally integrated into the 
multienzyme subunits, and located at the C-terminal end of the modules which are involved in 
adding the last amino acid to the linear peptides [91]. These TEs are responsible for cleavage 
of the linear peptide products. Type II TEs are normally discrete proteins that perform a 
crucial proof-reading function by hydrolyzing aberrant substrates from the respective carrier 
proteins [100;105]. We could identify two discrete TE domains (on genes geA and geN) in the 
GE81112 biosynthetic gene cluster which showed the conserved motif, indicating that they 
are functional enzymes. As they were both discrete proteins, it appeared as if they were both 
TEII enzymes. However, while BLAST analysis (see Table 3.12) revealed that the protein 
GeA showed high homology to a type II TE, protein GeN was similar to type I TEs. This 
finding was surprising, as GeN is a discrete protein like a type II TE, and not integrated into 
an NRPS as is typically found in bacterial NRPS systems.  
 
3.2.9.4.4 Docking domain analysis  
The analysis of all domains with the NRPS subunits revealed that they all contained the 
respective conserved regions, indicating that all proteins/domains are probably functional. In 
the vast majority of NRPS complexes, the modules are distributed over two or more NRPSs 
which have to interact selectively with each other to bring about the synthesis of a defined 
product. The molecular basis for the selective interaction between NRPSs are the so called 
‘communication-mediating (COM)’ domains [106;107]. A donor COM domain (ComD) 
located at the C terminus of an aminoacyl- or peptidyl-donating NRPS and an acceptor COM 
Domain (ComA) located at the N terminus of the accepting partner NRPS form a matching 
set, required for the proper intermolecular interaction between adjacent modules. In contrast, 
ComD and ComA domains of nonpartner NRPSs are considered nonmatching, preventing false 
contact between enzymes [106]. The C-terminal COM domain, which consists of 
approximately 20–30 amino acids, most often follows a PCP or E domain, while the N-
terminal COM domain, which typically precedes a C or HC domain, comprises 15–25 amino 
acids. Although the overall sequence similarity between COM domains is low, the amino acid 
composition is relatively uniform. The C-terminal COM domains incorporate a higher than 
average proportion of acidic amino acids, while N-terminal COM domains are biased toward 
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polar residues, suggesting that specificity is mediated largely by polar/or electrostatic 
interactions between key residues. 
To obtain insight into how the different NRPS proteins from the GE81112 cluster 
might interact with each other to form a defined biosynthetic template, we analyzed the 
GE81112 NRPS proteins for putative COM domains. In contrast to linear NRPS, the 
GE81112 system is a nonlinear systems in which many of the modules are split (Figure 3.43). 
Thus, we devised an NRPS pathway in which individual multienzymes interact to reconstitue 
standard C-A-PCP modules (for example GeE and GeH, Figure 3.43). This task was aided by 
the in silico prediction of the substrate specificity of the A domains which gave us some hints 
as to the ordering of the proteins within the pathway.  
 
Figure 3.43: GE81112 biosynthetic gene cluster.  
 
Domains that are postulated to interact with each other are highlighted in the same color. 
 
We predict that protein GeE (harboring the single A domain GeEA1 which is predicted to 
incorporate pipecolic acid) interacts with subunit GeH to form the loading module. Interaction 
of GeH with GeG would then form the next two modules (A domains GeGA2 (Orn/Gln) and 
GeGA3 (Trp/Tyr)). Protein GeG would than interact with either GeJ (A domain GeGA4 (His)) 
or GeM (A domain GeGA5 (His)) to form the last module. The protein GeN has a TEI 
function and is therefore proposed to hydrolyze the final tetrapeptide from the assembly line.  
 
Figure 3.44: Predicted interaction of NRPS enzymes from the GE81112 biosynthetic gene cluster. 
 
It is not clear if proteins GeG and GeJ or GeG and GeM interact with each other to form the 
last module. 
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In contrast to standard COM domains which normally facilitate the interaction between PCP 
and C domains located on separate multienzymes, intersubunit protein-protein interactions in 
the GE81112 system must reconstitute interfaces between C and A domains (between proteins 
GeH/GeG, and betwee GeG/GeJ or GeG/GeM, see Figure 3.44) to provide a functional 
pathway. To determine if we could identify COM domains between C and A domains, GeHC1 
and GeGA2 (module 2), and GeGC3 and GeJA4 (module 4) or GeMA (module 5), we 
constructed a sequence alignment (attached in the appendix, Table 5.1) comprising putative 
modules 1–5. In this alignment, the sequences of modules 1–5 (Figure 3.44) were compared 
to standard C-A-PCP modules (modules from NRPS pathway from cosmid FD10). This 
analysis revealed large putative recognition sequences at the C terminus of the C domains and 
the N terminus of the A domains in modules 2 and 4 (Figure 3.45).  
 
Figure 3.45: Proposed NRPS interaction and order of subunits in the GE81112 biosynthesis.  
 
However, these recognition sequences did not match the standard size of COM domains (20–
30 amino acid residues). Instead, we found stretches of approximately 100 amino acid 
residues at each terminus; to reflect this difference, we’ve designated the sequences as 
‘recognition elements’ instead of COM domains. Nonetheless, the C-terminal recognition 
elements incorporate a high proportion of acidic amino acids while the N-terminal linker 
domains are biased towards polar amino acids, providing the basis for electrostatic 
interactions as in classical COM domains (the recognition elements contained approximately 
the same proportion of acidic and polar amino acid residues as COM domains). Such 
recognition sequences are normally not found between C and A domains, indicating that in 
this special case, these sequences have a docking function, enabling the interaction between 
NRPS proteins. 
  
At this stage, it remained unclear why the cluster contains an apparently superfluous fifth 
module. One hypothesis was that both bidomains GeJ and GeM can interact with the C 
domain of protein GeG to form the fourth module of the NRPS, incorporating histidine in 
either case. To evaluate this hypothesis, we aligned the sequences of proteins GeJ and GeM, 
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in order to evaluate the extent of their sequence similarity (Table 5.2, appendix). We reasoned 
that a high degree of sequence identity would provide evidence for the evolution of the two 
didomains by gene duplication, supporting the idea that they might both be able to interact 
with the C terminal C domain from GeG. However, the alignment showed that the proteins 
exhibit only 25% mutual sequence identity, consistent instead with a lack of shared partner 
specificity. Indeed, GeM lacks the putative recognition sequence for GeG which is present at 
the N-terminus of GeJ. Taken together, these data indicated that the didomain protein GeM 
was not derived from duplication of GeG, and should therefore have a specific function in the 
pathway (Figure 3.45). To provide further support for the proposals concerning domain order 
and functions of GeJ and GeM, we investigated the gene cluster using both gene inactivation 
and expression analysis of recombinant proteins. 
 
3.2.10   Insertional mutagenesis of the GE81112 biosynthetic gene cluster  
To first verify the identity of the gene cluster, we aimed to inactive the gene geE. For this, a 
knockout construct was designed by amplifying an internal fragment (660 bp) of the gene, 
which was then cloned into the knockout vector pKC1132 [10] leading to the construct 
pKC1132_BI11_PipA. Initial attempts to transform S. 14386 with the knockout plasmids 
pKC1132_FD10 and pKC1132_AI6 however, were unsuccessful, necessitating the 
development of a revised transformation method. The classical procedures for streptomycetes 
transformation are protoplast transformation and conjugation [10]. We tried both methods 
with the knockout vector, using a replicative vector pOJ446 [10] and an integrative vector 
pSET152 [10], as controls. The protoplast transformation method did not produce any 
exconjugants using the knockout vector or with the controls. The conjugation was then 
attempted with varying amounts of E. coli. In the standard procedure, a certain amount 
(normally 500 µl) of E. coli culture (OD600 = 0.6) is mixed with an equal volume of 
Streptomyces cells. Using this approach, we only obtained a low number of colonies with the 
replicative and the integrative vector controls, and no colonies with the knockout construct 
(Table 3.14). We then tried 100-fold and 1000-fold more E. coli cells, but obtained the same 
result. 
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Table 3.14: Transformation efficiency of S. 14386 by biparental conjugation 
 
Transformation
Method 
E. coli amount 
0.5×108 
E. coli amount 
50×109 
Biparental 
conjugation 
pKC1132_BI
11_PipA 
pOJ446 
replicative 
pSET152 
integrative 
pKC1132_B
I11_PipA 
pOJ446 
replicative 
pSET152 
integrative 
 – 20 50 50–100 100–200 500–1000 
 
We next modified the procedure by mixing 5 mL of an overnight culture of E. coli which had 
a very high cell density, with 5 ml of Streptomyces cells. This change finally led to several 
exconjugants containing the knockout vector, indicating that the amount of E. coli is crucial 
for the conjugation efficiency with this strain. The obtained mutants were verified by PCR 
amplifying the ampramycin resistance gene as well as an internal region from the genomic 
DNA, proving the correct integration (primers: apra_for and apra_rev, lacZ1 and lacZ2 and 
BI11A1_pip_for and BI11A1_pip_rev) (section Table 2.12). The mutants were cultivated in 
production medium, as before. The extracts were then analyzed for the presence of the 
GE81112 compounds by high-resolution MS (Figure 3.46).  
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Figure 3.46: High resolution MS analysis of extracts of S. 14386 wild type and S. 14386::pKC1132 
_BI11_PipA mutant. 
 
A) BPC of S. 14386 wild type extract. B) EIC of GE81112 factor B showing a molecular ion of 
the mass m/z = 659.22953 [M+H]+ from S. 14386 wild type extract. C) EIC of GE81112 B 
showing the analysis for a molecular ion of the mass m/z = 659.22953 [M+H]+ of S. 
14386::pKC1132_BI11_PipA  
 
This analysis clearly showed that production of GE81112 factor B (mass m/z [M+H]+ = 
659.22953) was abolished in the mutant, verifying the identity of the gene cluster. As an 
alternative approach we tried the heterologous expression of the cosmids, as described before 
3.2.6.1. Heterologous expression couldn’t be observed from the cosmids. This was not 
surprising as they both didn’t contain the whole cluster. 
 
3.2.11 Feeding experiments 
Inspection of the GE81112s metabolite structures suggests that they incorporate modified 
versions of pipecolate, histidine and ornithine/glutamine. Thus, it was possible that the 
corresponding proteinogenic amino acids were incorporated and then modified, or 
alternatively that the modifications occurred prior to activation of the building blocks by the 
A domains. To investigate this question directly, we designed feeding experiments with 
labelled substrate. As the stereochemistry of GE81112 compounds has not yet been solved, 
we decided to feed separately both D- and L-pipecolic acid. In an independent experiment, we 
also fed U13 C-labelled histidine. Unfortunately, we did not detect any incorporation of the 
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labeled amino acids into GE81112, a result which we attribute to the very low production 
yield of the GE81112 compounds.  We also did not observe any incorporation of the labeled 
amino acids into the newly- discovered substances 631, 645 and 659. As these substances are 
produced in reasonable amounts and could be clearly detected in HPLC-MS, we could 
exclude production yield as the underlying problem. Thus, it is likely that none of the amino 
acids used in this experiment could be incorporated into the substances. These findings are 
consistent with the structure elucidation results, as to date, no structural elements similar to 
pipecolic acid or histidine have been found.  
 
3.2.12  Biochemical characterization of the GE81112 biosynthetic gene cluster 
An alternative approach to feeding experiments to evaluate the proposed biosynthesis is to 
express key enzymes involved in substrate biosynthesis or selection in recombinant form, and 
assay them in vitro. As we still had no experimental proof that the expected amino acids are 
incorporated from the A domains proposed in section 3.2.9.4.4 we tried to express three of the 
A domains in recombinant form in E. coli to assay them in vitro. Additionally the 
cyclodeaminase was chosen for recombinant expression to confirm its proposed function. 
 
3.2.12.1  Expression and purification of the lysine cyclodeaminase GeD 
Lysine cyclodeaminases have been shown in vitro to generate L-pipecolic acid from L-lysine 
[82;83;108] (and Y. Chai et al. unpublished data). The enzymes were obtained in recombinant 
form from E. coli  [108] and in some cases it could be determined that the L-stereoisomer of 
pipecolic acid was formed. Based on this precedent, we intended to express the 
cyclodeaminase geD from the GE81112 cluster in E. coli as a C-terminal fusion to GST, and 
to test its function in an assay in vitro. For this, we amplified the open reading frame of geD 
from cosmid BI11 and cloned it as an EcoRI-NotI fragment into the expression vector pGEX-
6P-1 (Figure 3.47). 
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Figure 3.47: Construct pGEX_cyclo for the expression of geD as a GST fusion protein in E. coli. 
 
The expression construct was sequenced, and then transformed into E. coli BL21 by 
electroporation. Cultivation was then carried out at both 16 °C and 30 °C. Analysis of 10 μl of 
the supernatant and the pellet using a 12% SDS polyacrylamide gel showed that most of the 
protein was present in the pellet, following growth at both 16 °C and 30 °C (Figure 3.48).  
 
 
Figure 3.48: Expression of the construct pGEX_cyclo in E. coli BL21.  
Protein expression was carried out at 16° and 30 °C. The expected GST-fusion protein (69 
kDa) was only present in the pellet. Key:  P, pellet; S, supernatant. 
 
To attempt to obtain soluble protein, we tried expression in E. coli Rosetta BL21 (DE3) 
pLysS/RARE. In addition, we evaluated whether two sets of chaperones (Chaperone Plasmid 
Set, www.takara-bio.eu) would increase the solubility of the protein in E. coli BL21. 
Chaperone set 1 contained chaperones GroE, GroL, trigger factor and chloramphenicol (cm) 
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resistance [109], while chaperone set 2 contained chaperones GroE, GroL and cm [110] (E. 
coli Rosetta BL21 (DE3) pLysS/RARE was not suitable as an expression host for the 
chaperones because it already carries a plasmid with chloramphenicol resistance). Both strains 
were cultivated as described in section 2.18.1.  
 
E. coli Rosetta BL21 (DE3) pLysS/RARE/pGEX_cyclo was induced with 0.1 mM IPTG, and 
the E. coli strains containing the chaperones with 1 mM IPTG (according to the 
manufacturer’s instructions). Cultivations were performed at 16 °C for all three expression 
cultures. As before, most of the protein was found to be insoluble. However, during 
expression with chaperone 1 in E. coli BL21 and independently in E. coli Rosetta BL21 
(DE3) pLysS/RARE, some soluble protein was present in the supernatant (Figure 3.49). 
 
Figure 3.49: Expression of the cyclodeaminase GeD. 
 
Expression was performed at 16 °C with chaperone set 1, chaperone set 2 and in E. coli Rosetta 
BL21 (DE3) pLysS/RARE. Soluble protein is indicated by the arrows. Key: P, pellet; S, 
supernatant. 
 
The GST-fusion protein was purified from the crude cell extract using GST minicolumns, 
coupled with on-column digest using PreScission Protease. The final yield of purified GeD 
from expression in E. coli Rosetta was approximately 0.8 mg/ml protein. Figure 3.50 shows 
the GST fusion protein (26 kDa) which was eluted with reduced glutathione, and the cleaved 
GeD (43 kDa) after on-column cleavage with PresScission Protease. 
Results 124 
 124
 
Figure 3.50: Purified protein GeD.  
GeD expression in E. coli Rosetta BL21 (DE3) pLysS/RARE and co-expression with 
chaperone set 1. The gel shows the protein with the GST tag and following cleavage with 
PreScission Protease. Cleaved protein is indicated by the arrows.  
 
The identity of the protein (from both samples) was verified by MALDI-MS (data not shown), 
and frozen at –80 °C until use.  
 
3.2.12.2 Cyclodeaminase assay  
On the basis of its homology to TubZ and RapL, GeD was presumed to act as a lysine 
cyclodeaminase, converting L-lysine to L-pipecolic acid [82]. In order to evaluate whether 
GeD could catalyze the same reaction, we used a method previously established by A. 
Sandmann and Y. Chai method to detect L-pipecolic acid by HPLC/MS.  
 
In brief, treatment of the pipecolic acid standard (a racemic mixture of L- and D-) with 9-
fluorenylmethyl chloroformate (Fmoc-Cl) converted the amine to the corresponding Fmoc-
carbamate. The Fmoc-pipecolic acid was then straightforwardly detected by HPLC/MS (m/z = 
571.2 [M-H]–  (Figure 3.51 A)). Additionally pure L- and D-pipecolic acid standards were 
derivatized and analyzed to establish the retention times of L- and D-pipecolic acid, showing 
that D-pipecolic acids elutes first. As a positive control, we simultaneously assayed the 
enzyme TubZ from the tubulysin cluster, which had previously been shown to catalyze the 
formation of L-pipecolic acid from L-lysine, in vitro (Y. Chai, A. Sandmann, unpublished 
results). As expected, incubation of TubZ with L-lysine resulted in the formation of L-
pipecolic acid (Figure 3.51 B)). To verify that exclusively the L-stereoisomer was formed, we 
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mixed the standard reaction mixture with the product of TubZ. A clear increase of the signal 
corresponding to the L-stereoisomer was observed (Figure 3.51 C)).  
 
Figure 3.51: Cyclodeaminase assays.  
A) Standard of D- and L-pipecolic acid. B) L-pipecolic acid formed by TubZ in the presence of 
L-lysine. C) Mixture of assay reactions A) and B), to verifiy the stereochemistry of the 
pipecolic acid generated in B). D) Incubation of GeD with D-lysine. E) Incubated of GeD with 
L-lysine. 
 
Disappointingly, incubation of GeD (both fractions were used from expression in E. coli 
Rosetta and also from coexpression with the chaperones) with both L- and D-lysine under the 
same conditions failed to produce any pipecolic acid of either stereochemistry. As the assay 
worked efficiently with the control protein TubZ, GeD is apparently inactive under the assay 
conditions, or L-lysine (D-lysine) is not the correct substrate. 
 
3.2.12.3  Expression of A domains 
In order to directly investigate A domain substrate specificity, we aimed to express the first 
three A domains from cosmid BI11 as N-terminally His6-tagged proteins from pET28b. DNA 
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fragments coding for the adenylation domains of geE (1 domain, GeEA1) and geG (2 
domains, GeGA2 and GeGA3) were amplified from cosmid BI11, and cloned into pET28b 
vectors using NdeI and BamHI. Cosmid BA23 was not completely sequenced at this timepoint 
so that we couldn’t amplify the other two A domains from geJ and geM encoding GeJA4 and 
GeMA5. The constructs were confirmed by sequencing and transformed into E. coli Rosetta 
BL21 (DE3) pLysS/RARE. Cultivation was carried out at 16 °C. Expression was induced 
with 0.2 mM IPTG, at OD600 = 0.8–1.  
 
Figure 3.52: Expression of A domains in E. coli Rosetta BL21 (DE3) pLysS/RARE at 16 °C.  
Soluble proteins are indicted by the white arrows. Key:  P, pellet; S, supernatant 
 
Protein GeEA1 was found in the soluble fraction after French press lysis of E. coli cells, as 
judged by SDS-PAGE (Figure 3.52). However, only a small amount of both GeGA2 and 
GeGA3 were present as soluble proteins. Nonetheless, the observed sizes of the proteins were 
in good agreement with the calculated molecular masses of 56.6, 59.9 and 61.7 kDa, 
respectively. To try to improve the solubility of GeGA2 and A3, we co-expressed them with 
the chaperone set described in section 3.2.12.1. Coexpression with chaperone set 2 led to 
soluble protein in the case of GeGA2, allowing the enzyme to be purified by Ni2+-affinity 
chromatography using the Äkta prime system (Figure 3.53 and section 2.18.2.2). GeGA3 
could not be expressed as soluble protein until now. In the future further attempts to increase 
solubility need to be done. 
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Figure 3.53: SDS-PAGE of adenylation domains overexpressed in E. coli.  
A) Purification of A domain GeEA1. Lanes 1–6: various fractions after Äkta purification; 
Lanes 4–6 contain the purified A domain used for biochemical analysis. B) Purification of A 
domain GeGA2. Lane 1–9: various fractions after Äkta purification; Lanes 4–8 contain the 
purified A domain used for biochemical analysis.  
 
All proteins were analyzed by MALDI-MS, which identified them as the desired proteins. 
Both the SDS-PAGE (Figure 3.53B) and the MALDI-MS analysis (data not shown) revealed, 
however, that a proportion of protein GeGA2 was truncated from its C-terminal end. As this 
was not expected to interfere with the substrate specificity of the intact domain, the mixture 
was used in subsequent assays.  
 
3.2.12.4  ATP-PPi exchange assay 
The substrate specificity of the two purified adenylation domains was evaluated using the 
well-established ATP-PPi exchange assay [58;111]. This assay measures the amino acid-
dependent exchange of radiolabel from 32PPi into ATP. For this, each protein was incubated 
with a panel of different amino acids, including the anticipated substrate of each domain. As a 
control, each protein was incubated in the absence of added amino acid. 
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Figure 3.54: Relative substrate specificities of the adenylation domains GeEA1, GeGA2. 
 
The substrate specificity of the A domains was investigated using the ATP-PPi assay. The 
highest activities were set to 100%.  
 
GeEA1 activated L-Pip (100%), D-Pip (82.88%) and L-Pro (80.3%). The background and 
controls were between 0.85% and 3.79%, confirming that the measured activity reflected the 
true substrate preference of the A domain (Figure 3.54). GeGA2 activated L-Orn (100%) as 
well as L-Gln (62.7%). L-Glu and L-Asp were also activated to a minor extent. So the 
preferred activation of ornithine and glutamine was clear. Taken together, our results prove 
that the two internal enzyme fragments investigated exhibit the enzymatic properties of 
adenylation domains. The determination of the A domains specificity enabled us to place the 
first two A domains in the correct order within the synthetase. As predicted previously, the A 
domain GeEA1 activates pipecolic acid, and thus forms a part of the loading module (module 
1). It is followed by module 2, which harbors an A domain (GeGA2) specific for 
orithine/glutamine. It remains to test the other three A domains GeGA3, GeJA4 and GeMA5 to 
determine their function.  
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4 Discussion 
4.1 General scope of this work 
This thesis deals with the biosynthesis and heterologous production of complex secondary 
metabolites from streptomycetes. A method for the heterologous expression of these 
compounds in streptomycetes was developed, using the phenalinolcatone biosynthetic 
pathway as a model system. The established expression system provided the basis for the 
modification of the pathway, leading to the production of a new derivative.  
Identification and biochemical characterization of the GE81112 biosynthetic gene 
cluster provided information about the biochemistry of this unique family of secondary 
metabolites and of nonlinear NRPS megasynthetases more generally. In the course of these 
studies, genetic manipulation methods for a new streptomycetes strain were developed, 
leading to the formation of a knockout mutant.  
 
4.2 Phenalinolactone - Heterologous expression of a complex secondary 
metabolite 
4.2.1 Heterologous expression of natural product pathways 
Heterologous expression of complex natural product biosynthetic gene clusters in amenable 
host strains has become an important tool in natural products research and drug discovery. 
This strategy provides an alternative to (over)producing structurally complex substances that 
would be difficult or impossible to access by other means, and can enable the generation of 
novel analogs by combinatorial biosynthesis approaches. However, successful heterologous 
production of natural products faces significant challenges, deriving both from complicated 
nature of the secondary metabolites, and the complexity of the biosynthetic enzymes. In 
addition to laboratory convenience, excellent growth characteristics, and an array of available 
genetic tools, the heterologous host must be able to express relatively large proteins (e.g. PKS 
and NRPS proteins) [30;112], post-translationally modify them to their active forms, and 
produce adequate amounts of activated intracellular building blocks. As the codon usage is 
usually [113] critical for efficient expression, it is generally important that the GC content of 
the foreign genes and the host genome are similar. Furthermore, the functionality of 
regulatory elements and promoter structures as well as mRNA stability need to be considered 
when choosing the host organism. To date, the most successful heterologous expression 
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experiments have relied on hosts which are closely-related to the natural producer strain. For 
example, many clusters derived from Streptomyces clusters have been reconstituted in related 
actinomycete strains [29;33;114-116]. As most of these gene clusters were relatively small 
(<30 kbp), it was often possible to retrieve the entire gene set from a single cosmid within a 
genomic library of the natural producer strain [30]. In cases where the libraries were prepared 
in E. coli-Streptomyces shuttle vectors (e.g. the medermycin and griseorhodin A biosynthetic 
gene clusters [31;117]), transfer of the pathways into heterologous strains was 
straightforward.  
 
However, many natural product biosynthetic gene clusters are larger than the average insert 
size of common cosmid vectors. One strategy for overcoming this size limitation is to use 
BAC shuttle vectors for library construction, as they can accommodate inserts in excess of 
100 kbp. This approach enabled the successful expression of the 128 kbp daptomycin 
biosynthetic gene cluster from Streptomyces roseosporus in a related Streptomyces strain 
[118]. Another option is to clone subsets of the biosynthetic gene cluster into compatible 
expression plasmids, followed by their stepwise introduction and co-expression in suitable 
host strains [34;119]. As the cloning procedure allows the introduction of artificial promoter 
regions, heterologous production can be performed even in non-related host organisms. Using 
this strategy, natural products from Streptomyces were produced in E. coli, and myxobacterial 
compounds were obtained from Streptomyces host strains [120-122]. 
 
An alternative to these classical, time-consuming cloning and mutagenesis approaches is the 
reassembly of large natural product pathways on a single transferable vector system, using 
Red/ET technology. This recombination approach was developed by the Stewart group in 
1998 [37], and is ideal for manipulating large pieces of DNA as it does not depend on the use 
of restriction enzymes. Phage-derived protein pairs (RecE/RecT from the Rac prophage or 
Redα/Redβ from the lambda phage) are employed to precisely alter target DNA molecules by 
homologous recombination within E. coli strains [36]. The first notable proof-of-principle for 
the cloning of a large PKS/NRPS hybrid pathway using Red/ET recombineering was provided 
by Wenzel et al. [35]. The 29.6 kb pathway directing the biosynthesis of myxochromides S 
was rebuilt on one molecule and the DNA elements for transfer, stable maintenance, and 
inducible expression were introduced, enabling the production of the natural product in 
Pseudomonas putida.  
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In Streptomyces strains, Red/ET cloning has been used to modify the backbone of cosmids 
containing complete biosynthetic pathways, enabling the heterologous expression of the 
aminocoumarin antibiotics novobiocin and clorobiocin [123]. In these examples, all of the 
genes were oriented in the same direction, consistent with the presence of a single 
transcriptional unit. In comparison to the aminocoumarin pathways, the phenalinolactone 
gene cluster of Streptomyces  Tü6071 is more complex, as it consists of 35 orfs which appear 
to be organized into 11 individual transcriptional units [66]. This highly divergent architecture 
would seem to present a significant challenge to the regulatory apparatus of heterologous host 
strains.  
 
Thus, in attempting to achieve heterologous expression of the phenalinolactone pathway, we 
developed a Red/ET-based methodology to reconstitute the entire gene cluster on one 
construct to ensure that all transcriptional units were intact. Whereas similar approaches had 
already been used to engineer myxobacterial systems [35;42], the ‘stitching together’ of 
complex actinomycete pathways via Red/ET recombineering had not been previously 
described when the Ph.D. thesis was started which intended us to start this project. Shortly 
after our work was published another example for the heterologous expression of a gene 
cluster using Red/ET was published by the Gust group [124]. Using this method they were 
able to stitch and express the coumermycin A1 biosynthetic gene cluster in S. coelicolor 
M512. Using Red/ET recombineering the entire gene cluster of PL was rebuilt from 
overlapping cosmids based on the integrative E. coli-Streptomyces shuttle vector pOJ436, and 
transformed into different heterologous hosts. 
 
4.2.2 Heterologous expression of the PL pathway in pseudomonads 
Pseudomonads has been shown to be suitable heterologous hosts for the production of natural 
products [125]. These microbes possess a high GC content, have a relatively short doubling 
time, and genetic tools are well established. Therefore we aimed to heterologously express the 
PL gene cluster in Pseudomonas putida. As we had integrated an oriT-tet-trpE cassette into 
the expression construct, transformation and integration of the vector into the Pseudomonas 
genome was possible. Integration into the genome was proven by PCR and the obtained 
mutants were cultivated, extracted and the extracts analyzed by HPLC-MS. Unfortunately we 
did not observe any heterologous production of PLs in P. putida.  
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One of the major issues for the heterologous expression of biosynthetic pathways in unrelated 
bacteria is the supply of adequate precursors. In the case of the polyketide myxothiazol, 
heterologous expression in P. putida initially failed. However, integration into P. putida of an 
operon responsible for production of an essential building block, methylmalonyl-CoA, 
resulted in myxothiazol production [43]. To investigate whether the absence of a precursor 
could explain the failure to obtain the PLs from P. putida, we considered the biosynthetic 
model for phenalinoalctone biosynthesis published by Dürr et al. [66;80] (Figure 4.1). The 
pathway can be divided into four major parts: (1) formation of the terpene backbone and its 
extension with phosphoenolpyruvate; (2) modification and rearrangement of the 
phosphoenolpyruvate-derived side chain toward the γ-butyrolactone moiety; (3) biosynthesis 
of L-amicetose and pyrrole-2-carboxylic acid; and (4) group transfer reactions and late-stage 
tailoring. The precursors for each portion of the biosynthesis are derived from (1) the 
nonmevalonate pathway (terpene biosynthesis); (2) pyruvate (γ-butyrolactone biosynthesis); 
(3) glucose (L-amicetose biosynthesis); and (4) L-proline (pyrrole-2-carboxylic acid 
biosynthesis). 
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Figure 4.1: Proposed biosynthetic pathway for phenalinolactone formation.  
 
Figure adapted by Dürr et al. [66]. 
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As the nonmevalonate pathway is present in P. putida [126] and the respective genes are also 
present in the cloned gene cluster, we eliminated this pathway from consideration. The 
remaining precursors such as pyruvate, glucose and L-proline are derived from the primary 
metabolism, and were therefore also expected to be present in P. putida. Thus, we assumed 
that P. putida is able to produce all precursors which are needed for PL biosynthesis.  
 
As pseudomonads posses a high GC content similar to that of streptomycetes, we also 
assumed that codon usage was not a problem. This focused attention on the native 
Streptomyces promoters, which may not be recognized in Pseudomonas putida. To date, 
heterologous expression of natural product biosynthetic pathways in pseudomonads has only 
been succesful when the native promoters were exchanged against the inducible Pm promoter 
[35;43;125]. For this reason, we also aimed to exchange several promoters in the PL 
biosynthetic gene cluster to achieve heterologous expression in P. putida. As the PL 
biosynthetic gene cluster contains 35 orfs and 11 transcriptional units, we expected that at 
least one promoter would be present in each operon, for a total of 11 promoters. As a starting 
point, we decided to exchange the promoter in front of the operon containing the genes 
responsible for assembling the core structure of the PLs. The proteins PlaT1–PlaT6 (Figure 
4.2) comprise the enzymatic machinery to biosynthesize the phenalionalctone terpenoid 
scaffold. The isoprene building blocks for phenalinolactone biosynthesis are derived from the 
nonmevalonate pathway which is also present in P. putida. So it can be assumed that the 
isopentenyl pyrophosphate (IPP) should be produced in primary metabolism of P. putida. The 
genes plaT5 and plaT6 in the PL cluster comprise additional copies of the dxp (1-deoxy-D-
xylulose 5-phosphate) and hmbpp (1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate) 
synthase genes from the nonmevalonate pathway. It is speculated that PlaT5 and PlaT6 
probably enhance the IPP production [66]. PlaT4 catalyzes the head to tail condensation of 
four isoprene monomers toward geranylgeranyl diphosphate (GGDP), the phenalinolactones 
direct terpene precursor. PlaT1 is suggested to catalyze an epoxidation of the C-14/-15 double 
bond of GGDP prior to its cyclization. PlaT2 is responsibe for the cyclization of GGDP to PL 
precursor 1. PlaT3 might be considered for the phosphoenolpyruvate transfer to the terpene 
backbone. The next step would be the dehydrogenation of the newly established C-C linkage, 
giving the C-15/-16 double bond. PlaZ would be a candidate for this dehydrogenation reaction 
(Figure 4.2). 
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Figure 4.2: Proposed biosynthesis of possible PL precursors. IPP: isopentenyl pyrophosphate, 
GGDP: geranylgeranyl diphosphate. 
 
Unfortunately the corresponding genes plaT1-3 and plaT4-6 are located in two different 
operons, making it impossible to attempt to upregulate transcription with a single promoter 
switch. We started by targeting the operon containing the first three biosynthetic genes, 
plaT4-6. The native promoter was exchanged against a cassette containing the Pm promoter, 
the xylS gene and a resistance gene (chloramphenicol) using Red/ET cloning, and mutants 
were verified by PCR. We expected at least the direct precursor GGDP to be produced as 
plaT4-plaT6 are present in the operon where the promoter was exchanged. But analysis by 
HPLC-MS analysis failed to reveal the presence of GGDP, PL precursors or PL in the 
mutants. This result demonstrated that exchange of this single promoter was insufficient to 
achieve production of any precursors in P. putida.  
 
In principle, a follow-up strategy would be to attempt to exchange all of the native promoters 
against the same Pm promoter cassette or other Pseudomonas promoters. However, this 
approach is likely to cause difficulties, as the introduction of promoters by Red/ET 
recombination is based on homologous recombination; the presence of the same promoter 
sequence at multiple locations within the cluster would probably result in undesired 
recombination events. Alternatively, it might be possible to use a set of different promoters. 
However, only a few inducible promoters are currently known for pseudomonads. Taking 
these considerations into account, we concluded that it would not be feasible to exchange all 
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of the promoters within the PL cluster. We therefore pursued heterologous expression in an 
alternative host. 
 
4.2.3 Heterologous expression of the PL pathway in streptomycetes 
The Red/ET engineering enabled the efficient transfer and integration of the whole PL 
pathway into several Streptomyces strains, as the construct contained a vector backbone with 
an attP site and the integrase gene. The 62 kbp construct was successfully conjugated with 
high efficiency into the host strains S. lividans TK24 and S. coelicolor A3(2), and integration 
into the chromosomes confirmed by PCR. In contrast to the Pseudomonas mutants, the 
resulting mutant strains of S. lividans TK24::CPhl8 and S. coelicolor A3(2)::CPhl8 were both 
shown to produce phenalinolactones A and D. This result strongly suggests that the inserted 
cluster contains all genes necessary for the biosynthesis of phenalinolactone, although 
participation of enzymes native to the heterologous hosts cannot be ruled out. Evidently, all of 
the regulatory elements required for transcription of the pla genes were recognized in the 
heterologous hosts, albeit at reduced efficiency relative to the native host strain (Table 3.2).  
 
One potential complication of using S. lividans and S. coelicolor as heterologous hosts is their 
endogenous production of the antibiotics prodiginin (Red), actinorhodin (Act) and calcium-
dependent antibiotic (CDA), which may hamper the simultaneous biosynthesis (and detection) 
of a desired new compound. This problem has been circumvented in several cases by using a 
mutant strain of S. coelicolor M512, in which the Act and Red gene clusters have been 
deleted [123;127]. Therefore, S. coelicolor M512 was also used here as an additional 
heterologous host for phenalinolactone biosynthesis. Indeed, after successful expression of the 
cluster in the strain, production of phenalinolactone was 5- to 50-fold higher at 28 °C relative 
to that in S. lividans TK24 or S. coelicolor A3(2) (Table 3.2). Interestingly, cultivation at 37 
°C in S. lividans yielded a further enhancement in productivity (up to 100-fold compared to 
cultivation at 28 °C) although the optimal growth temperature for S. lividans is 30 °C. An 
increase in phenalinolactone biosynthesis was not observed for the S. coelicolor strains at 37 
°C. In fact, incubation at 37 °C completely abolished PL biosynthesis, consistent with the fact 
that production by the native host Streptomyces Tü6071 is also significantly lower at this 
temperature (200 µg/L). Thus, under optimized fermentation conditions, it is clear that S. 
lividans is a superior heterologous host for phenalinolactone biosynthesis than the S. 
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coelicolor strains, although the production is still 50-fold lower than from the natural 
producer.  
 
An attempt was also made to increase phenalinolactone production by feeding of the putative 
precursor mevalonolactone, but no increase in the yield of PL was observed. Analysis of the 
pla cluster shows that it incorporates genes for producing isoprenoid building blocks via the 
mevalonate-independent pathway, and indeed this biosynthetic origin has previously been 
demonstrated [66]. In addition, genes belonging to the mevalonate pathway have not yet been 
identified in either S. lividans and S. coelicolor [128;129]. Thus, it seems that the 
heterologous host strains used here lack the enzymes to metabolize mevalonate, which 
accounts for our failure to increase phenalinolactone yields by supplementation.  
 
In a further attempt to increase productivity, we exchanged two of the native promoters 
against the strong constitutive ermE promoter using Red/ET recombineering again. The 
advantage in this strategy was the ermE promoters sequence could be introduced with the 
primers, so that two promoters could be exchanged in a single step. The two promoters were 
placed in front of the two operons harboring the first biosynthetic genes (plaT1-3 and plaT4-
6).  It has previously been demonstrated that introduction of the ermE promoter can increase 
the yields of heterologously-expressed natural products, or even lead to initiation of 
production. For example, cloning of eight validamycin biosynthetic genes under the control of 
the ermE promoter led to heterologous production of this metabolite in S. lividans [130]. 
Another example was the heterologous expression of an intermediate of the kendomycin 
starter unit. The heterologous expression of a gene set of 7 genes revelaed that 3,5-
dihydroxybenzoic acid is an intermediate in the kendomycin starter unit biosynthesis [131]. 
Successful heterologous production was only achieved in S. coelicolor but not in S. lividans.  
Cloning of the ermE promoter in front of the gene set initiated the heterologous expression in 
S. lividans.  Production under the control of the ermE promoter in S. lividans was even much 
more higher (150mg/ml) compared to production in the natural producer or the heterologous 
production in S. coelicolor with and without the ermE promoter (S. C. Wenzel unpublished 
data). Unfortunately, exchange of the native promoters against the ermE promoter in the pla 
biosynthetic gene cluster did not yield any increase in productivity.  As we introduced two 
ermE promoters in front of both operons containing the first biosynthetic genes we expected 
at least a production of GGDP or precursor 1 (Figure 4.2). As PlaZ which is probably needed 
for the formation of precursor 2 was not part of both operons precursor 2 was not directly 
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expected to be produced. But no GGDP or any other precursors could be detected; instead, PL 
production was completely abolished. These results led us to conclude that promoter 
exchange interrupted transcription or led to problems with regulation or both, probably as a 
result of the complex operon structure of the pla cluster. Again, a solution might be to 
exchange of all the promoters within the cluster, but this approach would raise the same issues 
as in the pseudomonads. Thus, overall we achieved the greatest success in improving PL 
production by changing the growth temperature of S. lividans showing that standard 
microbiological optimization methods can still be effective. 
 
4.2.4 Genetic modification  
The expression system described here further enabled the generation of an unglycosylated 
phenalinolactone derivative. For this, Red/ET technology was combined with the FRT/FLP 
recombinase system to construct a markerless deletion of the glycosyl transferase gene plaA6. 
Heterologous expression of the modified construct resulted in the unglycosylated derivative 
phenalinolactone E (PL E), demonstrating that the glycosyl transferase PlaA6 catalyzes the 
attachment of L-amicetose to the hydroxylated terpenoid backbone. Surprisingly, biosynthesis 
of PL E was only observed in S. coelicolor M512, although yields of the parent glycosylated 
compound from S. lividans TK24 were much higher. In this case, the utility of S. coelicolor 
mutant strain M512 as suitable host may stem from its overall lower background of secondary 
metabolism. The use of the FRT/FLP recombinase system in combination with the Red/ET 
technology is a powerful tool to create a markerless gene deletion in a single expression 
construct. This modification is conveniently achieved by introducing the FRT recognition 
sites into the PCR primers. Recombination with FLP recombinase results in a markerless 
mutation, in which only a 34 bp scar sequence is left in place of the deleted gene of interest. 
This scar sequence does not present a problem for further recombination procedures. To 
construct two mutations simultanesouly, the Cre/loxP system can be employed in parallel.  
 
A similar approach has been used by Heide et al. [132]. New aminocoumarin antibiotic 
derivatives were generated by targeted gene replacement using Red/ET recombineering. 
However, instead of introducing FRT or loxP recognition sites with the primers, they 
introduced recognition sites for the restriction enzymes SpeI and XbaI which are rare cutters 
in the Streptomyces DNA. Digestion of the cosmids by SpeI and XbaI resulted in compatible 
overhangs, and religation then resulted in a cosmid in which only an 18 bp scar sequence was 
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left in place of the deleted gene. One drawback of this approach in comparison to the 
FRT/FLP or Cre/lox system, however, is that a ligation step is always required. Additionally, 
no other SpeI or XbaI sites can be present in the target sequence, whereas the recombinase 
system is not dependent on restriction sites but on the FRT/loxP recombination site.  
To obtain additional PL derivatives, we generated two constructs containing markerless 
deletions of the genes plaP2 and plaP5. By removal of the acyltransferase- encoding gene 
plaP2, we aimed to generate a PL derivative lacking the 5-methylpyrrole-2-carboxylic acid 
moiety (Figure 4.3). The gene plaP5 is proposed to be responsible for the methylation of the 
pyrrole carboxylic acid [66], and thus deletion of this gene was expected to give an 
unmethylated PL derivative (Figure 4.3). In this case, we exploited the Cre/lox system instead 
of the FLP/FRT system. Using both systems in combination, we aimed to obtain a small set of 
different PL derivatives (Figure 4.3). 
 
Figure 4.3: PL derivatives expected after deletion of different biosynthetic genes, in heterologous 
streptomycetes hosts.   
 
Unfortunately, no variant PLs could be detected in extracts of mutants carrying the deletions 
in plaP2 and plaP5, and instead, PL production in these strains was completely abolished. 
The failure to detect new derivatives might be explained by very low production levels: as PL 
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E is already produced in miniscule amounts, it seems reasonable that production of 
derivatives could fall under the detection limit. However, we cannot rule out the possibility 
that deletion of the genes interrupted transcription, or that regulatory problems occurred.  
 
4.2.5 Future aspects 
Although several Streptomyces gene clusters have been relocated to heterologous hosts using 
Red/ET cloning, transcription in each case was under the control of a single promoter [123]. 
Thus, the pla cluster represents the most complicated gene set yet to be heterologously 
expressed in any Streptomyces sp. In future, efforts to understand the regulatory factors 
governing phenalinolactone biosynthesis should aid in efforts to optimize heterologous 
production, for example by overexpressing positive regulators. Also other heterologous 
actinomycetes hosts could be tried to optimize heterologous production. In addition, the 
results described here set the stage for further engineering the biosynthetic machinery in E. 
coli towards the generation of additional novel PL analogues. 
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4.3 GE81112 family compounds - Novel tetrapeptide inhibitors of bacterial 
protein synthesis 
Identification of the biosynthetic gene cluster 
The emergence of multi-drug resistant microbial pathogens is driving the search for novel and 
more effective antibiotics, especially those with new mechanisms of action. The majority of 
known antibiotics inhibit the fundamental process of protein synthesis. Prominent examples 
of antibiotics which target this machinery are the macrolides erythromycin and azithromycin, 
the aminoglycosides kanamycin and tobramycin, and the tetracyclines [133]. Elongation 
activities such as aminoacyl-tRNA binding and decoding in the ribosomal A-site, 
transpepdidation, and translocation are frequently found to be affected by antibiotics, albeit by 
different mechanisms. However, other functions such as translation initiation and termination, 
are only rarely targeted [133]. Thus, the tetratpeptide GE81112 compounds represent a unique 
class of novel antibiotics, as they selectively and effectively inhibit the formation of the 
prokaryotic 30S initiation complex [67]. To obtain a better understanding of the biosynthesis 
of these unique metabolites, we set out to identify and clone the corresponding biosynthetic 
gene cluster. We hoped that insights into the biosynthesis would enable the directed 
engineering of novel GE81112 derivatives.  
 
4.3.1 Attempts to identify the GE81112 biosynthetic gene cluster  
4.3.1.1 Generation of a cosmid library and hybridization strategy 
At the beginning of the work, we obtained the GE81112 producer strain S. 14386 from the 
company KtedoGen. In order to enable the identification and cloning of the biosynthetic gene 
cluster, we started by optimizing production conditions for the GE81112 compounds. After 
establishing cultivation and detection of the GE81112 metabolites, we aimed to locate the 
corresponding gene cluster by generating a cosmid library, and screening it with suitable 
probes. Before rapid genome sequencing methods became available, numerous NRPS and/or 
PKS biosynthetic gene clusters were sucessfully identified using this approach [134-137]. 
  
We therefore generated a 2304 clone cosmid library from the genomic DNA of the GE81112 
producer strain containing. A suitable probe was obtained by applying a “retrobiosynthetic 
strategy”, which allowed us to predict some aspects of the composition of the GE81112 
cluster from the metabolite structures. On this basis [67], we predicted that the biosythesis 
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would be carried out by a non-ribosomal peptide synthetase, and so designed probes to 
identify NRPS genes. Furthermore, we were able to predict that the starter unit would 
probably derive from pipecolic acid, which is known to be formed from lysine via the action 
of a lysine cyclodeaminase [82]. As cyclodeaminase genes are relatively rare in the genome 
[86] this gene was used to design a second probe to identify the GE81112 cluster. 
 
4.3.1.2 Identification of an unkown NRPS biosynthetic gene cluster 
Screening of the cosmid library with both probes revealed two cosmids apparently harboring 
overlapping regions of a gene cluster. Furthermore, sequence analysis revealed that both 
cosmids harbored NRPS biosynthetic genes. As the modules in both clusters contained 
comparable domains in the order C-A-PCP [56] (Figure 4.4), we expected the two cosmids to 
contain the same biosynthetic gene cluster. Surprisingly, however, a more detailed sequence 
analysis revealed that the gene clusters, although highly similar, were not identical. This 
finding might indicate that they have arisen from a recent gene duplication event, followed by 
sequence divergence.  
 
Figure 4.4: Module and domain arrangement from NRPS biosynthetic gene cluster on cosmid AI6 
and FD10. Identical domains from both clusters are highlighted in the same colors.  
 
The prescence of two highly-similar clusters was unexpected, but might have accounted in 
principle for the biosynthesis of the GE81112 family of tetrapeptides (e.g. each of the clusters 
might have given rise to a subset of family members). However, no examples of such ‘in 
parallel’ biosynthesis of similar metabolites within the same strain have been described to 
date, although closely-similar derivatives of a single natural product have been isolated from 
different strains (e.g. myxochromide A and S) [138].  
 
As it was not clear at this stage if the identified clusters were responsible for the biosynthesis 
of the GE81112 compounds, we analyzed the NRPS domains from each module. For the 
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incorporation of four amino acids we expected four modules containing the standard C-A-
PCP organization and additionally a cyclodeaminase for the generation of the starter unit 
pipecolic acid. The four module arrangement was present on cosmid FD10 as we predicted, as 
well as a cyclodeaminase gene. These results supported the hypothesis that the identified 
assembly line on cosmid FD10 is able to biosynthesize a tetrapeptide or tetrapeptides, as 
expected in the biosynthesis of the GE81112 family. The gene cluster on cosmid AI6 was not 
completely present on the cosmid. Three complete modules could be identified on this cosmid 
indicating that the cluster should at least be able to synthezise a tripeptide. Module four 
contains a C and an A domain but lacks a PCP where the cluster is interrupted. This could 
imply that there would still be a PCP in the the genome sequence so that the cluster would 
also be able to synthetize a tetrapeptide or even a longer peptide, as we don’t know what 
sequence follows. When considering the similarity with FD10 one could also conclude that 
the cluster on AI6 ends with the C domain on gene nrps_3 (same domain arrangement than in 
cosmid FD10) and that the additional A domain would belong to another cluster. To answer 
these questions the overlapping cosmid providing the whole pathway for the NRPS on AI6 
would need to be identified which failed until now. 
 
To test if all domains are likely to be functional, the conserved regions of all C, A, PCP and E 
domains [91] were analysed and found to be present. Using the specificity-conferring code of 
adenylation domains, we were able to predict the substrate specificity of some of the A 
domains (Table 3.8). As both clusters had an overall high content of sequence similarity, it 
was not surprising to find three A domains from each cluster which showed the same apparent 
substrate specificity. The identical A domains are found to be in the same order assuming that 
module 1 has been deleted/added to the FD10 cluster (Figure 4.4: identical domains are 
highlighted in the same colors). The A domains FD10_A2 (AI6_A1) showed substrate 
specificity for the incorporation of phenylalanine/tryptophan. A domain FD10_A3 and 
AI6_A2 were predicted to show substrate specificity for the activation of threonine. No 
confident predictions could be made for the remaining A domains, possibily indicating that 
they active uncommon amino acids.  
 
Overall, the two predicted A domain specificities for both clusters did not fit well with the 
biosynthetic hypothesis for the GE81112 compounds, as it was expected from the 
“retrobiosynthetic analysis” that pipecolic acid and two histidines would be incorporated.  
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In addition to the NRPS genes, we found the expected cyclodeaminase gene, but it was only 
present on cosmid FD10. Furthermore, sequence analysis revealed that more than half of the 
protein was missing relative to previously-described cyclodeaminases [82;83;85]. We 
assumed, therefore, that the truncated protein was no longer functional. This result provided 
an additional strong hint that the identified gene cluster was probably not responsible for 
GE81112 biosynthesis. As these results were based solely on in silico predictions, however, 
we aimed to obtain experimental validation for the identity of the gene clusters. 
 
4.3.1.3 Heterologous expression 
The most straightforward strategy to verify a gene cluster is to knockout one of the NRPS 
genes which are normally clustered in the genome and essential for the biosynthesis. We tried 
to do this knockout but, to date, it has not been succesfull. We therefore pursued an alternative 
strategy to determine the identities of the identified gene clusters, using heterologous 
expression [30;118;139;140]. Both cosmids were transferred into heterologous hosts S. 
lividans TK24 and S. coelicolor M512 and the extracts were checked for GE81112 
production. Unfortunately, the desired compounds could not be detected in the heterologous 
hosts. Instead three new compounds were detected in the heterologous host carrying cosmid 
FD10, which were not present in the wild type. These substances exhibited exactly the same 
fragmentation pattern as three compounds that were found during our initial analysis of the 
natural producer strain S. 14386, and which attracted our attention because one of them had 
the same mass (659) as GE81112 factor B. In addition, their fragmentation patterns suggested 
that they are chlorinated. Thus, the compounds might be structurally-related to the GE81112 
metabolites, but were definately not the desired GE81112 compounds.  
 
Taken together, these results indicated that the biosynthetic gene cluster present on cosmid 
FD10 is not responsible for biosynthesis of GE81112. The new compounds were not 
expressed from cosmid AI6, although it contained a highly similar gene cluster. One possible 
explanation for this result was that the cluster was interrupted in the nrps_3 gene and was not 
fully present on the cosmid. When we expect the cluster on AI6 to biosynthesize a tripeptide 
(as discussed earlier) then this tripeptide should at least incorporate the three identical amino 
acids than cosmid FD10, which could lead to a similar fragmentation pattern of the 
compound.  But no such tripeptides could be identified. This result rather indicates that the 
cluster was not complete and was therefore not heterologously expressed as essential genes 
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are missing. We also concluded that the cluster on AI6 is not responsible for GE81112 
biosynthesis, due to its high overall similarity to the gene cluster on FD10 which has been 
proofen to biosynthesize the new compounds.  However, to provide further support for our 
conclusions, we aimed to purify the novel compounds from the wild type and elucidate their 
structures. All three compounds could be purified in reasonable amounts for NMR elucidation 
using standard chromatographic techniques. We focused our initial structure elucidation 
efforts on compound 631, as it was obtained in the highest yields following purification. The 
NMR data obtained to date suggest that the structure of compound 631 contains four amino 
acids, consistent with the four modules found within the NRPS biosynthetic gene cluster on 
cosmid FD10. However, in silico analysis of the A domain specificity predicted that FD10_A2 
would incorporate phenylalanine and FD10_A3 threonine, while it appears that the compound 
includes a starter most likely derived from proline and a second amino acid derived from 
alanine. Analysis of the A domains FD10_A1 and FD10_A4 did not yield a clear prediction 
for their substrate specificity, consistent with the idea that they are uncommon A domains 
which may activate two unusual, modified ornithines.  
 
The gene cluster found on cosmid FD10 exhibits few additional features that hint as to how to 
put together the structural elements identified to date by NMR. One element of note is that the 
cluster ends with a C domain and not with a TE, as is typical for bacterial NRPS. This 
observation suggests that the C domain might catalyze a head-to-tail condensation to yield a 
cyclic product, as found for the cyclosporine synthetase [141]. However, evaluating this 
hypothesis awaits the full structural elucidation of the compounds. Additionally there was also 
a PKS part found to be present on FD10 but not on AI6. But this gene was also not fully 
present on the cosmid. So it cannot be excluded that the PKS is somehow involved in the 
biosynthesis of the new compounds, but this seems rather unlikely as it is not expected to be 
functional when interrupted. Final evidence would be given by a knockout in the natural 
producer or even on cosmid FD10 which was heterologously expressed. As the new 
compounds contained unusual amino acids harboring modifications it is also not clear how 
they can be biosynthesized from the relatively simple cluster on the cosmid. One explanation 
would be that the heterologous host provides some of the enzymes which are needed for this 
most likely complicated biosynthesis. One fact which is supporting this hypothesis is that the 
new compounds were only expressed in S. lividans and not in S. coelicolor, indicating that S. 
lividans has probably some advantages (e.g. special enzymes) for the biosynthesis of the new 
compounds.  
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4.3.2 New strategy-new probe  
 Identification of the GE81112 biosynthetic gene cluster 
As we had proven by heterologous expression that the gene cluster on cosmid FD10 (and 
probably also on AI6) were not responsible for the biosynthesis of the GE81112 compounds 
but for a new class of peptides, we developed an alternative strategy to identify the GE81112 
gene cluster. The basis for our approach was to screen with a novel probe. We knew from the 
earlier experiments that our previous probe had successfully identified the cyclodeaminase 
gene on cosmid FD10. However, the protein was truncated and therefore presumed to be 
inactive. As such pseudo-genes typically arise from gene duplication of an original active 
gene copy, we assumed that there might be a second, complete cyclodeaminase in the 
genome. To evaluate this hypothesis, we designed a probe specific for additional copies of the 
cyclodeaminase gene, on the basis of the sequence of the truncated cyclodeaminase. 
Screening the genome with this probe by Southern Blot revealed two signals in addition to 
that corresponding to cosmid FD10, indicating that the genome contained a second or even a 
third copy of the cyclodeaminase gene. Importantly, this gene was likely to be associated with 
the remainder of the GE81112 gene cluster. We therefore re-probed the cosmid library with 
the specific cyclodeaminase probe, leading to the identification of new cosmids. We further 
confirmed that the cosmids contained the cyclodeaminase sequence by PCR. As we strongly 
expected NRPS sequence to be present on the cosmids, we used degenerate NRPS primers to 
amplify A domain sequences. Using these primers, we successfully amplified A domains 
from four of the identified cosmids. Prediction of the A domain substrate specificity revealed 
one cosmid containing an A domain with specificity for proline/pipecolic acid, exactly as 
predicted for the GE81112 starter unit. Sequencing of the cosmid revealed a biosynthetic 
pathway which harbored different genes (e.g. cyclodeaminase) which we expected for 
GE81112 biosynthesis. However, as the entire gene cluster was not present on the cosmid, we 
identified an overlapping cosmid. Furthermore, we verified that the genetic organization on 
both was co-linear with the genome.  
 
To confirm the identity of the cloned biosynthetic locus, we first aimed to establish a method 
to genetically manipulate the strain. Although genetic manipulaton systems are well 
established for some streptomycetes strains [10], it turned out that the GE81112 producer was 
significantly less amenable to genetic manipulation. Nonetheless, using biparental mating, we 
developed a method for DNA transfer from E. coli via conjugation. We started method 
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development by conjugating both a replicative and an integrative vector as controls to test 
transformation efficiency. Using the standard amount of E. coli as described in Kieser et al. 
[10], we only obtained low numbers of colonies. As it was known from studies with other 
bacteria that the amount of E. coli can be crucial for conjugation efficiency [142], we tested 
different amounts of E. coli. Indeed, we found that transformation efficiency was 10–20-fold 
higher when large numbers (50×109) of E. coli were used. With a conjugation method 
established, we were able to inactivate gene geE, which resulted in the complete abolishment 
of the main GE81112 derivative factor B, which we could detect by high-resolution MS. This 
result provided clear evidence that the identified cluster was responsible for the production of 
the GE81112s. 
 
4.3.3  Analysis of the GE81112 biosynthetic gene cluster 
Sequence analysis of the identified cluster revealed that it harbored only NRPS components. 
Many clusters have a co-linear genetic and protein organization, following the so-called co-
linearity rule, in which each module is responsible for one discrete chain elongation step and 
the specific order of the modules defines the sequence of the incorporated amino acids [64]. 
Contrary to our expectation that we would find such a linear NRPS system providing four 
modules with the standard C-A-PCP domain order, the cluster exhibited a highly nonlinear 
genetic arrangement (Figure 4.5).  
 
 
Figure 4.5: Nonlinear arrangement of the GE81112 biosynthetic gene cluster.  
Domains that are proposed to interact are highlighted in the same colors. 
 
Several examples of such nonlinear NRPS systems have been reported  and initially, these 
NRPS were thought to be rare exceptions to the co-linearity rule [56]. However, during the 
past few years it has become clear that nonlinear NRPS are not an exception, but constitute a 
considerable fraction of the NRPS repertoire present in nature. The characteristic feature of 
these nonlinear NRPSs is at least one unusual arrangement of the core domains C-A-PCP. The 
GE81112 system also revealed a highly split genetic and module architecture, but when 
rearranging the domains they provide a linear assembly line as described in the results part. 
Although four amino acids are incorporated into the structure which would normally require 
Discussion  148 
 148
four modules, five modules harboring five distinct A domains were identified. Further 
unusual features of the cluster include two freestanding A-PCP didomains encoded by genes 
geJ and geM, and a stand-alone A domain, encoded by gene geE. Such stand-alone A 
domains have previously been identified in the nonlinear NRPS pathways to myxochelin 
[143] and yersiniabactin [144]. Similarly, freestanding A-PCP didomains have been found in 
the zorbamycin and syringomycin gene clusters [145;146]. 
 
The conserved regions of all domains in the GE81112 cluster were analyzed, and predicted to 
be functional. However, from the domain assignment alone, the order of subunits (modules) 
could not be predicted, as there were more modules present then expected for the biosynthesis 
of a tetrapeptide. We therefore began our analysis of the cluster with the prediction of the 
substrate specificity of the A domains, which we anticipated would give us a hint as to the 
order of the subunits. Based on analysis of the GE81112 structures, we expected that four 
amino acids would be the precursors of the biosynthesis incorporated into the compound in 
the order: pipecolic acid-ornithine/glutamine-histidine-histidine (Figure 4.6).  
 
Figure 4.6: GE81112 tetrapetide structure and corresponding amino acid sequence Pip-Orn/Gln-His-
His. 
 
The predicted specificity for four of the five A domains correlated with our expectations 
(Table 3.13). Together with an analysis of putative docking regions, we were able to predict 
how the NRPS proteins interact with each other to biosynthezise the GE81112s (Figure 4.7). 
Overall, we suggest that the linear assembly line consists of four modules exhibiting the 
standard C-A-PCP domain arrangement, and that the pathway incorporates one additional A-
PCP didomain, where the function was not clear, as well as a stand-alone thioesterase domain 
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for chain release. On both ends of the cluster additional orfs have been (Table 3.12) found 
where it was not clear if they have a function in the biosynthesis. What we suggest here is a 
first preliminary model of the biosynthesis where it remains to determine the boundaries of 
the gene cluster by knockout experiments. 
 
Figure 4.7: A) Nonlinear genetic arrangement of the GE81112 NRPS and B) proposed interaction of 
NRPS proteins to yield a linear assembly line. REs: Recognition elements. 
 
Nonetheless, the function of the apparently superfluous module 5 remained unclear. One 
hypothesis was that the corresponding gene geM arose by gene duplication of geJ (or the 
opposite way around), as both genes showed the same domain arrangement and the encoded 
A domains were both predicted to activate histidine. If true, the protein GeM would also be 
expected to be able to interact with GeG to form the last module. However, sequence analysis 
revealed that the two proteins are not highly homologous, and that in addition, GeM was 
missing a putative recognition sequence for interaction with GeG as was present in GeJ. We 
therefore concluded that GeM is unlikely to interact with GeG, and therefore assigned the role 
of the fourth extension module to protein GeJ. However, as the two domains from GeM were 
predicted to be functional, we assumed that the didomain must have a specific function in the 
biosynthesis. A detailed discussion about a possible biosynthesis and the function of the 
single proteins will be given in the next chapter. 
 
4.3.3.1 Biosynthetic proposal for the GE81112 compound family 
Our data taken together allowed us to propose a pathway to the GE81112 metabolites, albeit 
incomplete. GE81112 biosynthesis likely starts with the biosynthesis of L-pipecolic acid from 
L-lysine via the action of the putative cyclodeaminase (Figures 4.8A and 4.14). Unfortunately 
we were not able to reconstitute this reaction in vitro when we expressed the GE81112 
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cyclodeaminase GeD, as GeD was inactive under our assay conditions. Pipecolic acid would 
then be activated by the A domain GeEA1 in module 1 and loaded onto the adjacent PCP 
(Figures 4.8 B and 4.14). To evaluate the function and substrate specificity of the A domain, 
we performed an ATP-PPi exchange assay in vitro. This experiment clearly showed that L-
pipecolic acid was activated, supporting our hypothesis that this is the starter unit for the 
biosynthesis. The pipecolic acid moiety in GE81112 is hydroxylated at the β-position; a 
reaction which we predict is catalyzed by the putative L-proline-3-hydroxylase, GeF. 
However, the timing of hydroxylation (on the free amino acid [147], while the amino acid is 
thethered to the PCP [148], or following release of the chain from the assembly line [55;90]), 
remains unclear and several examples of all three reactions have been reported [55]. 
 
Figure 4.8: Proposed biosynthetic mechanisms. 
 
 A) Generation of pipecolic acid from lysine via the action of a cyclodeaminase (GeD). B) 
Activation and loading of pipecolic acid by module 1 followed by subsequent hydroxylation at 
position 3 by a putative β-hydroxylase (GeF). Alternative timings of the hydroxylation reaction 
are possible.  
 
It might have been possible to evaluate whether hydroxylation occurs before or after 
activation by the module 1 A domain, by assaying for the domain’s relative specificity for 
pipecolic acid and hydroxypipecolic acid. However, as the required hydroxypipecolic acid 
was not commercially available, it was not possible to carry out this experiment. Nonetheless, 
we propose, based on literature precedent [148], that  GeF most likely hydroxylates the PCP-
bound pipecolic acid (Figures 4.8 B and 4.14).  
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It was not directly obvious from which amino acid the second building block is derived as 
there are two different structures found in the GE81112 factors A, B and B1 which differ at 
position 6. In GE81112 factor A and B the second amino acid incorporated into the structure 
is hydroxypentanoic acid, which is hydroxylated at position 4 and O-carbamoylated at 
position 6. In factor B1 it is an ornithine which is hydroxylated at position 4 and N-
carbamoylated at position 6. To account for the biosynthesis of these two derivatives, we 
hypothesized that the A domain GeGA2 of module 2 can activate either glutamic acid or 
glutamine, followed by reduction of the carboxylic groups which would lead to 
hydroxypentanoic acid (factor A and B) or ornithine (factor B1), respectively. The proposal is 
shown in Figures 4.9A and B. 
 
Figure 4.9: Proposed biosynthetic mechanisms for generation of the second building block. 
 
A) Reduction of PCP-bound glutamate to hydroxypentanoic acid. B) Reduction of PCP-bound 
glutamine to ornithine. 
 
The timing of the reduction is not clear, nor is the enzyme which would catalyze this reaction. 
The next step in either case, however, would be the hydroxylation of the γ-carbon putatively 
catalyzed by GeI. Finally, the hydroxypentanoic acid/ornithine would be modified by N-/O-
carbamoylation. Again, the timing of the carbamoylation is not clear, but precedent examples 
suggests that it would happen following chain release [149;150]. Carbamoylation is normally 
catalyzed by a carbamoyltransferase, which we couldn’t find in the biosynthetic pathway. So 
we cannot exclude that the carbamoylation is catalyzed by another mechanism. Additionally it 
might be possible that the carbamoyltransferase gene is located somewhere else in the 
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genome. Alternatively, ornithine (factor B1) would be activated directly by the A domain, but 
this model does not explain how factors A and B are generated. To determine directly which 
amino acid is activated by this A domain, we tested the function of the enzyme in vitro using 
the ATP-PPi exchange assay. According to our hypothesis, the A domain must show a broad 
substrate acceptance, activating at least two different amino acids (glutamate, glutamic acid or 
ornithine) to generate all three GE81112 derivatives. Indeed, activation of all the three amino 
acids was observed, although the A domain showed a preference for ornithine. Thus, it 
appears that ornithine is directly activated by GeGA2, which accounts for the structure of 
factor B1. The reduced degree of activation of the other two substrates may indicate that 
modified versions of glutamic acid and glutamine are preferred.  
 
The third amino acid incorporated into the chain is either histidine (in GE81112 factor A) or 
aminohistidine (as in factors B and B1). In the case of GE81112 factor A, histidine is likely to 
be incorporated directly, but the origin of the aminohistidine is less obvious. One hypothesis 
is that the aminohistidine might be derived from cyclization of arginine by nucleophilic attack 
of the γ-carbon (Figure 4.10). This step could be catalyzed by an arginine cyclase operating 
on a PCP-bound substrate. This proposal implies that the A domain GeGA3 tolerates different 
substrates, activating both histidine (factor A) and arginine (factors B and B1). However, an 
additional possibility is that cyclization of arginine to aminohistidine occurs before the amino 
acid is thethered to the PCP, making aminohistidine the second substrate of the A domain. 
Thus, according to this alternative hypothesis, the A domain should be able to activate both 
histidine and aminohistidine. 
 
Figure 4.10: Proposed mechanism for the PCP-bound cyclization of arginine by a putative arginine 
cyclase. 
 
As the cluster lacks an obvious arginine cyclase, it appears likely that aminohistidine is 
generated by another mechanism. The in silico analysis of GeGA3 appears to support this 
proposal, as it suggests a specificity for Tyr/Trp and not arginine. This prediction may 
indicate a general preference for aromatic residues, accounting for activation of both histidine 
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and aminohistidine, but it is not clear how aminohistidine could be generated from tyrosine or 
tryptophane. Furthermore, amination of the PCP-bound histidine or after release of the chain 
cannot be excluded. To evaluate one of the hypotheses the suggested putative substrates must 
be tested in the ATP assay, which remains to be done. 
 
The last amino acid to be incorporated in GE81112 is a 6-chlorinated histidine. The 
chlorination reaction is expected to be catalyzed by a halogenase. Halogenation is a common 
modification of natural products and many halogenated compounds are known [151-153]. The 
timing of halogenation reactions during natural product biosynthesis has been shown to vary. 
For example, pre-assembly line chlorination of tryptophane occurs in rebbecamycin assembly 
[154], a PCP-bound threonine is modified during the biosynthesis of syringomycin [155], 
while β-tyrosine is chlorinated following release of the peptide chain, in the assembly of 
chloroereomycin [156]. A candidate for catalyzing the chlorination of the GE81112 
compounds is the halogenase GeF. A number of different scenarios can be proposed for how 
the histidine is chlorinated and incorporated into the metabolites (Figures 4.11 A, B and C). 
Common to all three is the role of module 4 in incorporating the (chloro)histidine, which is 
also hydroxylated at the β-position. 
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Figure 4.11: A linear model for the GE81112 NRPS templated assembly from four amino acids.  
 
In the first proposal (A), biosynthesis starts with the activation of histidine by the A domain of 
GeM (which is predicted to show specificity for this amino acid) which is then bound to the 
PCP of GeM (didomain protein). The putative halogenase GeL would then chlorinate the 
PCP-bound histidine to afford chlorohistidine, as has been proposed for the chlorination of L-
threonine in the syringomycin biosynthesis [146]. The hydroxylation could then occur on the 
Cl-His-S-GeM intermediate; alternatively hydroxylation would occur on the free histidine 
(prior to PCP attachment), or following release of the tetrapeptide from the synthetase. 
However, as the majority of hydroxylations have been shown to occur on PCP-bound amino 
acids [148], we believe that this mechanism is most likely. Nonetheless, it is unclear whether 
hydroxylation proceeds or follows the chlorination. The 3-hydroxy-6-chlorohistidine would 
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then be transferred onto the PCP of GeJ. There are several examples of such PCP-to-PCP 
shuttling in the literature. In the syringomycin pathway, for example, the freestanding A-PCP 
protein SyrB1 activates and loads threonine. The halogenase SyrB2 then acts on the Thr-S-
SyrB1 intermediate to produce 4-Cl-Thr-S-SyrB1. The Cl-Thr is then shuttled in trans to the 
PCP of a C-PCP didomain of the NRPS synthetase SyrE. This reaction is catalyzed by the 
acyltransferase SyrC, a protein belonging to the hydrolase superfamily [157]. Postulated 
functions for members of this protein family also include thioesterase and haloperoxidase 
[158]. A similar mechanism has been elucidated recently for zorbamycin biosynthesis [145], 
in which L-valine is loaded onto the PCP domain of ZmbVIIb, hydoxylated by ZmbVIIc, and 
subsequently transferred onto the PCP domain of ZmbVIIa by the predicted type II 
thioesterase ZmbVIId (Figure 4.12). 
 
Figure 4.12: Proposed mechanism for the biosynthesis and incorporation of L-hydroxyvaline in the 
zorbamycin biosynthetic pathway.  
 
The coronamic acid biosynthetic pathway incorporates a further example of the shuttling of 
aminoacyl moieties [159]. In this example, the aminoacyltransferase CmaE shuttles an allo-Ile 
moiety between the pantetheinyl arm of the PCP domain of CmaA (A-PCP didomain) and the 
freestanding PCP domain of CmaD. By mechanistic analogy, the histidine in GE81112 
biosynthesis may be loaded onto the PCP domain of GeM, chlorinated by GeL and/or 
hydroxylated by GeI, and subsequently transferred onto the GeJ PCP domain by the predicted 
type II thioesterase GeA, acting as acyltransferase (Figure 4.11A). In this model, the A 
domain in module 4 would not be necessary.  
 
Alternatively (pathway B) histidine is loaded onto the PCP of GeM and chlorinated by GeL 
leading to chlorohistidine. The chlorohistidine would then be released by GeA acting as a 
thioesterase, as described for BarC from the barbamide biosynthetic pathway [160]. The free 
chlorohistidine would then be activated by the A domain GeJA4 and loaded onto the PCP of 
module 4. In the next step, β-hydroxylation catalyzed by GeI would take place on the PCP-
bound species.  
Discussion  156 
 156
In these proposed pathways, GeA is predicted to function either as an acyltransferase or as a 
type II thioesterase, both of which are known to release amino acids from PCP domains [100]. 
To attempt to provide support for one or the other of the pathways, we aligned GeA against 
other known acyltransferases/thioesterases. The aminoacyltransferases identified to date have 
been assigned into two groups [145]. The first group, comprising SyrC, CmaE, ZmbVIId, 
contains a GxCxG motif harboring an active site cysteine; enzymes in this group are predicted 
to act as acyltransferases. Indeed, the active-site cysteine of these enzymes has been shown to 
be directly involved in aminoacyltransfer [159]. The second group contains acyltransferases 
BarC [160] and CouN7 [161], which both contain an active site serine (GxSxG) and are 
predicted to function as ordinary thioesterases. For example, in the barbamide biosynthetic 
pathway, BarC is proposed to release trichloroleucine by hydrolysis [160]. When we aligned 
the two thioesterase-like proteins GeA and GeN from the GE81112 biosynthetic gene cluster, 
the presence of an active site serine was clear, suggesting that the proteins both function as 
normal thioesterases (Figure 4.13). Thus, it seems likely that GeA is acting as a type II TE 
catalyzing the release of chlorohistidine (pathway B). The second thioesterase, GeN, is 
expected to catalyze the realease of the peptide from the assembly line (Figure 4.14), even 
though it is a discrete protein (i.e. type II architecture).  
 
 
Figure 4.13: Sequence alignment of acyltransferase/thioeseterases found in NRPS clusters. 
TheGxC/SxG is highlighted. 
 
The final alternative (pathway C) is that free histidine is chlorinated, and then activated and 
loaded onto the PCP of module 4. The remainder of the pathway would then follow that of 
proposal B. Thus in pathway C, module 5 does not play a role, but according to sequence 
analysis it is probably active. 
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Figure 4.14: Proposed GE81112 biosynthetic pathway of factor B1.  
 
Overall, pathway B appears to be the most reasonable, as the TE is clearly predicted to act as 
a thioesterase catalyzing the release of the chlorohistidine, rather than its transfer to GeJ. 
Further supporting pathway B is the fact that in pathways A and C, no function is required of 
a single domain or a didomain, respectively, when there is no evidence from sequence 
analysis that any of these domains should be inactive. Indeed, there are a number of examples 
in the literature in which apparently superfluous modules have been shown to be essential for 
natural product biosynthesis [157;159-161].  
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4.3.4 Summary and Future aspects 
The cloned GE81112 biosynthetic pathway could be identified and cloned and comprises a 
complex NRPS biosynthetic machinery. Many unusual features were found in its modular 
architecture, including A domains which likely incorporate unusual amino acids, such as 
pipecolic acid and chlorohistidine. Although many questions about the biosynthesis remain, 
the availability of the GE81112 cluster as well as tools for genetic manipulation now provide 
a platform for attempts to decipher these issues, and to generate new GE81112 derivatives by 
genetic engineering. A future goal will be to define the cluster boundaries by further gene 
inactivation experiments. To obtain further experimental evidence for the proposed 
biosynthetic pathway selected proteins can be studied in vitro. At first the three remaining A 
domains should be expressed and tested in the ATP assay for the activation of the suggested 
substrates. Furthermore it would be interesting to characterize the PCP of module 5 to 
demonstrate that this module is really needed for the biosynthesis. Another possibility to 
further investigate the gene cluster and to increase the production of the GE81112 compounds 
would be the heterologous expression. Therefore the cluster would need to be stitched from 
the two cosmids as it was already described for the phenalinolactone cluster and transferred 
into heterologous hosts, such as S. lividans. 
Additionally to the GE81112 biosynthetic gene cluster another novel NRPS cluster could be 
identified from Streptomyces 14386. Successful heterologous expression of this gene cluster 
revealed that it was responsible for the biosynthesis of three new peptides, which we 
speculated to be related to the GE81112 family as they seemed to be also chlorinated 
tetrapeptides. To get an idea about the structure of this compound family we purified all three 
compounds and tried to elucidate their structure by NMR. Although structure elucidation was 
not completely finished, it turned out that theses substances incorporate unusual amino acids. 
To finally determine if these substances are related to the GE81112 family, full structure 
elucidation needs to be done. Once the structure elucidation is finished investigations on the 
mode of action of these substances can also be done. However, with the heterologous 
expression of these substances and the genetic manipulation methods developed for S. 14386, 
we now have the basis for gene deletion experiments to investigate the biosynthesis of this 
new class of peptides.  
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5 Appendix 
Table 5.1: Sequence alignment of putative modules 1-5 from the GE81112 biosynthteic pathway 
with two modules of the NRPS pathway from cosmid FD10.  
 
C-A-PCP_FD10_2    1 ---------------------------MLFLALYDEQAVDTYTFQLAFELEGDVDAAGLRAAGDALLRRY 
C-A-PCP-FD10_3    1 -----------PYARPDVIPLSVGQRGQWFLNRFDD-GSGAYNILHTLRLTGALDREALRLALDDVVARH 
C-A-PCP_4         1 -------------ADDGFLPLSRAQRRVWLTSRRAG--SETFVISDLVRLGRRIDADALRRALGAVVERQ 
C-A-PCP_5         1 -------------ADDGFLPLSRAQRRVWLTSRRAG--SETFVISDLVRLGRRIDADALRRALGAVVERQ 
C-A-PCP-3         1 ---------VLWPETPGPVPASNAQRRMWFLEQYEGGELRPYNMVEAFRLPGRHEAADVAVALERTVRRH 
C-A-PCP-2         1 EPAGPAVPRQRPADPLPGTEVSAATRWLWLERQRADGDFGAYTVPCLLEGDGPLDTDRLAAALTVVARRH 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2   44 PNLRAGFRHEKLSRPVQVIPHQ-AEVPWREVDLRAESADGRAAALARLADEDRTHRFDLSRPPLLRFTLV 
C-A-PCP-FD10_3   59 ESLRT-IYPEIDGISRQVILEG-AEVDWTVREVPEEQLAG---ALAAEAAEG----FDLSLDIPVRAALF 
C-A-PCP_4        56 DMLRAQALPRGTEAELTVLDRLPDGVPLVVVELPGADPSGPEAAAALRDARRTG--FALDRAPLFELRLL 
C-A-PCP_5        56 DMLRAQALPRGTEAELTVLDRLPDGVPLVVVELPGADPSGPEAAAALRDARRTG--FALDRAPLFELRLL 
C-A-PCP-3        62 QALRTVFRTEPEGLRQIVLTPGEARPELRVHRARGTDMAG---LLRRVADAEQRHVFDPATGPLLRAHWL 
C-A-PCP-2        71 RALRTVFTEAHGEPRAVVTDDVPALEVADLRGQDAG-----DARFAACVDERVAVPFDPATGPLVRATVF 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  113 ----RLGD---------------------EQYRLMIVLHHILLDGWSFPLLVNDLFELYGRRGDETGLPR 
C-A-PCP-FD10_3  120 ----VLGD---------------------TECVLLLSMHHIASDGWSLAPLSRDLSVAYRARLAGAAPSW 
C-A-PCP_4       124 ----TGVV---------------------GGDLLTVTAHHLIYDGASVDVLLRDLFTAYEQAVAGEPPRL 
C-A-PCP_5       124 ----TGVV---------------------GGDLLTVTAHHLIYDGASVDVLLRDLFTAYEQAVAGEPPRL 
C-A-PCP-3       129 ----VEGANAGGDEGGDKSGDESGDSGGEAGGTLLLSVHHSVCDGWSFAVILRDLLRFLDGTEELPAPTQ 
C-A-PCP-2       136 LLPG-------------------------DRWSLLLLADHLVCDGRSLEILADQLVAAYADPASDVGRPP 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  158 VTPYREYLAWLSRQ-----DKAGAEA-------AWRGALDGVTEPTLLAPAAAANAVRVAPEEFTVDLSQ 
C-A-PCP-FD10_3  165 AGLPVQYADFALWQREVLGDEADPESELCRQLSFWTGRLDGLPQ-ELTLPADRQRPTESSGRGGLVDFTL 
C-A-PCP_4       169 PPLTYTYQEWVREERE---WLAGPEAER--EVAFWRERLRGLAE--SPDPVDPARRRSRRGRTGQVHRTV 
C-A-PCP_5       169 PPLTYTYQEWVREERE---WLAGPEAER--EVAFWRERLRGLAE--SPDPVDPARRRSRRGRTGQVHRTV 
C-A-PCP-3       195 YGAYALGQHTRRDDMEG--------------LEFWRRTLDGAPA--VDLPLDRRRPRERGSAAGTVRLAV 
C-A-PCP-2       181 GGEPAEETPAARPADPR------------AALDHWRSVLEPPPA-PLPLPVRGPRTEPAGSTTGIAAREI 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  216 ET--TAALDSLARARGLTMNTLVQGAWGLLLGSATGRSDVLFGATVSGRPAELPGVQSMVGLFINTIPVR 
C-A-PCP-FD10_3  234 EPGLHQGLVELARSGRASVFMVLQAGVAALLSRLGAGSDIPIGTPVAGRTDEA--LDDLVGFFLNTLVLR 
C-A-PCP_4       232 PA-------VLLRATAATPFAQVVTAFALTVRHHTGATDLVLGFAAGLRDRPE--ADQLIGYLVNAVPLR 
C-A-PCP_5       232 PA-------VLLRATAATPFAQVVTAFALTVRHHTGATDLVLGFAAGLRDRPE--ADQLIGYLVNAVPLR 
C-A-PCP-3       249 GEDTTRAVQGLCRELGTTSFTAMVAAVRVLLLRWSGADDIVLGTVVSGRDQPE--LADSVGLFVNTVALR 
C-A-PCP-2       238 GPDVLRRLTDLGRHHHAGPFVPLAAAVARTLAGLTGSADICLGTAVDRRARAG--AKDAVGFHVATVPLR 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  284 VGLDPAESVAGLFGRIQDQQTELMDHHHVGLT------EIQRLTGQSVLFDTLAVFEN---YPLDSGELE 
C-A-PCP-FD10_3  302 TDTSGDPAFDELVGRVREVNLAAYAHQDVPFERLVEALKPERSTARHPLFQVMLALQNQAEARLELPGLH 
C-A-PCP_4       293 VTLDDTVTGGELLPRVQHGIVEAYEHARLPFDVLAERLALRAGPGRSLLLDLGVSWEN---------AAL 
C-A-PCP_5       293 VTLDDTVTGGELLPRVQHGIVEAYEHARLPFDVLAERLALRAGPGRSLLLDLGVSWEN---------AAL 
C-A-PCP-3       317 TPVEPERGFAELVAAVAAHAREARAHEEYPFEHLVEALGAERVMGRNPLFDVLVEASVSG---TDPLGSG 
C-A-PCP-2       306 LDVRDEMSADDLVRHVARRTMDAVDHSDVTFDGLVAALDPPRSPGRMPFFDVWVALYP-----RIDTGPR 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  345 KSVDGVRVRGLTARDATHYPLSLIAYPG-EHMVLRVGHRPDLVDRETAETLVGRLVRILEAVAADPDRSV 
C-A-PCP-FD10_3  372 VVPEPVDIATSKFDLALDFTERFAADGTPDGVDGFLQYSADLFDRETAETLVARLSRFLGSVAAEPGQRI 
C-A-PCP_4       354 RPESQVVEDLLPDDLPATSDLWLYARVKGDELHLDLTYDDNLLDEAEAGAYADDVAAVLRGLAAGATAPP 
C-A-PCP_5       354 RPESQVVEDLLPDDLPATSDLWLYARVKGDELHLDLTYDDNLLDEAEAGAYADDVAAVLRGLAAGATAPP 
C-A-PCP-3       384 DGPAAEHIRLDSGAEGFDLAFSFTEPAPGRPIEVAITYREDVLDAATVHRAAGQLRHLLTALVADPSVPV 
C-A-PCP-2       371 PPDGIALRGGPTPLRVGMFELSFQCVEHAHGMRLTLQYDALRYAADTAERMVQRLGDEVARLLGDPTEPA 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  414 ASLDMLSVG----------ERRLVLGEWAGVGGVVSED-------------------------------- 
C-A-PCP-FD10_3  442 GAVEVLAPA----------ERERVLVEWNDSAHELAP--------------------------------- 
C-A-PCP_4       424 AQPTVPPPCPPPPAAPPAPNPSAPGPVWSDTRYDFLIPEQGKVRMTSDSAVPATTVRPRRLGPAHSAPAR 
C-A-PCP_5       424 AQPTVPPPCPPPPAAPPAPNPSAPGPVWSDTRYDFLMTPENELKAP------------------------ 
C-A-PCP-3       454 GSAPLLPPD----------QRDALLAAGTGPRGPVPRTAG------------------------------ 
C-A-PCP-2       441 PETAPAHRSFGGFQFDALAAGHQVPFLDVVSSAGGTPECALDPSATERLDALTGGDPTG----------L 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
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C-A-PCP_FD10_2  442 ---------------------------------------------------------------------- 
C-A-PCP-FD10_3  469 ---------------------------------------------------------------------- 
C-A-PCP_4       494 ARLPLTGAAADGLAKVSGGRPLEELVGLTAAATVVVGSAEHTDEPVVAVSGPSGPVLCGIGAAAPATVAD 
C-A-PCP_5       470 ---------------------------------------------------------------------L 
C-A-PCP-3       484 ---------------------------------------------------------------------- 
C-A-PCP-2       501 LLLTVAAARLALAALDEESRHVVLVPAPTNASRADPAADADTAPRELALCAPLDRSAPASVFLTSLHAEL 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
C-A-PCP_FD10_2  442 ---------------------------------------------------------------------- 
C-A-PCP-FD10_3  469 ---------------------------------------------------------------------- 
C-A-PCP_4       564 LVRAVDAALRSAPAADVRDAALAGAVLVSSARVGTAGAPAVRRDAIELTLSEPGADGGRDLVAEAAPERA 
C-A-PCP_5       471 ITRSVGARLRESRIHDN-------------------------------------SAGGRLSTNRDDPK-- 
C-A-PCP-3       484 ---------------------------------------------------------------------- 
C-A-PCP-2       571 ESALPLAWHDREDVASRLRLAGVPAAHALARLGVVCEEAGGKLLQPVGLCLTLRRSAGRLVLTAEAGGEL 
A-PCP_Loading1    1 ---------------------------------------------------------------------- 
 
 
C-A-PCP_FD10_2  442 ------------------------------------------------------VTLPGLFEAQVVRAPG 
C-A-PCP-FD10_3  469 ------------------------------------------------------ATLADLFEAQAARTPA 
C-A-PCP_4       634 EAWFLEVLLRSVARVLAGFTDPHDAVADLPRAGADDVAAATDFGRRGFEPDGVTTTLIAPIEAAVHAYPD 
C-A-PCP_5       502 -------------------------------------------------------TLTFLFEECARNVPG 
C-A-PCP-3       484 -------------------------------------------------------TLLDLVLAQVRRAPE 
C-A-PCP-2       641 PVAATALLRCAAAALEALGRSPRHPVAALDVLGPAQRAELERWSGLPVVAEFADATLTGVLDDAAARFPG 
A-PCP_Loading1    1 ------------------------------APSPPGHAGPVVDTGVSTVLELIDREVAAHPGDPAVREPG 
 
 
C-A-PCP_FD10_2  458 STALVFGGESVSYGELNARANRLARFLIARG-VGPERFVAVSLPRSVELVVAVLAVLKAGGAYVPVDPDY 
C-A-PCP-FD10_3  485 GTALVHGEESLSYGELNARANRLARLLTGRG-VGPEQVVALALPRSPDLVVALLAVVKAGAAYLPVDPEY 
C-A-PCP_4       704 RTAVVAGARTLTYREFWRATEAVADRLRASG-IGRGQRVGVLTGKSVHAVPAITGTLLAGAAYVPLDPRS 
C-A-PCP_5       517 NIALEFEGEFLSYGELNRRANKLAHHLRETGGVRPDDRVALLVRHPPDVIIAELAVLKAGGAYVPLDPDN 
C-A-PCP-3       499 GRAVVCGDRVLTYGDLDRRADALAARIAAVAPTGPDRVVAVVCDRSEWMPAALLAVLKTGSAFLPLDPEQ 
C-A-PCP-2       711 REAVSDGTVVWSHRDLAERSSRAARTLALDHGLKPGDRVALLLPKSPELVLAVLAVLRAGASFVPLDPSH 
A-PCP_Loading1   41 REVT--------YAELDRLADTVAGRLVGEFGIGRGDVVLLAARAGADFTAAVLGTLRAGAAYLPVDTAY 
 
 
C-A-PCP_FD10_2  527 PAERVAYLLEDSAPSFVLD---------------EAAFAGADVSGFSDVDVRDGERLGVLSGLS------ 
C-A-PCP-FD10_3  554 PAERIAFMLRDAAPALVLTTSGTGIGTTAPALPLDAAETVAALADHSDADLTDADRTTPLTDRH------ 
C-A-PCP_4       773 PAARLAEILDDAACGAVLVAPDMLDALPEGLAAPVIDLAAVAGGDAGAPAPGEQSAPAAPTAPTG----- 
C-A-PCP_5       587 PPGVTQRIIEDVTPRAMVIES------SAAAGAVFFDGELFVIDVMSDALETPESDPEPEVTPS------ 
C-A-PCP-3       569 STARLVGVLRDSGAVAAVASAQFAGVTAGAGLPTVTVGAPGAAAGQDAPVRGARDQDAPVLDEPREARAA 
C-A-PCP-2       781 PPARVARQLRLSGAVCVISARDELPGDLAVPVVSP---RALSAAPGPGATADAGTPSGPAPDDE------ 
A-PCP_Loading1  103 PPERIAQILGASSAALLVLADPGSLDTGAAGTPATGLAGLVAPEPSGGPVPAAAVRRGPAPEDP------ 
 
 
C-A-PCP_FD10_2  576 -----AAYVIYTSGSTGRPKGVVVPHGNVVRLFSATDRWFDFGPDDVWTLFHSFAFDFSVWEIWGPLLHG 
C-A-PCP-FD10_3  618 -----PVYVIYTSGSTGTPKGVVVTHGALTGQLRWLAAETELTPRDVVLARTPVSFDAAGAELWPPLVSG 
C-A-PCP_4       838 PLPDDLAYVVYTSGSTGRPKGVEIRHRAIASYVHWKLRNHGLDHDTRVLQLPSLAFDSSVADLFPVLASG 
C-A-PCP_5       645 ----DLAYVIYTSGTTGTPKGIAVEHQAIVNTLTWRNAYYGFGTDAVNLAIPRPSFDSSVADTFCSLTTG 
C-A-PCP-3       639 AGHADLAYVVYTSGSTGAPKGVMVEHGGIVNSVRFRVDHYGLGADGAVLQVDPIHADAGIVDVFSALASG 
C-A-PCP-2       842 ------AILFFTSGSTGLPRPVALTHRQLAHKVLASGRLVGFDEEIRCALLSAVTSDALTYQIFTTLAAG 
A-PCP_Loading1  167 ------AYVIFSSGSTGAPKGIVQTHRCLANFISWQVEGSGLGRGRRVLQVAPLTFDVSVQEMFYTLASG 
 
 
C-A-PCP_FD10_2  641 GRLVVVPFAVSRSPREFRALLVREGVTVLSQTPSAFYQLMAADAECGAGDGELVLRRVVFGGEALDLWRL 
C-A-PCP-FD10_3  683 AAVALASAEVTRDPEQLLAFIGHHGVTVAQFVPS----LLAATPLDERGRG---IRVLLMGGEALPAALA 
C-A-PCP_4       908 GLLVLADTHKLVPR-QLAELAEQHRVTHMTTVPSLYRVLLDELP-----RAADSLRAVTVAGEATTPDLV 
C-A-PCP_5       711 TRLVLPRRDRITDRRYLTGLMESAGVTHFLITPVLYKRLLGAMDA----QRLKTLRCVTVAGEWFTSSLT 
C-A-PCP-3       709 APMVIITRDQLLTPEEVAAVVRQHPIRHVLLVPSLYQVLLDEVGP-----AFRGVREIVLGGERVTRALA 
C-A-PCP-2       906 GCVVPMDSPQTLAPQEFWTTTRRLRVNVINCVPSLLAVMAEG----LPPGAAEDVRICLLGGDEIPAGFL 
A-PCP_Loading1  231 GCLHVPEAHVRRDPRDLIDFVIDERIEVVDFPQSLIDVVMTLPT--TFEHAADLRHIISAGETVRVNEAL 
 
 
C-A-PCP_FD10_2  711 GDWYARHGDAAPVLVNMYGITETTVHVSYVALDAG------------RVAGNAGSVVGRGIADLRVYVLD 
C-A-PCP-FD10_3  746 GQAAAAWG---AQVINVYGPTEATIQATSGRPDGS------------GDDATT-VPIGRPAWNTRVYVLD 
C-A-PCP_4       972 RRHHELLP--GVRLINEYGPTECSVGATAFDHG---------------TDAGPGVPIGWPISNTVATVTG 
C-A-PCP_5       777 KEHYRRLP--EVGLFNEYGPSENAVCSTVHPLA---------------ATDES-VLIGKPVDHTEAFVLD 
C-A-PCP-3       774 ARHAELLP--GVRLYNEYGPAEDSVLTTVELVEPAGTDGGSGAPDTRSPTASGDASIGRPLPGKWVDLLD 
C-A-PCP-2       972 PRLADRLR--VGTFANLYGPTEATIEATTFTCPGSALP------------ALTTVPVGRPSEGFGVVVLT 
A-PCP_Loading1  299 EALLTRRP--EITLHNHYGPAENHMVAAHSMS-GAAGN------------LEPGPPVGSLVWNTYIYLLD 
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Table 5.2: Sequence alignment of proteins GeJ and GeM from the GE81112 biosynthetic pathway 
Sequence homology was 29%. Protein GeJ shows an N-terminal linker sequence which is not 
present in GeM. 
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